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Abstract 
Chapter 1 introduces the modern pharmaceutical industry in terms of the drug discovery 
process leading into a discussion of the relevance of heterocyclic compounds with 
particular focus on the synthesis of multifunctional pyrimidines and pyrazines. An 
introduction into organofluorine chemistry is included followed by a review of the 
literature on 5-chloro-trifluoropyrimidine, tetrafluoropyrimidine and tetrafluoropyrazine. 
Chapter 2 describes a study of the reactivity of 5-chlorotrifluoropyrimidine with mono-
and difunctional-nucleophiles. This research demonstrates the former are not selective 
and in the latter the 5-position chlorine atom is inert to nucleophilic aromatic substitution 
and cross-coupling methodologies. 
Chapter 3 explores the reactivity of tetrafluoropyrimidine with nitrogen, sulphur and 
oxygen containing nucleophiles and describes the development of a methodology for the 
synthesis of multisubstituted pyrimidines by establishing the regioselectivities of such 
processes. 
Chapter 4 investigates the reactivity of tetrafluoropyrimidine with difunctional 
nucleophiles. This study indicated it was not possible to synthesise [5,6]-ring fused 
systems and that in some cases dimers were formed owing to the 5-position fluorine atom 
being inactive substitution. 
Chapter 5 discusses the use of tetrafluoropyrazine in the syntheses of [5,6] ring-fused 
systems. The reactivity of the system towards N,N-dinucleophiles and C,O-dinucleophiles 
was investigated. Further functionalisations by nucleophilic aromatic substitution of the 
remaining fluorine atoms with nitrogen and oxygen nucleophiles are also discussed. 
Chapter 6 contains the experimental data for Chapters 2 to 5. 
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Chapter 1 
Introduction 
1.1 The Pharmaceutical Industry- A Brief History 
Tracing the historical roots of the modern ~harmaceutical industry leads to precedents 
established in the 19th century as a consequence of the development of synthetic dyestuffs. 
The earliest dye to be commercially successful was mauveine synthesised by William 
Perkin who, in 1865, serendipitously discovered that oxidising allyltoluidine with 
potassium dichromate produced a purple dye. 1 Further research in this field led to numerous 
synthetic compounds for dying fabrics, including dyes based on aniline, toluidine and 
quinoline. Companies including F. Bayer & Company and Farbenfabriken Hoeschst 
recognised that dyes and aromatics could have pharmaceutical applications as proven by 
the discovery of Aspirin in 1897. In the 21st century, the challenge remains to produce new 
and improved pharmaceuticals to advance the treatment of diseases and drug discovery 
remains as relevant today as in previous centuries. 
1.1.1 The Modern Pharmaceutical Industry- The Drug Discovery Process 
The process required to develop drugs for the market is highly co~plex and commercially 
risky because thousands of compounds screened for biological activity prove to be 
unsuccessful. To overcome these problems a number of strategies are employed in the early 
stages of drug discovery using targeted programs in an attempt to discover commercially 
viable candidates. In the late 1980s and early 1990s the major focus for drug discovery 
involved developing high throughput strategies (HTS) and combinatorial methods to supply 
many thousands of compounds that could be screened in vitro to deliver lead compounds 
possessing desired pharmacokinetic properties.2-6 
In fact it is now widely accepted that creating vast libraries of compounds by this process 
has not resulted in the expected rise of lead compounds and in creating libraries of diverse 
compounds, many molecules possess undesirable properties, low diversity or few 
functional groups and consequently were not 'drug-like' in nature.7-9 Attempts to 
understand and develop a systematic way of screening compounds have shown that 
molecules that are most likely to become lead compounds have to possess the right 
physicochemical (e.g. solubility, stability) and biological properties (e.g. absorption, 
distribution, metabolism, elimination and toxicity; ADME-Tox). 10 Thus library design had 
to change to become more oriented towards designing compounds with drug-like or lead-
like properties. 
In 1997 Lipinski published work outlining his "rules of five" (R05) which gives a series of 
defined physiochemical relationships for medicinal chemists to use when developing 
compounds that have an increased likelihood of passing through successive screening 
campaigns as orally taken medicines, which are outlined below. 11 · 12 
Rule of 5. 13 
• Molecular Weight :S 500 
• The calculated log of the octanol/water partition coefficient, ClogP :S 5 
• Hydrogen-bond donors :S 5 
• Hydrogen-bond accepters (sum of N and 0 atoms) :S 10 
Extensions. 14 
o The Polar surface area :S 140 A2 or sum of hydrogen-bond donors and acceptors :S 12 
o Rotatable bonds :S 10 
The R05 is a useful set of physiochemical filters and if a compound fails to match the 
outlined criteria it is highly probable there will be issues with, for example, solubility and 
permeability. It must also be noted that structural features which make compounds 'drug-
like' are not fully understood 15 as exemplified by some of the exceptions 11 e.g. antibiotics, 
- antifungals, vitamins, and cardiac glycosides. Also, R05 compliant molecules may not 
2 
possess the correct efficacy even though the rules have been met. Nevertheless, the R05 is 
a useful criteria for analysing and categorising drug-like entity libraries and there has been 
a recent paradigm shift of thinking for medicinal chemists to encompass such ideas. 12 
The R05 is useful in terms of defining physicochemical properties to improve lead-like 
compounds but do not guide the medicinal chemist on which types of structures need to be 
synthesised. Other approaches that have been undertaken involve increasing the structural 
diversity of molecules through modification of functional groups in an effort to provide a 
versatile mode of binding the pharmacophore, which is termed a 'privileged structure'. 16• 17 
Privileged structures 
• Physiochemically active (obeys "rules of five" particularly MW:::; 500)18 
• Present in a large amount of natural products with various biological activities 
• Contains one or more rigid ring systems and easily chemically modified to produce a 
diverse library range. 
Consequently numerous libraries of compounds have been synthesised 18 but the challenge 
still remains to develop candidates that will be effective against a biological target and 
possess excellent efficacy. 
1.1.2 Heterocyclic Compounds 
Heterocyclic compounds are very important in drug discovery as emphasised by the fact 
that 70% of all drug-like entities are based around a heterocyclic sub-structure and are often 
found in biologically important systems. 19 However, synthesising functionalised 
heterocycles - especially analogues for drug discovery - is challenging owing to, in general, 
a low reactivity towards Iiucleophiles and electrophiles as well as difficulties in obtaining 
defined regiochemistries?0• 21 It therefore becomes imperative to design and implement 
synthetic strategies to synthesise functionalised heterocycles in a flexible and 
straightforward manner to provide compounds for lead identification. 
3 
To overcome such synthetic challenges many methodologies have been employed including 
parallel, combinatorial, diversity orientated and rapid analogue synthesis.22 As this thesis is 
concerned with the synthesis of multifunctional diazine systems the following section 
provides an overview of methodology for the synthesis of relevant diazine systems as an 
introduction to the field. 
1.1.3 Multifunctional Diazines - Pyrimidines and Pyrazines 
Diazines such as pyrimidine and pyrazine are heterocycles that contain two nitrogen atoms 
with either a 1,3 or a 1,4 nitrogen pattern as shown in Figure 1.1. 
Pyrirridre 
1 
1 
Pyrazire 
2 
Figure 1.1 
Heterocyclic compounds containing a pyrimidine or pyrazine ring are targets for medicinal 
application due to their observed pharmacological activity which can be shown from the 
extensive range of commercially available drugs containing these motifs, examples of 
which are shown in Figure 1.2.Z3 
4 
BarrenazineA 
7 
~N ~ )l~~ 
Figure 1.2 
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1.1.4 The General Syntheses of Multifunctional Diazines -Pyrimidines and Pyrazines 
Comprehensive reviews within the literature show there are numerous routes to synthesise 
pyrimidines and pyrazines.24-28 The following sections will briefly review the most 
common methods to construct multifunctional systems from aliphatic, carbon- and 
heterocyclic synthons as these motifs will appear frequently within this thesis. 
1.1.5 Multifunctional Pyrimidines and Pyrazines from Aliphatic Precursors 
Synthesis of the pyrimidine core most commonly involves cyclocondensation by the 
reaction of amidines, guanidine or thiourea (N-C-N reagents) with 1,3-diketones, or 1,3-
diesters (C-C-C reagents).29 
5 
0 0 
"X: ~N = "Lo•• + Jl A NH ====> A 0 )l_ H2N R 0 N Ph OEt Ph NH2 0 OEt 
R R R £N r~H, ~0 + NH2 B ====> ====> H2N~S 
R I NAS R N~s R 0 
H H 
Scheme 1.1 
For example, pathway A (scheme 1.1) has recently been utilised in the creation of a library 
of compounds as M3 antagonists and PDE4 inhibitors used for treating bronchodilating and 
anti-inflammatory ailments. 
NH a 
~~--0-0--
10 B~CE 
1\te 
11 
c 
IVJA 
14 
:f~ 
12 
a 
:r~ 
13 
b 
16 17 
a) NaCEt, Ba;, 00 OC, b) PC03 , 1\(Ndiethylaniline, 100 OC, c) neat 14, 45 OC, d) 
neat 16, 1(X)-1200C, 
Scheme 1.2 
Compound 17 is synthesised through the reaction of compounds 10 and 11 in the presence 
of base to give the dihydroxypyrimidine, 12, that is subsequently chlorinated with 
phosphorus oxychloride. Pyrimidine 13 is then subjected to reaction with primary and 
secondary amines 14 and 16 to displace the chlorine atoms, with compound 17 exhibiting 
the most potent physiochemical properties.30 
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Pathway B was also used in the synthesis of pyrimidine derivatives from the cyclisation of 
a 1,1, 1-trifluoropentane-2,4-dione, 19, with thiourea, 18, to yield a functionalised 
pyrimidine, 20.31 
Me 
s 0 0 cCN ~jlNH.! + ~CF3 
F3 ~s 
19 H 18 
82% 
20 
Scheme 1.3 
Similarly, functionalised pyrazines can be synthesised through various methods of 
cyclocondensation as outlined in the general retrosynthetic treatment below, although it 
must be noted this is not an exhaustive list. 
R 
cJrR 
An 
D N B () 
~ c 
Scheme 1.4 
Retrosynthetic path A illustrates the synthon is N-C-C-N-C-C with the pyrazine formed 
through the cyclisation of intermediates such as when compound 21 is cyclised to 2,3,5-
trimethylpyrazine, 22, by brief thermolysis at 300 °C in toluene as shown in Scheme 1.5. 
7 
86% 
21 22 
Scheme 1.5 
Use of a one-atom and a five-atom synthon approach (Path C) ts exemplified when 
ammonia is reacted with compound 23 as shown in Scheme 1.6. 
23 
Scheme 1.6 
85% 
24 
Path D shows a two-atom and four-atom synthon approach which has been used to 
synthesise biologically relevant compounds as shown in Scheme 1.7. 
The pyrazine botryllus, 9, has been shown to exhibit tumour inhibiting properties and is 
extracted from the red ascidian Botryllus Leachi.32•33 
8 
25 26 
0\.le §)yra Q a) 11-tF, 1BuU, -100 OC a)S:::02, heat /- N___} + b)H;P. ~CXh 
b) l'vbrpholine, 0 
DCM,OOC 81% Br 
30 31 
a)HBr(48%),heatff~ (Y~ 
b) A::VC (10%), I ~  
~. l\la.O-i ~ 0 
43% 
32 9 
Scheme 1.7 
Synthesis was achieved through the oxidation of acetophenone, 25, by Se02 with 
subsequent ring closure by reaction of the racemic 2,3-diaminopropionic acid, 27, in 
methanolic NaOH solution. The isomers 28 and 29 were separated and the required isomer, 
29, was reacted with morpholine after conversion to the acid chloride and subsequent 
reaction with 4-methoxyphenyllithium. Two-fold demethylation using hydrobromic acid 
gave compound 9. 
Two three-atom building blocks can be employed (path E) and in the following example 
pyrazine was formed from the condensation of 2-aminoethanol: anN-C-C building block?7 
33 
Scheme 1.8 
31% 
2 
9 
1.1.6 Conclusion 
The previous section has demonstrated that it is possible to synthesise a selection of 
functionalised diazines by cyclocondensation processes but, in many syntheses, there 
remains difficulty in further derivatisation procedures. The following section will discuss 
how functionalised pyrimidines and pyrazines can be synthesised from halogenated 
precursors in order to furnish a range of functionalised pyrimidines and pyrazines. 
1.1.7 Functionalised Pyrimidines and Pyrazines from Halogenated Precursors 
As outlined above, multifunctional pyrimidines and pyrazines are highly desired due to the 
numerous natural products and synthetic pharmacophores that contain these central 
heterocyclic cores?7• 34• 35 Section 1.1.5 demonstrated that routes to synthesise heterocycles 
containing pyrimidine and pyrazine can be achieved though cyclocondensation reactions 
and yet such methodologies can suffer from a lack of regio-control as was shown in 
Scheme 1.7, and there is an added difficulty of synthesising multiple structurally related 
analogues. In attempts to provide syntheses to a range of structurally related heterocyclic 
analogues polyhalogenated heterocycles are frequently used as starting materials in drug 
discovery programmes. Many of the halogenated pyrimidine and pyrazine precursors 
utilised contain chlorine atoms that can be subjected to nucleophilic aromatic substitution 
(SNAr) to produce diverse libraries of compounds and as such are relevant to the research 
discussed in this thesis?4• 36 It must be noted at this point that SNAr is not the only method 
to introduce functionality into heterocycles as palladium catalysed cross-coupling is 
commonly used for the functionalisation of heteroaromatic rings. Such methodologies will 
not be outlined in detail in this thesis but there are a number of reviews that cover this 
subject area.36• 37 
Pyrimidines are electron-deficient in nature and, when halogenated, become very amenable 
to nucleophilic aromatic substitution. There are numerous chloro-pyrimidines that are 
commercially available and there are various routes to create pyrimidine-based libraries 
from these cores.27• 34 Similarly chloro-pyrazines are used in the preparation of 
' functionalised pyrazines as they are readily available from 'Commercial 'SOurces.24• 38 , 
10 
Nucleophilic aromatic substitution methodologies can be employed for the synthesis of 
carbon-nitrogen and carbon-oxygen bonds which are very useful in creating numerous 
hetereoaromatic compounds which have been utilised for drug discovery programmes.39 
The next section 1.1.8 will involve discussing the syntheses of functionalised pyrimidines 
and pyrazines starting from chlorinated precursors. 
1.1.8 Syntheses of Functionalised Pyrimidines 
One of these commonly used compounds is 2,4-dichloropyrimidine which has been 
extensively utilised to synthesise libraries of functionalised pyrimidines. This is 
exemplified by the development of the imidazolylpyrimidine-based CXCR2 chemokine 
receptor antagonists that can be used to treat inflammatory diseases. Compound 40 has 
been synthesised from compound 34 and has been shown to have good potency (Ki < 50 
nM) and oral availability (> 20%) in rats. 
34 
a) lsorrer separation 
0 
b) ~~cf"--
= H y 39 
!:XX:)= 2,3-dichloro-5,6-dicyaro-1 ,4-benzoquinone f\b yields 11\oere reported 
Scheme 1.9 
11 
One of the key steps in the synthesis is the substitution reaction of the 4-
trifluoromethoxyphenylimidazole with compound 35 which leads to a product with 
increased potency against the biological target. Unfortunately, the reaction of compound 35 
with the imidazole nucleophile, 36, gives two isomers by substitution of the chlorine atom 
at the 2- or 4- position which have to be separated by column chromatography.40 
In a second example, compound 47 was shown to exhibit behaviour as a novel and potent 
non peptide gonadotropin releasing hormone (GnRH) receptor antagonist and is also 
synthesised from compound 34. 
34 
a) Isomer separation 
41 
EhN, THF., 
rt, 2 h 
ElaN, chlorobenzene, reflux, 24 h 
70% 46 
A= H 
-N 
R-COCI 
ElaN. CH2CI2 
rt, 24 h 
0 
Scheme 1.10 
42 85% 43 
90% 
47 
20%KOH, 
ethyleneglycol 
130 °C, 24 h 
In Scheme 1.9 it was demonstrated that separation of the isomers must be accomplished 
before further reaction can take place upon the scaffold. This is also true of the reaction 
shown in Scheme 1.10. Once this is achieved, further functionalisation is carried out by 
· reaction of compound 42 with compound 44 to displace the chlorine atom at the 2-postion 
12 
to give compound 45. Compound 47 is obtained through deprotection of the masked amine 
in compound 45 and reaction with acyl chloride.41 
In a third example, compound 52 has been shown to be a non-peptide antagonist of the SH2 
domain of GRB2. This methodology, as shown in schemes 1.9 and 1.10, suffers from the 
formation of regioisomeric pyrimidines in the first step, leading to a low overall yield.42 
!J"Y a) NH2, EtOH, rt H2NI(NYCI + 11 Cl N Cl CI~I~N..., 
N~ b) Separation of 48 from 49 N~ N ~ 
~NH2 
(0Et)2(0)PO SO 
49 NH2 34 48 Isopropanol, reflux, 24 h 
10% 23% 
TMSi, DCM, 0 OC-rt 
15% 
Scheme 1.11 
The methodology demonstrated for the reaction of 2,4-dichloropyrimidine can be extended 
to the study of 2,4,6-trichloropyrimidine, which has the added advantage of an extra 
chlorine that is available for further functionalisation. Subsequently, compound 53 is 
coupled at the 4-position under Suzuki-Miyaura conditions with 4-tluorophenylboronic 
acid, 54, leaving two chlorine atoms for further reaction. 
53 54 
Pd(OAc2h (2 mol%) 
PPh3 (4 mol%) 
Scheme 1.12 
~ 90% ~-:N Cl I NACI 
Ar = 4-F-C6Hs 
55 
Palladium-catalysed amination of the 6-aryl derivative using aliphatic amines or anilines 
displaces the chlorine at the 4-position. Reaction with amines gives mixtures of 2- and 4-
amino derivatives depending on the conditions that are used. 
13 
AT ~NH AT AT £; Ftl catalyst (2 rrd%) ~ £; ~N + UHMDS, ll-iF I~ a a ~ a a ~ 
AT = 4-F-Cal-\:; 
55 
entry arrine ratio 6:2 (%yield of 6) 
56 CNH >99:1 (93%) 
51 CNH 97:3 (92"/o) 
58 ~ 91:9(89'%) 
H 
59 A1N'Me 97:3(93%) 
Table 1.1 
One limitation is that only aliphatic secondary amines and anilines can be utilised because 
primary aliphatic arnines give his-aminated side products.43 
Recently an inhibitor of the cyclin-dependent kinase has been developed starting from 
compound 53. However, as regioisomeric products were formed, separation was required as 
shown in the previous examples. Moreover, the addition of the aniline in the second step 
was only accomplished under forcing conditions leading to the formation of compounds 62 
and 63 which also require a separation. 
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53 
64 88"/o, R = p-anisidine :::::J d 
65 91% R=H 
c 
e 
a) bis-(4-rrethoxybenzyl)arrine, B 3N, n-B..O-i, 75 OC, b) p-anisidine, B 3N, n-a.o-t, avs:::>, 95 OC, 
c) ~d1exytll'l3thard, Na, 170 OC, d) lFA 00 OC, e) P£.0-1, fi20, ~ 
Scheme 1.13 
Subsequently, development of a more efficient synthesis using 6-amino-2-
mercaptopyrimidin-4-ol was undertaken to allow for reaction with a range of anilines 
followed by reaction with compound 67 to eliminate the regioselectivity problems found 
when starting from compound 53 but the yields obtained were moderate.44 
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a 
68 92% 
e 
-
69 72"/o, X= S :=J c 
70 89"/o, R = ~ 
a) B:a-1, 1\BQ-l, n-B.JBr; b) cyddlexylrrethanc:'A, PPf1:3, DEAD, lHF, 0 CC, 
c) ntYBA, DCM; d) A-aniline, 1FE, TFA; e) Pca-i, H;P. ~-
Scheme 1.14 
Therefore a need remains for synthetic methodologies that allow for the synthesis of 2,4,6-
polysubstituted pyrimidines that are regioselective in all steps and thus amenable for 
development of compounds of polyfunctional pyrimidine libraries. This is of particular 
importance within this thesis as a methodology for the sequential nucleophilic aromatic 
substitution of highly halogenated pyrirnidines and pyrazines will be studied in detail. 
1.1.9 Syntheses of Functionalised Pyrazines 
The pyrazine moiety is not as common as pyrimidine moiety in commercially available 
drugs but they have been shown in recent studies to exhibit very useful pharmacological 
activity. 
For example, compound 81 has been shown to act as a SCDl inhibitor that could be used in 
the treatment of obesity. 
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c 
--
>Wira;o e 
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0 
78 
79X=O\I ) f or81 X=O 
80X=O-O 
a) (i) ~~. 18u.t-O, B 3N, NWP, 1500C, (ii) Pc02(~-~02, CXJ(OOpsi), Maa-i, 1000C, (iii) 
1-0 (4 N in dioxane); b) 4-(2-chlorq:tlenoxy)pperidine hydrochloride, TBTU, B 3N; c) (i) Ua-1, (ii) arrines, 
TBTU, B 3N; d) (i) NBoo-gl~ne, TBTU, El:3N, (ii) 2-cHorq::Alenol, A1:3P, DEAD, (iii) 1-10 (4 N in dioxane); e) 
2-cHoro-3-cyano-pyrazine (for 79 and 80) or 73 (for 81), B 3N, NM>, 140 OC, f) OEW.-H 
Scheme 1.15 
Synthesis of compound 74 was achieved through palladium-catalysed carbonylation with 
the glycyl moiety added through nucleophilic aromatic substitution. Compound 81 showed 
the most potent activity of a series of analogues.45 
1.1.10 Conclusion 
Both of the proceeding sections have demonstrated that although there are some strategies 
to synthesise functionalised heteroaromatic compounds by sequential SNAr processes there 
is still further potential for a more effective methodology. This is particularly true in the 
case of pyrazine compounds were there are relatively few examples. The aim of this thesis 
is to utilise the inherent reactivity of perhalogenated pyrimidines and pyrazines towards 
nucleophilic aromatic substitution to develop a methodology for the synthesis of highly 
functionalised heterocycles (Chapters 2-5). 
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1.1.11 Syntheses of [5,6] Ring-Fused Diazines 
In this section, discussion of the synthesis of [5,6] ring-fused diazines will be outlined as 
this area is the second major concern of this thesis. 
Syntheses of [5,6] ring-fused systems are important because many of these systems exhibit 
biological activity and correspondingly are in the top eight most frequently occurring 
motifs in medicinal drugs. Synthesis of [5,6] ring-fused heteroaromatic compounds 
containing either a pyrimidine or pyrazine core can be accessed from a variety of routes to 
furnish a selection of compounds as shown in Figure 1.3. 
N Y
;r-x 
j 
X, Y, Z=CH, NR, N, 0 
Figure 1.3 
1.1.12 Syntheses of [5,6] Ring-Fused Pyrimidines 
Ring-fused pyrimidines are import within the drug discovery arena as there are a wide 
range of drug compounds that contain the pyrimidine system. Novel purines have been 
shown to exhibit properties as inhibitors of various biological processes and the 
development of methodologies to synthesise these structures is of importance particularly 
as they are present in DNA and RNA 46• 47 • The following section will highlight the most 
common methods available to synthesise such compounds. 
A library of purines starting from 82, was synthesised with one example shown in figure 
1.16 to exemplify the synthetic methodology utilised. Elaboration of 4,6-dichloro-2-
(methylthio )-5-nitropyrimidine, 82, starting with the nucleophilic displacement of chlorine 
at the 4-position with methylbenzylamine, followed by displacement of the chlorine at the 
6-position by isopropylarnine. Subsequently the methylthiol group can be oxidised to the 
sulfone which is then displaced by piperidine. The final step requires the reduction of the 
. . ·-- ,, - . -· . . . . .. . .- ' 
nitro group followed by acid catalysed cyclisation to afford purine 85.48 
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82 
83 84 85 
a) I\/Bthylbenzylarrine (1 eq), THF, DIPEA, 20 nin, rt, then isoprq:Jflarrine (3 eq); b) 
rr(PBI\, CCM, 16 h, rt, then piperidine; c) 002 (10 eq), 20:1 J:l'vF:MO-I, 4 h, rt then 
l'v\3qCXl-i3h, f'v\900aH (cat.), 24 h, 100 OC 
Scheme 1.16 
Recently biological evaluation of 2,8-disubstituted 9-benzyladenine has shown that they are 
potent interferon (IFN) inhibitors which are important in the treatment the Hepatitis C 
virus. 
NC a NCX.N 
>-NH2 I )-NHCH2Ph 
NC H N S 
86 
;/ 
2 87 
Nf' 
lb 
NCX.N HS~ I~ c I )-sH f'J N NH2 H2N f\{ PhH2C 
89 88 CH2Ph ~ 
NH2 HS--f J(:N 90 
t'l NANHC4H9 
PhH2C 
a) PhCH2NCS, THF, 40 °C; b) 5% Na2C03, reflux; c) H2NC(NH)NH2.HCI, 
NaOEt, reflux; d) C3H~HO, NaBH3CN, MeOH, rt 
Scheme 1.17 
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An example of how an 2,8-disubstituted 9-benzyladenine is synthesised is shown in 
Scheme 1.17. The synthesis starts by reaction of aminomalonitrile, 86, with benzyl 
isothiocyanate, followed by ring transformation of the resulting thiazole into an imidazole, 
88, under alkaline conditions. Formation of the [5,6] ring-fused system was achieved 
through reaction with guanidine to form 8-mercaptoadenine, 89, which was alkylated at the 
2-amino position to yield 9-benzyl-2-butylamino-8-mercatoadenine, 90.49 
This is by no means an exhaustive list but demonstrates the more commonly employed 
methods. More detailed reviews outlining the synthesis of purines and related compounds 
can be found in the literature but will not be discussed further in this thesis. 50-52 
1.1.13 Syntheses of [5,6] Ring-Fused Pyrazines 
The syntheses of imidazo[4,5-b]pyrazine ring systems as purine analogues are not as well 
represented in the literature as for the syntheses of pyrimidines but there are a few general 
methodologies that have been utilised.53 One of the first syntheses of an imidazo[4,5-
b]pyrazine involved the condensation of 2,3-diaminopyrazine, 91, with an acid chloride or 
urea. 54 
92 W/o 
flle):N)Ni12 _FCOa __ 
M3 ~Ni12 
91 
Scheme 1.18 
We ):H l: ~)-R 
M3 N 
R yield% 
93 H 52 
94 a-la 65 
95 A1 53 
Alternatively, acylation of a selection of 2,3-diaminopyrazines followed by ring closure 
through heating in xylene has also been reported.55 
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X :x~ ) : ~ + (RX>);P xylene X ):H ) : }-R 
X R yield% 
96 a D-la Tl% 
w H D-la 62% 
98 Br CF3 371% 
99 F CF3 60''/o 
Scheme 1.19 
The disadvantage to such an approach is the difficulty in synthesising the diamino 
compounds 96-99 and related precursors for functionalisation along with the fact that such 
a methodology lacks flexibility. 
Recently a range of dimethylimidazo[4,5-b]pyrazine-2-ones have been synthesised utilising 
in situ ring construction and contraction from compounds 100 and 103.53 
0 
avt=/Ka-t 
avt=/Ka-t 
Scheme 1.20 
0 
102 
1\te N I 
l·yN)=o 
rf"N 
87'% 
I 
1\te 
1\te N I 
l·yN)=o 
rf"N 
I 
1\te 
104 Jg>/o 
Such methodologies for library synthesis are limited in respect to the availability of start 
materials and as such alternatives for the synthesis of libraries of compounds, which is an 
important requirement in drug discovery, is required 
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1.1.14 Conclusion 
This section shows that there is scope for new strategies for the synthesis of [5,6] 
pyrimidine and pyrazine fused-rings to complement those within the literature. 
The following sections will outline some of the principles behip.d organofluorine chemistry 
and how they can be applied to the synthesis of highly functionalised hetereoaromatic 
derivatives. This will include how perfluorinated aromatic systems are synthesised, the 
general reactivity with both mono and di-nucleophiles including a discussion of the 
regiochemistries of multiple reactions. To conclude the section will be a short discussion on 
the relevance of this literature to the work outlined in the thesis. 
1.2 An Introduction to Organofluorine Chemistry 
As the major focus of this thesis concerns the synthesis of highly functionalised pyrimidine 
and pyrazines from polyfluorinated precursors it is prudent to introduce the subject area of 
fluorine chemistry by outlining how systems containing fluorine atoms are synthesised and 
how the introduction of fluorine atoms into molecules can have significant effects upon 
reactivity, physical, polarity and biological properties. 
In general :-
);;- Fluorine is the most electronegative element56 and is able to inductively move 
electrons towards itself to highly polarise C-F bonds, thereby changing both the 
electronic environment and the reactivity of molecules. 
);;- The C-F bond is the strongest single bond to carbon and as such, many compounds 
that contain such bonds can be chemically stable and thermally inert as exemplified 
by Krytox® used in lubricating engine parts within high performance jet engines. 
);;- A fluorine atom contains three tightly bound electron pairs in its outer shell which, 
in certain molecules such as PTFE, act as a protective shell around the carbon chain 
thereby making the molecule highly chemically stable and thermally resistant. 57 
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);;> Fluorine has a van der Waals radius between that of a hydrogen atom and a 
hydroxyl group and can replace hydrogen with little disruption to the geometry of 
the system in which it is placed. 
);;> Fluorine can be used as an bioisostere to replace atoms or functional groups without 
a significant change to the biological behaviour. 58 
);;> Lipophilicity (logD) can be significantly increased when a fluorine is substituted for 
a hydrogen which is important for the biological adsorption and distribution of drug 
molecules (although this is not true in all cases).58 
);;> Fluorine in pharmaceuticals can lead to enhanced efficacy and selectivity due to the 
preferred orientation of the fluorine containing substituents towards the 
electropositive regions of the receptor sites. 58 
Organofluorine chemistry focuses upon the reaction and transformations of carbon-fluorine 
bonds. However, more recently the properties of fluorine have begun to be utilised in 
purification-orientated strategies through the use of what has been termed 'fluorous 
chemistry'. 
One of the strategies involves tagging the molecule with a highly fluorinated group so it 
dissolves into fluorocarbon solvents and thus is readily separated from the aqueous and 
organic phases into which it will not dissolve. This methodology also has environmental 
applications, as highly fluorinated catalysts can be recovered and re-used in other 
transformations. 
Fluorous solid-phase extraction is a purification employed in the separation of fluorinated 
molecules with an added feature that lightly fluorinated molecules can be separated upon 
the use of this technology. This is especially useful in drug discovery for the synthesis of 
large numbers of molecules in the creation of a library amenable for screening purposes. 59 
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1.2.1 General Synthesis of Perfluorinated Compounds 
Incorporation of fluorine atoms into aromatic and heterocyclic compounds to furnish 
perfluorinated compounds can involve numerous methods, some of which are of relevance 
to this thesis and they are outlined below. 
(i) saturation-rearomatisation by defluorination, involving electrochemical fluorination 
ofthe pyridine followed by defluorination over iron,60•61 
F 
0 
F2 
:Cc" FOF2 Fe F2 F2 .-<:: N F 
I 
F 
105 106 8% 107 26% 
Scheme 1.21 
(ii) direct replacement of hydrogen by fluorine by passing fluorine over cobalt 
difluoride at high temperatures to give polyfluorination.62 
Scheme 1.22 
(iii) replacement of chlorine by fluorine, termed a halex reaction (which is most 
commonly used due to the associated high yields) and which will be discussed in 
more detail due to its relevance to this thesis.63 
0 
a a:&a KF I .-<:: autooaJe 
a a 400 oc »> 
105 109 107 68% 110 
Scheme 1.23 
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1.2.2 General Synthesis of Perfluorinated Diazines- Pyrimidine and Pyrazines 
The following section will start by outlining how perfluorinated diazines including 5-
chlorotrifluoropyrimidine, tetrafluoropyrimidine are synthesised. All of these compounds 
are important as they are central to the work in this thesis and will be exploited to furnish 
highly functionalised hetereoaromatic derivatives. 
Tetrachloropyrimidine has been extensively studied and its use is reviewed in a number of 
publications.64-7° From tetrachloropyrimidine the synthesis of 5-chlorotrifluoropyrimidine, 
112, can be readily achieved and thus it is an inexpensive, commercially available 
compound. 
The first reported synthesis of 5-chlorotrifluoropyrimidine was achieved by the high 
yielding reaction of tetrachloropyrimidine with silver fluoride. 64 
a 
a0N /lgF 
~~;) a 1\f""a 
111 112 84% 
Scheme 1.24 
Methodologies involve fluorinating tetrachloropyrimidine with potassium fluoride in the 
protic solvent sulfolone or in the presence of 18-crown-6 have provided the compound 112 
in high yields.71 
:f~F 
112 
a KF, sulfolane 
b KF, 16-ao.M"H>, sulfolane 
Scheme 1.25 
a 71%yield 
b91%yield 
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The synthesis of compound 112 may also be achieved via the fluorination of 
tetrachloropyrimidine, 111, with potassium fluoride in a sealed tube or an autoclave giving 
mixtures of 112 and 113.72· 73 
Cl-..... XN KF, 325-345 °C J. .. ~ 25h Cl N Cl 
111 
F CI~N )_A+ 
F N F 
112 
Scheme 1.26 
F~ J.:l F N F 
113 
Tetrafluoropyrirnidine is most conveniently prepared by heating compound 112 in an 
autoclave with potassium fluoride due to the associated high yields.72-74 
112 
KF, autoclave 
48JoC 
Scheme 1.27 
F 
::C,;F 
113 85% 
Tetrafluoropyrazine, 116, is prepared by heating KF and tetrachloropyrazine in an 
autoclave at 310 °C. Compound 116 is synthesised from 2,3-dicarboxylic acid pyrazine by 
reaction with PCis in an hastalloy autoclave at 310 °C. 
H02ClNJ 
H02C N 
PCI CI):NXCI 
__ .::....s_.... I " 
31 0 °C 15 h Cl N~ Cl 
114 115 70% 116 90% 
Scheme 1.28 
Both tetrafluoropyrirnidine and tetrafluoropyrazine are currently not commercially 
available and as such are synthesised at Durham using high pressure facilities. 
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1.3 Reactivity of Diazines- Pyrimidine and Pyrazines 
Perfluorinated -pyrimidine and -pyrazine are generally unreactive towards electrophiles 
due to the highly electron withdrawing nature of the fluorine atoms but they are very 
reactive towards nucleophiles for this very reason. 
Perfluorinated pyrimidines react with nucleophiles due to their electron-deficient nature in 
reactions proceeding via a two-step SNAr mechanism with the addition of the nucleophile 
being the rate determining step.74• 75 
113 
Scheme 1.29 
The intermediate formed is called a Mesienheimer complex with evidence for the 
intermediate provided from the reaction of trifluoro-s-triazine with cesium fluoride in 
tetraglyme by observation of two distinct resonances in 19F NMR.76 
F F, F ~N O;F ~.x·N ~~Ftet~~~F 
117 118 
Scheme 1.30 
Initial attack on compound 113 occurs at the 4/6- position because it is most activated due 
to the stabilisation of the resulting negative charge in the Meisenheimer intermediate on the 
para nitrogen and is the main factor dictating the first position of attack.74 Attack at the 2-
position is less favoured owing to the presence of a fluorine para to this site which is 
destabilising. Attack at the 5-position is highly disfavoured due to the para fluorine at the 
2-position and due to the lack of stabilisation of the negative charge in the Meisenheimer 
complex onto either a para or ortho ring nitrogen (see figure 1.4). 
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2-Sl.II:Eitution 
:ijF-:t~F -:t~F 
I'll Nu - Nu 
4-sutstitution 
5-substitution 
N-X
F_ 
~F 
Figure 1.4 
A para fluorine is destabilising due to donation back into the ring through resonance even 
though it withdraws electron density through induction, although this depends on geometry. 
" c-c____. F --c__.. F 
12 13 
Strongly activating/stabilising Inductive electron withdrawal offset 
by electron-pair repulsions 
Figure 1.5 
Initial state effects also influence the position of nucleophilic attack in terms of 
regioselectively depending upon whether there is a fluorine ortho, meta or para to the site 
of nucleophilic attack. Kinetic studies have shown that an ortho fluorine is more activating 
than a meta fluorine which in turn is significantly more activating than a para fluorine. 
Fort/w > Fmeta >> Fpara 
The 5-position has two ortho fluorines but also a para fluorine and most importantly there 
is no stabilisation of the negative charge on to a para nitrogen in the Mesienheimer 
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complex which is a dominating effect. Thus the 4- position contains one ortho fluorine, two 
meta fluorines and no para fluorines whereas the 2- position has two meta fluorines but a 
destabilising para fluorine and so 4- is substituted rather then 2-. 
Tetrafluoropyrazine differs in reactivity with nucleophiles due to the lack of a para ring 
nitrogen which contributes to a significant drop in the rate of reactivity in comparison to 
that of tetrafluoropyrimidine.72• 74 As all the fluorine atoms are equivalent there are no 
problems encountered in regioselectivity in the first step. 
1.3.1 Reactivity of 5-Chlorotrifluoropyrimidine with Nucleophiles 
In the literature it has been demonstrated that compound 112 reacts with ammonia, sodium 
methoxide, or sodium azide leading to the 4-substitued derivatives as the major products 
(see section 1.3 for rationale) with the minor product arising from substitution at the 2-
position.73. 77 
91 9 112 94 6 
121 122 1~ 119 120 
1\b 1\b 
:eN O::CN I~+ I~ 
F "*3 F 
88 12 
123 124 
Scheme 1.31 
It must be noted from this review that there is very little work within the literature 
documenting the reaction of compound 112 with nucleophiles and that orientation of 
nucleophilic substitution with a range of nucleophiles has yet to be fully established. 
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The use of compound 112 as a fibre reactive dye has been well discussed and many patents 
issued, charting this subject.78 
1.3.2 Palladium-Catalysed Substitution Processes Involving 5-
Chlorotrifluoropyrimidine 
As shown in previous examples, nucleophilic aromatic substitution of compound 112 can 
be accomplished although this has not been adequately exploited. Although C-F bond 
activation is not a direct concern of this thesis it is important to note that systems 
incorporating compound 112 are able to undergo such reactions and in doing so new 
functionalised pyrimidines can be developed and exploited. 
F 
PB3F F Ot3RN,.PCy3 a-x PB3 ~N PCy3 a;r;N B3P I JF [N((X)[))21 I~F [N(<XD)21 I~F 
126 112 125 
Scheme 1.32 
Braun has shown that compound 112 can be reacted with various nickel catalysts to insert 
into either the C-F bond or the C-Cl bond depending upon the size of the attached 
phosphine moiety as shown in Scheme 1.32. 
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a 
C>y3R N ..... PO:I3 
NaQ :eN I~F 127 
F ~J~ 
C>y3R N ..... PO:I3 
1-0 H :eN a;e I~F -[N] I ~F 128 
125 
I 
12 :eN I~F 129 -[N] 
Scheme 1.33 
Additionally the nickel catalyst can be removed through treatment with excess HCl or 
iodine as shown in Scheme 1.33 to leave hydro- or iodo pyrimidine derivatives 
respectively. 79 
1.3.3 Reactivity of Tetrafluoropyrimidine with Nucleophiles 
Reaction of 113 with a series of nitrogen- and oxygen-containing nucleophiles under basic 
conditions, as shown in Scheme 1.34, results in nucleophilic attack at the 4-position. More 
forcing conditions result in the replacement of further fluorine atoms attached to the ring 
and in the case of methoxide these reactions are believed to proceed in a regioselective 
manner with the following order; 4- < 6- < 2-.73. 74• 80 It should be noted that at this point 
this is the only example of regioselective replacement of several fluorine atoms starting 
from tetrafluoropyrimidine and that further research is required to elaborate the subject 
area. 
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~' f' r:· F F I~ 130 ~ e ~~ 141 f' ~' F N F MeO N OMe MeO N F F ~ 132 14o 1 ~ ~!·/ 131 H2N N F F ~b F 
F )~P> f h :(:;_ a 139 I~ ~ 133 F N F F N F F N F 
y 'F~ FfP> )~,, 
13s 1 ~ Fy:M• NHMe Ff"' 1 ~ 134 
'1: I~ PhHN N F Me2N 137 I~ 13& 1 ~ F N F 
F N F MeHN N F 135 
a) H20!THF, AT; b) CH2N:fether, 20 °C; c) MeOH/Na2C03, AT; d) MeOH/MeONa, 0 °C; 
e) MeOH!MeONa, reflux; f) NH3 (aq), rt; g) NH3 (aq), 60 °C; h) PhNH:fNa2C03/THF, 15 °C; 
i) PhNH2/THF, reflux; j) MeNH2 (aq), 0-20 °C; k) MeNH2 (aq)/DMF; I) Me2NH (aq), 0-20 °C; 
m) Me2NH (aq)/DMF, 60 °C 
Scheme 1.34 
N F 
Reaction of compound 113 with sodium azide provides mainly the 4-substituted pyrimidine 
with some formation of the his-compound which is readily isolated by distillation. 
F~N 
~~F 
113 142 58% 143 7% 
Scheme 1.35 
The azide functionality may be further reacted to give a selection of unique compounds.77 
Al A1 
A1-.p.-A1 t~ ~ 11 NN N N 
:eN :eN :c~F ~F ~F 
81%yield 34%yield ?CJ"/o yield 
144 145 146 
Figure 1.6 
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Addition of a sulfur-containing group such as a sulfone at the 4-position can be achieved 
via two different routes; either directly by reaction with sodium benzenesulfinate or 
reaction with benzenethiol and subsequent oxidation to the sulfone.77 
A1 ~g:.o 
F0N CF3~H,DCM 
~~F 
147 
Scheme 1.36 
F~N ~1\B. 
~~F avt=, 1200C 
113 
Reaction of compound 113 with carbon nucleophiles is feasible in the presence of 
butyllithium as formation of the mono 4- substituted pyrimidine is seen exclusively.81 
&JU 
-
F F:t; ~ 
F N""F 
113 
Scheme 1.37 
150 
Other carbon nucleophiles such as pentafluorophenylmagnesium bromide result in 
replacement of the fluorine atom at the 4-position to form compound 152 as the major 
product. However, in this example a small percentage of the his-substituted compound 153 
is formed. 
113 151 152 40"/o 153 9% 
Scheme 1.38 
The remaining fluorine atoms are still labile to nucleophilic aromatic substitution and this is 
shown when compound 152 is reacted with ammonia and methoxide nucleophiles as 
replacement of the fluorine atom at the 6-position is observed. Moreover, reaction of 
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compound 152 with an excess of methoxide and ammonia results in formation of a 
trisubstituted pyrimidine due to replacement of the fluorine on the attached aryl group. 82 
F~Fs 
Jl A 154 
MeO N F F 
74% 
a l : 
CsFs CsFs X, 
159 F~N _F0-N MeO )lA e )lA 75% 
H2N N F F N F 
F 
91~0 1r: ~ c F Fy::156 
MeOANAOMe CsFs FX: F F 158 I A 
F F H2N N NH2 
74% 
61% F 157 ~N 
lA 
H2N N NH2 
47% 
a) MeOH-Na2C03 , -10-20 °C, b) 3 N NaOMe in MeOH, 0-20 °C, c) 2 N 
NaOMe in MeOH, -35-0 °C, d) xs. NH3 aq. (d = 0.880), 100 °C, e) NH3 
aq. (d = 0.880), 70 °C, f) NH3 aq. (d = 0.880), 60 °C, 
Scheme 1.39 
Reaction with carbon nucleophiles such as N-methylindole, also results in substitution of 
the fluorine atom at the 4- position.83 
Fv,tN ;~ ~~F + ~ MaJ. reflux 
113 160 161 
Scheme 1.40 
34 
1.3.4 Polyfluoroalkylation of Tetrafluoropyrimidine 
Polyfluoroalkylation of compound 113 occurs due to its ability to undergo nucleophilic 
attack by anions created via the reaction of fluoride ion (CsF), with polyfluoro-alkenes. 
-F~CXY + P ~ CF3CHXY 
(RP) 
octalfll.DI'dsd:x.Jtene; X=Y=CF3 
hexafluoropropenene; X=F, Y=CF3 
tetrafluoroethylene; X=Y=F 
Figure 1.7 
Reaction with heptafluoropropyl anions, results in the formation of perfluoro-(4-
isopropylpyrirnidine) and perfluoro-(4,6-di-isopropylpyrirnidine) as shown in scheme 
1.41.84 
113 
Scheme 1.41 
Similarly reaction with nonanefluorobut-2-yl anion gives analogous results to 
hexafluoropropene, although no tetra-substituted product was formed85 . 
Scheme 1.42 
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Reaction with the perfluoroacetylene derived anion at 20 °C forms czs- and trans-
perfluoro-4-(1-methylprop-1-enyl) pyrimidine and reaction at 100 °C yields the 
disubstituted product 171 as shown in scheme 1.43.86 
200C 
169 + 170 
'----v----' + 
26% 
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F;c:C, ~C-F 
F "N I A + 
F N F 
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f JF~- :-cF, F3C A F 
F CF3 
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Scheme 1.43 
170 (7%) 
Compound 113 reacts readily with the nitrogen anion 172, to generate the expected 4- and 
4-,6- substituted pyrimidines as shown in Scheme 1.44. 
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Scheme 1.44 
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Conversely, when cesium fluoride was used the 2- and 2-,4- substituted products were 
formed. 87 
Reaction with the trifluoromethanethiolate ion results in the substitution of the fluorine at 
the 4-position (compound 177) and other minor byproducts. Varying the reactant ratios 
gives compound 177, 178 and 179 in a 1.1:1.8:1 ratio when compound 113 and CF2S were 
mixed in a 1 :4 ratio in the presence of the fluoride ion. 88 
~' sa=3 Fsa;f;_F F ~F 
:x> CF~,Q;F 177 178 I~F -MeCN ;{-' ;&' 113 
F3 ~F F3 ~sa=3 
179 180 
Scheme 1.45 
When compound 113 is reacted with excess lithium iodide, substitution of the fluorine 
atoms at the 4- and 6-position occurs. Further reaction with ammonia and methoxide 
nucleophiles replaces the fluorine at the 2-postion. In addition the iodine atoms can be re-
exchanged for fluorine atoms under halex conditions to furnish compound 183.82 
F,~N JL .. ~ s 
I N NH2 NH~ 
F I / F~N ....biL. F~N MeOH )_ J___ )l __ J___ 
F N F 1 N F NaHC03 
113 181 ~OH 
Me ON a 
184 
F, 1 JLX 
MeO N OMe 
185 
Scheme 1.46 
F 
F0N 
)_J___ 
F N NH2 
183 
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Similarly replacement of two fluorine atoms can be utilised in the synthesis of 5-
fluorouracil, a chemotherapeutic agent, from tetrafluoropyrimidine by reaction with HCl, 
hydrogenation and subsequent hydrolysis.89 
F a 
N 1-0 F~N _fi F~N ~s ~-1 )l~~ A~~ N"''F a N"'F a N"''F 
113 186 187 
Scheme 1.47 
FYNH 
r!'N~O 
H 
188 
Substitution of three fluorine atoms can be achieved through the use of an autoclave and 
reacting compound 113 with an excess of HBr which replaces the fluorine atoms at the 2-, 
4- and 6- positions. Hydrogenation or reaction utilising cross-coupling conditions result in 
replacement of all three bromine atoms with either hydrogen atoms or various alkynyl 
groups as shown in scheme 1.48.90 
1-E!r, A18r3 
1500C, autoclave 
Br / F~ )l .. ~N 
8r ~Br~C 
189 ~ 
a) Pd'C, ~ (4 bar), BaN. %Q2 , rt; Ph 
b) OJI, (PhaP)aPdCI2, BaN; c)Phe=H 
Scheme 1.48 
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190 
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191 Ph 
Replacement of all four fluorine atoms may be achieved by reaction of compound 113 with 
di-n-butyl-amine as shown in Scheme 1.49.91 
F 
F0N 
J.A F N F 
113 
Scheme 1.49 
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This section has shown that only a small amount of literature exists on the reactions of 
compound 113. Further investigation is required to screen other nucleophiles and to define 
the regiochemistry of attack after replacement of the fluorine atom at the 4-position. Both 
these points are a major concern of this thesis and will be outlined in subsequent chapters. 
1.3.5 Reactivity of Tetrachloropyrazine with Nucleophiles 
The following section will highlight research carried out involving the chemistry of 
tetrachloropyrazine when reacted with a range of nucleophiles via nucleophilic aromatic 
substitution with nucleophiles being discussed first, followed by dinucleophiles. This 
section will lead through to a discussion of the reactions of tetrafluoropyrazine, 116. 
Reactions of compound 115 with nucleophiles to replace one or more chlorine atoms on the 
ring can be achieved as shown in Scheme 1.50.92 
minor 
193 
202 < 1% 203 -85% 
CI'J(I N}NHNH2 
_)!._ -::::-l... CuBr2 
Cl N Cl 
204 -15% 205 
Scheme 1.50 
CI)CNXBr 
Cl N Cl 
206 
Reactions of the mono-substituted trichloropyrazines (compounds 198, and 199) with 
methoxide and dimethylamine leads to replacement of a second chlorine atom at the ortho 
position to give the major product. However, compound 195 gives predominantly the meta 
product due to the steric influence of the dimethylamine preventing attack at the ortho 
position. 
39 
1.3.6 Reactions of Tetrachloropyrazine with Dinucelophiles 
Tetrachloropyrazine has also been reacted with a selection of dinucleophiles to furnish a 
range of novel ring-fused compounds, although this methodology has not been 
comprehensively developed. 
For example, formation of [5,6] ring-fused systems are possible by reaction of 
tetrachloropyrazine with dinucleophiles such as ethylacetoacetate and N,N-
diethylacetoacetamide anions.55 
2111 
0 0 
A.)lNB:! a)[N}a 
NaH a ~a 
115 
0 0 
A.)lc.e 
NaH 
Scheme 1.51 
209 54% 
Furthermore it has been shown that these systems can undergo ring expansion by reaction 
with cyanide ions to give [6,6] ring-fused systems albeit in low yields.93 
CIXNY}-
CI N~ 
COR 
207, R = OEt 
209, R =NEt 
THF rt 
KCN, 3d 
CIXNJOIO 
Cl N~ 
COR 
210, R= OEt, yield= 33% 
211, R = NEt2, yield= 30% 
Scheme 1.52 
Other [5,6] ring-fused systems can be synthesised including pyrazine-fused 
bistetrathiafulvalenes using a bidentate sulfur nucleophile to give either the 
unsymmetrically substituted pyrazine-:TTF or the pyrazine-fused bis-TTF which may have 
I . . l l . 94 app 1catwns as mo ecu ar wues. 
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Scheme 1.53 
Rxs SI(NyCI 
I )=( )__ ~ 
R S S N Cl 
213 R = CH3 
214, R = CH3 
215, R = n-hexyl 
Large macrocycles including velcraplexes and cavitands may be synthesised from 
tetrachloropyrazine due to the pair of vicinal chlorines which are able to undergo 
nucleophilic substitution with octol 216, to form nine membered rings.95• 96 
a):~a + 
a ~a 
115 
216 217 
Scheme 1.54 
As noted there is little in terms of literature precedent for the reactivity of compound 115 
with dinucleophiles and as such there remains the possibility for methodology development 
in this area by screening more candidates to expand upon this area. 
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1.3.7 Reactivity of Tetrafluoropyrazine with Nucleophiles 
The following section will outline the research present within the literature on the reactivity 
of tetrafluoropyrazine, 116 with a selection of nucleophiles followed by a review of the few 
methods available for synthesising fused ring systems 
In section 1.3.3 it was shown that reaction of tetrafluoropyrimidine with nucleophiles 
results in nucleophilic attack para to that of the ring nitrogen unlike tetrafluoropyrazine, 
which is reflected in the reduced reactivity72 of the system towards nucleophilic attack 
compared to tetrafluoropyrimidine.74 Scheme 1.55 outlines substitution reactions of 
compound 116 with nucleophiles.97 
F)N:CCI 
.. I 
/-
M eO N F 
224 
F)N:CMe I 22s 
/-
F N F 
!h "\ 
F)N:COMe 
F N OEt 
F)N:COMe 
F N Me 
F)N:CMe MeO)[NXMe 
MeO N F MeO N F 
230 229 226 227 
Reagents: a) NaOEt'EtOH; b) KOBuitBu10H/Et20; c) NH 3 (aq); d) N2H4, H20/Et0H; e) nsuli/Et20 
f) MeU/Et20; g) KOH/1BuOH; h) NaOMe/MeOH; i) CH2N2/Et20; D MeOH/H2S04; k) N2H4,H20/ETOH, 
then CuX2-HX aq. 
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Scheme 1.55 
The position attacked by the second nucleophile is reliant upon the character of the initial 
group in which alkoxy and amino groups direct ortho (unless sterically hindered) and alkyl 
and Cl groups direct para as shown in Scheme 1.56 and Scheme 1.57. 
major 
235 
+ 
MeO)[NXF 
F N NMe2 
minor (-10%) 
236 
F)(;(F~a-..~ F)[NXF 
F N F F N OMe 
116 
Me2N'r(NyF Fl(NyNMe2 Fl(NyF 
)_~ + )_~ + )_~ 
F N NMe2 F N NMe2 Me2N N NMe2 
242 80% 243 12% 244 8% 245 
Reagents: a) NaOMe/MeOH; b) Me2NH/MeOH 
Scheme 1.56 
NH3 ., 
dioxane 
F)[NXNH2 
F N OMe 
241 
The alkoxy and amino groups are electron withdrawing and so would be expected to direct 
incoming nucleophiles to the meta position relative to the first substituent, however, 
incoming nucleophiles are directed ortho and this is attributed to transition state influences. 
)):~ l\llc- :x:;:: )):~~ 1\lJc:- :x:;::~ 
aJkoxy - ortro aniro- ortro 
:x:;:: 1\l..c'" )):R :x:;:: l\llc- ..:x:;:: 1\lC F 
alkyl-para dlloride - para 
Scheme 1.57 
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In the case of situation A, B and C the nitrogen atom that is ortho to the incoming 
nucleophile has high electron density. In A and B the transition states have a fluorine atom 
adjacent to the negatively charged nitrogen atom which is a stabilising influence whereas 
situation C has a alkoxy or amino substituent which is less stabilising. Although it is not 
clear why A is favoured over that of B it is postulated that I11: repulsion that would occur 
between that of the nitrogen or oxygen para to the position of attack is similar or greater to 
the situation found in the case of when a fluorine is para.97 • 98 
F):N~X FlN~:uc A I Nuc .,.. .. 
F ~ F F N F 
F~NlX F~N X B 
Nuc N I F 
.... .. 
Nuc NXF 
F - F 
c 
NuJ:" X 
F ~ l 
F N F 
Figure 1.8 
More recently the Durham group has further developed this methodology (see Scheme 1.56 
and 1.57) by studying the nucleophilic aromatic substitution of tetrafluoropyrazine with 
mono- nucleophiles to form poly-substituted pyrazine systems. 
Scheme 1.58 demonstrates that phenoxy substituents direct para which differs from the 
early research in that alkoxy- substituents direct ortho to themselves. Other phenoxide 
nucleophiles with pendent groups containing either electron donating or electron 
withdrawing substituents are consistent with this observation. Reactions of mono-
substituted phenoxy pyrazine with nucleophiles varying in electronic and steric character 
show a lack of regio-control attributed to the steric hindrance of the ortho site. 
44 
29 10 
A9agents: a, C5H111\VTHFIDIPEA; b, A1CNl/THF; c, 2C6H58rO'THF/NaH; d, n-BuiJ/1HF;-700C; e, AllllgBr!ll-lF; f, NaCE/THF; g. ex. 
Na.CE/11-IF; h; tEil.JCNa'B2Q i, 2C31-180'Na1-VT; j, 203H4Mia03IBOi; k, C3HBO-VTHF/NaH; I, I\BCellHF; m, Na.CFhfTHF; n, 
tBuC::NliB2Q 0, 2BNH2/THF; p, I\BCellHF. 
Scheme 1.58 
Reactions with neutral nitrogen nucleophiles and tert-butoxide gave mono-substituted 
products exclusively. Subsequent reaction after piperidine was attached led to mixtures of 
products due to a lack of regio-control attributed to the steric hindrance of the ortho site as 
observed for the phenoxy compounds. Tri- and tetra- substituted pyrazine systems have 
been synthesised to form multi-substituted systems. Reaction with phenylmagnesium 
bromide gave the disubstituted compound a result that fits in with the observation that alkyl 
groups direct to the para position to avoid destabilising In repulsion from fluorine atoms.99 
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1.3.8 Reactions of Tetrafluoropyrazine with Dinucleophiles 
In initial work, the Durham group has also studied the reaction of compound 116 with a 
short series of dinucleophiles, synthesising a selection of novel [6,5] and [6,6] ring-fused 
compounds 100• 
1 
273 
2 
274 275 
Scheme 1.59 
Reactions of 116, with various dinucleophiles, including the symmetrical compounds 268 
and 269, resulted in the formation of the desired [6,6] systems in moderate to good yields. 
Reactions with unsymmetrical dinucleophiles such as ethylacetoacetate gave two 
compounds with the main product being the acyclic compound 274. On the other hand 
reaction with a nitrogen/sulfur dinucleophile results in the disubstituted product with no 
observed cyclisation. 100 
Similar velcraplexes can be formed from tetrafluoropyrazines as shown in the example 
where tetrachloropyrazine was utilised.95 
This review demonstrates how tetrafluoropyrazine may be used to form a senes of 
polysubstituted compounds but there is further scope for the development of the 
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methodology of reacting tetrafluoropyrazine with dinucleophiles, which is a major concern 
of this thesis. 
1.3.9 Conclusion 
The literature outlined in this Chapter has summarised the importance of drug discovery 
with particular focus on the syntheses of heterocyclic compounds such as pyrimidines and 
pyrazines and how such systems can be accessed through various methodologies. The main 
focus of the thesis will concern the reaction of perfluoro -pyrimidines and -pyrazines and 
how functionalised heterocycles can be prepared from these start materials. 
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Chapter 2 
Novel Multisubstituted Heterocyclic Synthesis from 5-Chloro-
trifluoropyrimidine 
2 Introduction 
As outlined in Chapter 1 this work concerns the formation of highly functionalised 
heteroaromatic derivatives which are important for drug discovery. Various methodologies 
to synthesise a range of polyfunctionalised pyrimidines and related ring-fused pyrimidines 
are available and because such functionalised pyrimidines are of great importance within 
the life-science industries many drug discovery programs have been implemented in an 
attempt to realise new compounds for commercial application. Consequently pyrimidine 
core scaffolds, which may be transformed into diverse ranges of functionalised derivatives 
through efficient and regioselective reactions, are very important. However, as was 
discussed in Chapter 1 it can be difficult to synthesise di- and trisubstituted pyrimidines in a 
regioselective manner. This Chapter will show how our methodology, starting from highly 
fluorinated precursors, attempts to overcome such problems for the synthesis of 
polyfunctionalised pyrimidines and related ring-fused pyrimidines. 
2.1 Aims and Approach 
Our approach towards the syntheses of functionalised heteroaromatic derivatives is to start 
from highly fluorinated heterocyclic precursors and replace fluorine atoms by sequential 
nucleophilic aromatic substitution as shown in Scheme 2.1. 
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~, ~. f\l.cs, I\Lc4 =N. 0 ard S centred m.deq::kliles 
Scheme 2.1 
This study will firstly involve the reaction of compound 112 with nucleophiles to form 
carbon-nitrogen bonds which is a highly desirable process but one that has been reported to 
be difficult to achieve in practice. 1 Methodologies that can be used to create carbon-
nitrogen bonds can either involve cross-couplings such as the Buchwald-Hartwig reaction 
or nucleophilic aromatic substitution by reaction of nucleophiles with sufficiently electron 
deficient haloaromatic compounds?· 3 The latter is the preferred choice for compound 112 
due to the precedent within the literature (see section 1.3.1) and it was hoped to fit well 
within the parameters of being an efficient and regioselective reaction which is desirable 
for library synthesis. 
The next stage of the experimental investigation involved screening a selection of 
dinucleophiles, including benzamidine and 2-aminopicoline by a short, simple and flexible 
strategy to synthesise [5,6] systems as purine analogues. 
Previous research has demonstrated the reaction of compound 112 with a few nitrogen 
nucleophiles such as ammonia resulted predominantly in the substitution of the fluorine 
atom at the 4-position with some replacement of the fluorine at the 2-position being 
observed as shown in Scheme 2.2. 
F NH2 F Cl X: NH3 (aq}, rt at: Clt:N 1;( I N + lA A 
F N F F N F F N NH2 
9 
112 121 122 
Scheme 2.2 
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2.2 5-Chloro-2,4,6-trifluoropyrimidine as a Scaffold 
As only a few examples of the reactions of compound 112 with nitrogen nucleophiles are 
reported in the literature4• 5 it was decided that a small study was required to screen the 
reactivity of compound 112 with various primary and secondary nucleophiles. The aim of 
this study was to assess the utility of compound 112 as a scaffold for library synthesis by 
establishing methodology that could be used to make numerous analogues with differing 
pendent amino groups amenable for biological screening. 
2.2.1 Reactions of Compound 112 with Monofunctional Amine Nucleophiles 
A series of reactions between compound 112 and a range of primary and secondary amines 
was carried out and the results are collated in Table 2.1. 
As this was a model study the reaction conditions of using acetonitrile as the solvent and 
DIPEA as the base to neutralise any acidic by-products were kept constant. All of the 
reactions were monitored via 19F NMR and the isomer ratios were measured by 19F NMR 
spectroscopy integration from samples taken directly from the reaction mixture. 
It was found that the reaction of compound 112 with ammonia results in two isomers 
shown by 19F NMR analysis with two distinctive peaks ( -48.18 and -69.47 ppm) for the 4-
substituted isomer and one peak (-65.44 ppm) for the 2-isomer in a 9:1 ratio, the chemical 
shifts being consistent with those from previous studies.6 Similarly, reaction with 
ethylamine yielded two distinct isomers in an 8:1 ratio by 19F NMR by reaction at the 4-
and 2- position shown by two fluorine signals (-47.48 and -70.83 ppm) and one signal (-
63.59 ppm), respectively. Distillation afforded the 4-isomer in good yield. Other reactions 
gave a mixture of products which were identified by 19F NMR as described above. In all 
cases, the major product could be isolated by either recrystallisation or column 
chromatography. 
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R R NH 
NH3 
F 
CI0N 
)LA 
F N F 
R1R2NH, CH3CN 
DIPEA, 0 °C 
112 
Products 
F 
CI0N 
)LA -H F N N 
122 H 
F 
ci0N 
F)LNAN,H 
I 
277 Et 
F 
ci0N 
)LA -H 
F 2:1 ~ 
F 
ci0N 
)LA 
F N 0 
285 
ratio yield% 
9:1 57% 
8:1 43% 
5:1 54% 
5:1 41% 
3:1 49% 
3:1 25% 
Table 2.1 The reactions of compound 112 with nitrogen nucleophiles. 
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Thus, reactions of compound 112 with various amine nucleophiles resulted in attack 
predominately at the 4-position which is the most activated site due to the para ring 
nitrogen. This is consistent with previous observations for these types of perfluorinated 
heterocycles (see section 1.3). However, as the steric bulk of the nucleophile increases there 
was a larger ratio of the 2-substituted regioisomer and this reflects the steric hindrance to 
nucleophilic attack on the chlorine atom located at the 5-position. 
It therefore becomes clear that this system is not ideal for analogue synthesis or for multiple 
substitution processes because before further reaction can take place, purification must be 
performed to remove the 2-substituted regioisomer from the mixture. In some cases, 
particularly for piperidine derivatives, this involves extensive purification and thus fails to 
meet either synthetic requirement for the reaction to be regioselective or efficient. 
2.2.2 Reactions of Compound 112 with Difunctional Nucleophiles 
Following on from the model studies with monofunctional nitrogen nucleophiles, 
compound 112 was reacted with benzarnidine in an attempt to synthesise a purine analogue 
via a ring-fusion process which has been shown in Chapter 1 to be highly desirable. 
Reflux of compound 112 with benzarnidine, which can essentially be considered to be a 
primary nitrogen nucleophile, in the presence of sodium bicarbonate predominantly reacts 
at the 4-position rather than giving a mixture of isomers, consistent with the above findings. 
Indeed, when compound 112 is reacted with benzamidine at room temperature it results in 
nucleophilic substitution of the fluorine at the 4- and the 2- position in a 40: 1 ratio shown 
by 19F NMR with two peaks corresponding to compound 286 (-47.48 and -66.05 ppm) and 
one peak for compound 287 (-60.70 ppm). Isomer 286 easily isolated by recrystallisation 
from acetonitrile. 
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F 
CI~N 
)_ ~ + 
F N F 
112 
MeCN, 4 NaHC03 
24 h, rt 
Scheme 2.3. 
S? 
X:
N NH 2 
Cl 
~+ 
F N F 
40 
286 69% 
Single crystal x-ray analysis provided further proof of this structure. 
Cl1 
CI~N I h-F2 
)_ ~ h 
F N N N 
H2 
287 
Figure 2.1 The X-ray crystallography structure of compound 286. 
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Attempts to synthesise a [5,6]-fused ring system through prolonged heating of the reaction 
mixture results in the formation of compound 286 as the major product and compound 288 
as the minor by-product. Proof of the synthesis of compound 288 was shown from 19F 
NMR because the shifts of 288, -47.99 ppm (lF, s, C-6) and -64.39 ppm (IF, s, C-2)) differ 
from those of compound 286, and the compound 288, has an m/z of 416 (~. 2%). This 
indicates the intermolecular reaction occurs faster then than intramolecular cyclisation onto 
the least activated 5-position. 
F 
ci0N ! )LA+ HN NH2 
F N F 
112 
MeCN, 4 NaHC03, reflux 
96 h 
Scheme 2.4 
286 23% 
Ph F )-._ N=( N7 N-{ ,~ 
c10NH M )LA Cl F 
F N F 
288 8% 
As neither experiment resulted in any annulation the next step was to attempt to form the 
cyclised compound 291 through the use of strong bases such as LDA or n-BuLi. 
The precedent for this methodology has been shown via the reaction of pentafluoropyridine 
with benzamidine which proceeds via substitution of the fluorine atom at the 4-position of 
the pyridine ring with annulation achieved through addition of LDA to yield compound 
290.7 
F MeCN, 4 NaHC03 , 2 LOA p 
reflux N
7 NH2 Il:lE N F~(:( Ph FtrF • FnN-H + HN~NH2 -78 °C-rt I .--; 16 h I .--; 24 h ~ I F N F 
.HCI F N F F N F 
107 289 69% 290 91% 
Scheme 2.5 
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This methodology was applied firstly using LDA which results in no conversion as shown 
through both 19F NMR and LCMS studies and secondly with n-BuLi which also gives no 
cyclised product. In both cases the starting material was recovered. 
2 
X:
N NH2 
Cl N 
~~· 
F N~F 
286 
LOA or Buli 
'( ~ 7 
THF 
-78 <>c-rt 
24 h 
Scheme 2.6 
291 
As both the nucleophilic aromatic substitution and the base induced cyclisations had failed 
the next step was to take attempt the annulation process through a copper-catalysed cross-
coupling such as the Buchwald-Hartwig C-N bond forming reaction. Such methodologies 
have been extensively utilised to provide a wide range of compounds and there are a 
number of comprehensive reviews of this subject area. s-I! 
Copper I Iodide was chosen initially due to the fact that experimentally it is easy to use and 
is amenable to microwave synthesis. 
xrrol% 
286 
xrroi%Q.JI 
IVIeHN~NI-Me 
2KeP04 
Dioxane 
rrw, 1000C, 1 h 
Scheme 2.7 
• 
Coupling onto a C-Cl bond is generally quite difficult to achieve and all of the reactions 
that were tried, including different loadings of catalyst (5%, 10% and 20%), failed to yield 
any cyclised products and resulted in mixtures of oligomers. At this point, this study was 
abandoned and no further attempts were undertaken. 
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2.3 Conclusion 
The conclusion that can be drawn is that reactions of compound 112 with nitrogen 
nucleophiles are not selective and the chlorine at the 5-position is not reactive towards 
either nucleophilic aromatic substitution or cross-coupling methodologies for fused-ring 
synthesis. Consequently, alternative fluorinated pyrimidine scaffolds will be used as 
precursors for polyfunctional ring-fused systems. 
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Chapter 3 
Multisubstituted Pyrimidine Derivatives From 
Tetrafluoropyrimidine 
3 Introduction 
In Chapter 2 it was detailed how 5-chlorotrifluoropyrimidine, 112, reacts with nitrogen 
nucleophiles to undergo nucleophilic aromatic substitution to create carbon-nitrogen bonds. 
However, as the steric bulk of the nitrogen nucleophile increases the amount of 2- isomer 
was amplified leading to more protracted purification. This meant the methodology was 
neither suitably efficient or regioselective enough to meet the requirements required for 
rapid analogue synthesis. 
In order to overcome this limitation it was considered that replacement of chlorine by the 
less sterically demanding fluorine would remove this problem and potentially lead to a 
series of mono substituted compounds which would be suitable for further derivatisation. 
F~N ~ 
~ri--F 
113 
~, ~. f'.llc:3 = N, 0 and S centred nucleophiles 
e.g. Aniline, Benzylarrine, Bhylarrine, Diethylarrine, 
11/brptdine, Alenoxide, Bhanethiolate, Benzenethiolate 
Scheme 3.1 
In Chapter 1 it was demonstrated that the reaction of tetrafluoropyrimidine, 113, is 
represented within the literature but a comprehensive study has not been discussed. 
Furthermore, such methodology could be extended to the reaction of compound 113 with 
oxygen and sulfur nucleophiles to form carbon-~xygen and carbon-sulfur bonds. These 
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classes of compounds are important in the development of pharmacologically active 
compounds and in the development of the scope of the methodology for multisubstituted 
pyrimidine synthesis. 
This chapter will discuss the reactivity of compound 113 with a range of nitrogen, oxygen 
and sulfur (both aromatic and aliphatic) centred nucleophiles with a view to synthesising 
trisubstituted pyrimidine systems. The importance of such derivatives was outlined in 
Chapter 1. 
A single precedent for sequential poly-substitution reactions to regioselectively replace the 
fluorine atoms has been described and occurs through the step-wise reaction of compound 
113 with sodium methoxide. 1 Development of this sequential methodology by reaction with 
nitrogen, oxygen and sulphur-centred nucleophiles to furnish highly functionalised 
heterocylic derivatives and establishing regioselectivity of such processes· is the aim of this 
work. 
Therefore, it may become a realistic possibility to develop routes to synthesise novel 
pyrimidines that are otherwise difficult to access and, thus, have the potential to be utilised 
by the pharmaceutical and life-science industries for drug discovery. 
3.1 Reactions of Tetrafluoropyrimidine 113 with Nitrogen Nucleophiles 
In Chapter 1 it was demonstrated that compound 113 undergoes nucleophilic aromatic 
substitution with various amine nucleophiles with replacement of the fluorine at the 
activated 4-position14 and this was also the case when primary amines such as ethylamine, 
benzylamine and aniline were screened. Each of the reactions was performed in THF and 
under basic conditions with an excess of DIPEA as a base to neutralise any hydrogen 
fluoride by-products. Stirring the reaction mixture at 0 °C for 1-2 hours and monitoring by 
19F NMR results in the appearance of three distinct resonances (see Scheme 3.2 for values) 
due to the regiospecific displacement of the fluorine atom at the 4-position. Subsequent 
63 
work-up using standard methods and either simple recrystallisation or column 
chromatography gave the products in good yields and high purity. 
x;: iJ+~ 
N F 
lHF, ooc 
DIPEA(3eq) 
113 
19FNMRppm 
- 48.00, - ff1.72. - 174.15 
-47.21,- 86.61,- 100.69 
-46.10,- 84.00,- 177.00 
Scheme 3.2 
o/o 
75 
59 
68 
292 
293 
139 
With these results in hand, reactions of compound 113 with secondary amines were carried 
out under identical conditions with substitution of the fluorine atom occurring at the 4-
position regiospecifically, as observed by 19F NMR. Recrystallisation from either n-hexane 
or DCM gave compounds 294 and 295 in fair yield and purity. 
F ~ :f;_F + 11-fF, ooc ~ DIPEA(3eq) ~F 
113 
~ 19F J\II\IF4 ppm 0/o 
NHB2 
- 47.61' - 86.76, - 177.38 26 294 
l'vbrpholine 
-47.00,- 84.00,- 172.39 84 295 
Scheme 3.3 
Each reaction was complete within a 1-2 hour period which was determined by 19F NMR 
spectroscopy. After full conversion of the start material to product a rapid work-up and 
purification sequence was completed making the turn around time very short for the 
production of 4-substituted heterocycles. Moreover, with ethylamine, aniline and 
morpholine, scale-up is possible and products were obtained in batches of up to lOg with 
high yields, providing ample material for further reaction. 
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3.2 Reactions of Tetrafluoropyrimidine 113 with Oxygen Nucleophiles 
As an extension to the study involving aliphatic alkoxides, 1 compound 113 was reacted 
with sodium phenoxide, an aromatic nucleophile, in THF at 0 °C, which resulted in the 
formation of a disubstituted compound 296 (even under high dilution conditions with only 
one equivalent of nucleophile) as shown via 19F NMR with two peaks appearing at -45.9 
and -174.2 ppm. A pure sample amenable for full analysis was obtained through 
recrystallisation from n-hexane. 
PhONa 
296, 43% 
Scheme 3.4 
This reaction indicates that the mono-phenoxide system must be more reactive towards 
nucleophiles than the starting material and the reasons for this are not clear as we would 
expect that the electronegative fluorine atom to activate the ring more strongly with respect 
to a phenoxide substituent. 
3.3 Reactions of Tetrafluoropyrimidine 113 with Sulfur Nucleophiles 
There are few examples of reaction of compound 113 with sulfur nucleophiles within the 
literature and so the reaction with EtSNa was performed in an analogous manner to those 
discussed previously. 
F~N 
~~; BSNa 
THF, OOC, 2h 
113 '2!11, 54 °/o 
Scheme 3.5 
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Monitoring the reaction by 19F NMR showed the appearance of two peaks at -50.25 and 
-139.16 ppm with a m/z of 236 (M+, 100%) corresponding to the formation of the di-
substituted compound 297. The formation of this compound is probably the result of the 
inherent reactivity of the sulfur nucleophile and also, as seen in the alkoxide case leads to 
the conclusion that the mono substituted product IS more reactive than 
tetrafluoropyrimidine. 
3.4 Conclusion 
It has been outlined how nitrogen nucleophiles are ideal for the synthesis of mono 
substituted derivatives preferentially over that of the oxygen or sulfur nucleophiles. The 
latter led to disubstituted compounds preferentially. 
This has concluded the study of compound 113 with mono nucleophiles and the next stage 
is to explore the reactivity of the mono substituted compounds with other representative 
nucleophiles which will be outlined in the subsequent sections. 
Consequently, extending the research by screening a selection of new nitrogen nucleophiles 
proceeded in accordance with literature precedent and the study moved on to exploring the 
possibility of further derivatisation by the replacement of the remaining fluorine atoms 
attached to the heterocyclic ring. 
3.5 Reactions of 4-Substituted Perfluoropyrimidines with Nucleophiles 
Given that the 4-amine substituted pyrimidines have three fluorine atoms remaining a study 
into their reactivity towards further nucleophilic aromatic substitution was carried out with 
a selection of nucleophiles. 
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Scheme 3.6 
In principle the nucleophile is most likely to attack at three positions when reacted with 
nucleophiles: the 6- or 2- positions involving displacement of the fluorine atom or the 4-
position involving displacement of Nuc1• The next section will outline the result of the 
reaction of compounds 292, 295 and 139 with mono nucleophiles. 
3.5.1 Reaction of 4-Substituted Trifluoropyrimidines with Nitrogen Nucleophiles 
Primary and secondary aliphatic nitrogen nucleophiles were reacted with the mono 
substituted systems 292 and 295. Reactions of 4-methoxybenzylamine with 292 and 295 in 
THF at room temperature gave two products with the major product being the 6-substituted 
isomer and minor quantities of the 2-substituted isomer in a 19:1 and 16:1 ratio 
respectively, which was determined by 19F NMR of the reaction mixture. Extraction and 
simple recrystallisations from n-hexane gave the 6-subtituted isomers as a white solids in 
good yield and excellent purity. 
X 
NHB 
IVbrpholine 
ratioA:B 
19:1 
16:1 
+ 
19F NMR ppm %of isorrer 6 isolated 
-49.58, -186.07 61 
-49.99, -175.45 66 
Scheme 3.7 
298 
299 
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The formation of the 6-substitued isomer can be attributed to the 6-site being the most 
activated site due to the presence of a para nitrogen although competing 2-substitution can 
occur due to activation by two ortho nitrogens. 
The reactivity of compounds 139 and 295 with the primary nitrogen nucleophile, 
ethylamine, resulted in attack at the 6-postion preferentially as seen by 19F NMR, with the 
formation of two distinct resonances (see Scheme 3.8). Heating of the reaction mixture was 
required to give full conversion to the disubstituted system and reflects the lower reactivity 
of the heterocyclic ring. 
X F0N ~~F+ B~ 
3DIPEA, lHF 
400C, 12 h 
X 19F l\lv1R ppm 
NHPI-I -49.12, -149.23 
l\lbry:tloline 
-50.11 '-175.77 
Scheme 3.8 
XXN .. ..1 B N''F 
o;o 
72 300 
61 301 
The next nucleophiles screened were secondary ammes such as piperidine which were 
reacted with compounds 295 and 293 and resulted in the formation of two regioisomers 
with displacement of the fluorines at the 6-position and the 2-position in a 1:1 ratio 
respectively. 
X ratio, A:B 
rvbrpholine 1:1 
Benzylanine 1:1 
11-F, rt 
DIPEA 
%of isorrer 6 isolated 
51 302 
36 303 
Scheme 3.9 
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This result demonstrates the formation of the products is not dependent on the initial 
substituent but on other factors present within the system. A possible explanation of this 
reactivity may come from the fact that as the bulk of the nucleophile induces steric 
repulsion from the fluorine atom at the 5-position becomes more pronounced resulting in an 
increased amount of substitution of the fluorine at the 2-position. 
Represented in Figure 3.1 is the x-ray structure of compound 303 which confirmed that 
reaction with secondary amines gives substitution of the fluorine atom at the 2-position. 
Figure 3.1 The x-ray crystallography structure of compound 303 
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In contrast to the reactions above, all attempts to react tetrafluoropyrimidine with aniline 
resulted in no reaction and the starting material was reclaimed. Following on from this 
result, the more reactive 4-methyl aniline was employed, however, no reaction was 
observed and this in turn reflects the lower nucleophilicity of aniline and derivatives even 
under prolonged microwave heating. 
lHF, rt I reflux/ rrw, 140 °C 
No oonversioo 
DIPEA 
X = NHEt, IVbrpholine, Aniline 
Scheme 3.10 
In summary, these results demonstrate novel polysubstituted pyrimidine systems can be 
synthesised by reaction of mono substituted perfluoropyrimidine compounds with aliphatic 
amines. In the case of primary amines there was selective replacement of the fluorine atom 
at the 6-position to yield a range of unique disubstituted systems whereas secondary amines 
led to a mixture of products that could be separated. 
3.5.2 Reactions of 4-Substituted Perfluoropyrimidines with Oxygen Nucleophiles 
In light of the excellent reactivity demonstrated towards nucleophilic aromatic substitution 
with primary amines, the study was extended to reaction of compounds 292, 295 and 139 
with oxygen nucleophiles in order to access a set of novel disubstituted pyrirnidines by 
reaction with aliphatic and aromatic alkoxides. 
Firstly compounds 292, 295 and 139 were reacted with the sodium phenoxide in THF at 
room temperature which gave exclusive replacement of the fluorine atom at the 6-position. 
Monitoring the reaction via 19F NMR showed the formation of two distinct resonances (see 
Scheme 3.11 for values) with the peak at around -80 ppm, corresponding to substitution of 
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the fluorine at the 6-position, which decreased over the time, with complete conversion 
achieved over a 12-13 hour period. 
X X 
::c~F 11-IF, rt ~N + A10\Ia ~F 
X 19FNMRppn o/o 
NHB -47.81, -100.23 63 304 
NHA-i -49.97, -179.31 79 305 
rvbrploline 
-49.59, -172.81 70 306 
Scheme 3.11 
THF which was used in previous reactions (see Schemes 3.7, 3.8 and 3.9) gave no 
conversion to any products. Consequently, due to the lack of solubility of the sodium 
ethoxide in solution ethanol was used in its place, see Scheme 3.12. 
X 
F~N 
~~F + ElQ\Ja 
X ratioA:B 
NHB 6:1 
NHA-i 5:1 
l'vbrpholine 6: 1 
F~N + 
--~~F 
F~N 
~~CB 
A B 
19FNMRppn 
-49.33' -186.07 
%of isorrer 6 isolated 
-49.97, -179.31 
-49.59 -172.81 
Scheme 3.12 
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Unlike the reaction with sodium phenoxide, a mixture of isomers formed with the 
predominate formation of the 6-substituted isomer with a general ratio of 6:1. As sodium 
ethoxide is a harder nucleophile then phenoxide it would be expected that there would be 
some substitution of the fluorine atom at the 2-position as it is a hard site due to the two. 
ortho nitrogens withdrawing electron density from the carbon. However due to the 
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stabilisation of the negative charge in the transition state onto the para nitrogen being the 
dominant effect the nucleophile is mainly orientated towards the 6-position. 
Also, ethoxide in ethanol as a solvent makes the nucleophile 'bigger' due to solvation and 
as the 2-position is less sterically demanding and there is some substitution of the fluorine 
atom (this also agrees with what was observed for the reactivity with HNR1R2 
nucleophiles). 
It must also be noted that as ethanol is a polar protic solvent and THF is a polar aprotic 
solvent direct comparisons between this nucleophile's reactivity and others in this series 
can not be made. 
Represented in Figure 3.2 is the x-ray structure of compound 308 which confirms the 
formation of this compound. 
Figure 3.2 The x-ray crystallography structure of compound 308 
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These results have demonstrated that it is possible to synthesise a selection of nitrogen and 
oxygen disubstituted pyrimidines and has significantly expanded the methodology of the 
second step which in terms of library synthesis is an ideal situation. 
3.5.3 Reactions of 4-Substituted Perfluoropyrimidines with Sulfur Nucleophiles 
The last part of this research was to study the reactions of compounds 292, 295 and 139 
with aliphatic and aromatic sulfur-containing nucleophiles. The site of attack is analogous 
to the oxygen-substituted systems as substitution of the fluorine at the 6-position is readily 
seen by the appearance of two distinct peaks in the 19F NMR when the reaction is 
performed in THF at room temperature. There was no substitution of the fluorine at the less 
activated 2-positon. 
THF, rt 
+ RsSI\Ia ----
X As 19F NNR I=P11 
NHEt B -56.67,-167.93 
NHEt A1 --48.55 ' -159.3) 
NHA1 B --48.50, -158.50 
NHA1 A1 -47.3), -157.10 
rvbrpholine A1 -49.10, -149.21 
Scheme 3.13 
o/o 
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51 
68 
71 
88 
310 
311 
312 
313 
314 
Furthermore, the regiochemistry of attack at the 6-position was confirmed by growing a 
single crystal of compound 312 from MeOH which was then subjected to x-ray analysis to 
confirm this structure. 
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Figure 3.3 The x-ray crystallography structure of compound 312 
At the start of this section the question of what would happen if a series of mono 
substituted amine derivatives were reacted with a second nucleophile was raised. Through 
reaction with nitrogen, oxygen and sulfur-centred nucleophiles it has been demonstrated in 
most cases that primary amines and soft nucleophiles react at the 6-position exclusively. 
Consequently, in two steps from tetrafluoropyrimidine, a sequential build up of 
functionality around the pyrimidine core was achieved to furnish a selection of novel 
disubstituted pyrimidine derivatives. 
3.6 Reactions of N-Ethyl-2,5-difluoro-6-(phenyloxy)-4-pyrimidinamine 304 with Mono 
Nucleophiles 
Following on from section 3.8 it was hoped that further nucleophilic aromatic displacement 
of the difluorinated derivatives to form a trisubstituted pyrimidine would be possible. 
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3.6.1 Reactions of N-Ethyl-2,5-difluoro-6-(phenyloxy)-4-pyrimidinamine 304 with 
Nitrogen Nucleophiles 
It must be noted that an exploration of the reactivity of disubstituted pyrimidines with 
nucleophiles was initially conducted by refluxing the components in THF but there was no 
conversion to any products even after varying the concentrations of the reactants and 
prolonged heating over several days. This lack of reactivity and the need for more forcing 
conditions to effect the substitution is due to the presence of the deactivating amine groups. 
It was therefore decided to employ microwave techniques in an attempt to synthesise the 
desired compounds which is a very useful technique due to the ability to optimise reactions 
quickly through screening a number of reaction conditions. In recent years the use of 
microwaves for chemical synthesis has become increasingly popular and there are many 
papers and books outlining such research.5 This proved very successful in synthesising a 
number of compounds as demonstrated in the proceeding sections. 
The next few sections will detail the reactions of compound 304 with various nucleophiles 
and how in certain cases a selection of novel trisubstituted pyrimidines were synthesised. 
The system chosen for the initial study was compound 304 as it was relatively easy to 
synthesise in large quantities. Firstly, compound 304 was reacted with an excess of 
piperidine under the reaction conditions shown below which resulted in substitution of the 
fluorine at the 2-position with a single peak at -191 ppm corresponding to compound 315. 
However, a second peak was also observed at -182 ppm which showed that replacement of 
the phenoxide group at the 6-position had occurred. The ratio of compound 315, to that of 
the his-substituted compound was 6:1 (see Scheme 3.14). 
19F NMR and mass spectrometry analysis of the reaction mixture showed that fluorine was 
displaced by piperidine exclusively before substitution of the phenoxy group occurred 
which reflects the electrophilicity of the C-F site at the 2-position. The structure of 
compound 315 was confirmed by x-ray analysis. 
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Scheme 3.14 
Figure 3.4 The x-ray crystallography structure of compound 315 
Reaction with an excess of ethylamine under the reaction conditions shown below resulted 
in substitution of the fluorine at the 2-position with a single peak observed at -190 ppm 
corresponding to compound 316. 
76 
NHEt 
F01 "'N 2 H2NEt )LA+ 
PhO N F 
NHEt 
THF, mw 140 0C F~N 
JLA 1 h PhO N NHEt 
304 316, 63% 
Scheme 3.15 
The structure of compound 316 was confirmed by x-ray analysis. 
Figure 3.5 The x-ray crystallography structure of compound 316 
These results indicate the 6-position is still activated towards nucleophilic attack and, 
furthermore, phenoxide is a good leaving group. However, reducing the time of the reaction 
led exclusively to the mono substituted product in the case of the piperidine nucleophile. 
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3.6.2 Reactions of Compound N-Ethyl-2,5-difluoro-6-(phenyloxy)-4-pyrimidinamine 
304 with Oxygen Nucleophiles 
Reaction of compound 304 with sodium ethoxide resulted in the formation of two products 
in a 1.5:1 ratio with the major product 317 corresponding to replacement of both the 6-
phenoxide group and the fluorine at the 2-position. The minor compound 318 resulted from 
replacement of the fluorine at the 2-position only. 
NHEt 
F0N 
JL.~ PhO N F + EtONa 
NHEt NHEt 
THF,mw140°C F+N + FI:N 
15 min EtOJLN ~~OEt I ~' PhO N~OEt 
1.5 
304. 317,16% 318, 13% 
Scheme 3.16 
All attempts to reduce the formation of the his-substituted compound by screening multiple 
reaction conditions such as varying the reaction times, solvents and concentrations of the 
reagents gave the same result and it was not possible to form only compound 318. 
However, purification of the two compounds was achieved through reverse phase 
chromatography allowing each compound to be characterised. 
Furthermore, structures of both compounds 317 and 318 were confirmed by growing single 
crystals from MeOH and subjecting them to x-ray analysis 
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Figure 3.6 The x-ray crystallography structures of compounds 317 and 318 
This result reflects that the phenoxide is a good leaving group and, when attached to an 
activated site, can be displaced in competition with fluoride at the 2-position. 
79 
3.6.3 Conclusion 
This research has demonstrated that the phenoxide group at the 6-positon is a good leaving 
group and can be displaced by reaction with nucleophiles. It has also shown that it is 
possible to functionalise the pyrimidine scaffold by reaction with a third nucleophile to give 
trifuctionalised pyrimidine systems. 
lHF, mN 
304 
Scheme 3.17 
3.7 Reactions of 2,5-Difluoro-4-morpholino-6-phenoxypyrimidine 306 with Mono 
Nucleophiles 
Following on from section 3.9 it was decided to explore the reactivity of the morpholine 
compound 306 with nitrogen, oxygen and sulfur nucleophiles to further extend the 
investigation of the methodology. This was to determine whether replacement of the 
phenoxide group would also occur. 
3.7.1 Reactions of 2,5-Difluoro-4-morpholino-6-phenoxypyrimidine with Nitrogen 
Nucleophiles 
Compound 306 was firstly reacted with the primary amine butylamine in an analogous 
manner to the reaction conditions for compound 304 detailed in section 3.9 which resulted 
in the selective replacement of the fluorine atom at the 2-position to form compound 319 
with a single peak observed at -179.4 ppm. Recrystallisation from n-hexane gave the 
compound in fair yield and purity which were then analysed using the standard analytical 
techniques (see Chapter 6). 
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Scheme 3.18 
319,50% 
A single crystal was grown from MeOH and subjected to x-ray analysis which confirmed 
the structure of compound 319. 
01 
Figure 3.7 The x-ray crystallography structure of compound 319 
Compound 306 was then reacted with an excess of the secondary amine piperidine. This 
resulted in replacement of the fluorine at the 2-position with a single peak observed at -
180.0 ppm corresponding to compound 320. 
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320,90% 
Scheme 3.19 
A single crystal was grown from MeOH and subjected to x-ray analysis. Although the 
structure was not fully resolved it gives clear evidence for the formation of the 
trisubstituted pyrimidine system of compound 320. 
Figure 3.8 The x-ray crystallography structure of compound 320 
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These reactions, when compared those of compound 304, showed that the methodology can 
be replicated to give more examples of trifunctionalised pyrimidines analogues. Less 
reactive nitrogen nucleophiles give rise to products from displacement of the fluorine only 
whereas more reactive nitrogen nucleophiles can give mixtures under forcing conditions. 
3.7.2 Reactions of 2,5-Difluoro-4-morpholino-6-phenoxypyrimidine 306 with Oxygen 
Nucleophiles 
Reaction of compound 306 with sodium ethoxide results in the formation of two products 
in a 7:1 ratio with the major product being that of compound 321, and the minor product 
compound 322, which is the result of 6-phenoxide group and the fluorine at the 2-position 
being replaced with the ethoxy group. 
1.5 NaCEt 
7 1 
306 
321, 25°/o 322 
Scheme 3.20 
Attempting to control the reaction to form only compound 321, by suppressmg the 
formation of the his-substituted compound 322, through screening reaction conditions such 
as varying the reaction times, solvents and concentrations failed to give the desired 
trifunctionalised pyrimidine as a single product and in all instances both compounds were 
observed. 
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3.7.3 Reaction of 2,5-Difluoro-4-morpholino-6-phenoxypyrimidine 306 with Sulfur 
Nucleophiles 
Subsequently, reaction of compound 306 with sulfur-centred nucleophiles was attempted 
and proved more problematic, in that a wide range of products were observed using either 
sodium ethanethiolate and benzene thiophenoxide. 
Reaction of compound 306 with sodium ethanethiolate led to the formation of two 
compounds 323 and 324 which could be seen from the 19F NMR with two peaks occurring 
at -171.8 and -173.5 ppm. 
EtSNa 
306 
C) 
THF, rrw, 1400C F0N + 
15nin ~~SEt 
Scheme 3.21 
1 
323 
1.4 
Reaction with the sodium benzene thiolate ion gave three main products including 
compounds 325, 326 and 327 which could be seen from the 19F NMR with three peaks 
occurring at -170.9,-148.3 and -180.2 ppm. 
C) C) C) 
N lHF rrw 140°C~-..:N JC-..:N +A1SNa ' ' I + I ~ F 15 rrin ~SPh ~SPh 
306 2 
325 
Scheme 3.22 
1 
326 
C) 
+~~ 
84 
Isolation of compounds from the mixture was attempted but met with little success. 
In conclusion, this result demonstrates again that if a sufficiently reactive nucleophile is 
used displacement of the phenoxide group at the 6-positon can occur similar to what was 
observed when compound 306 was reacted with the ethoxide nucleophile (see Scheme 3.2). 
3.8 Reactions of ~-Ethyl-2,5-difluoro-~ -phenylpyrimidine-4,6-diamine 300, with 
Mono Nucleophiles 
In section 3.9 it was demonstrated that when compound 304 was reacted with a selection of 
nitrogen, and oxygen-centred nucleophiles, a range of trifunctionalised pyrimidines could 
be synthesised. When compound 306 is reacted with amine nucleophiles, functionalisation 
of the pyrimidine is achieved if the conditions are carefully controlled, whereas reaction 
with alkoxides and sulfur nucleophiles led to mixtures of compounds and the occurrence of 
which was explained in terms of the labile nature of the phenoxide group (see sections 3.7.2 
and 3.7.3). 
It was, therefore, envisioned that using amines in this second step would result in a less 
labile group attached to the 6-position and lead to a set of trifunctionalised pyrimidines that 
could be easily obtained and purified. The system chosen for this study was compound 300 
which was readily synthesised in large quantities. It was anticipated that remaining fluorine 
atoms would be amenable for functionalisation by replacement with nitrogen, and oxygen-
centred nucleophiles. 
300 
lHF, llW 
Nl£:3 = piperidne, NaCFh, 
Scheme 3.23 
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3.8.1 Reaction of ~ -Ethyl-2,5-difluoro-Ni -phenylpyrimidine-4,6-diamine 300 with 
Nitrogen Nucleophiles 
Compound 300 was reacted with amines using similar reaction conditions to those 
described previously in section 3.6.1 for compound 304. 
Reaction with piperidine resulted in the formation of compound 328 with no replacement of 
either the ethylamine or aniline group. This is easily seen from the 19F NMR peak at 
-191.96 ppm and m/z (ES+) 316 ([M + Ht). Purification was readily achieved by 
recrystallisation from DCM:n-hexane mixtures. 
DIPEA 
~ 
F~N 
Et~~F + 0 H 
1HF, rTW 
300 328,56% 
Scheme 3.24 
3.8.2 Reaction of ~-Ethyl-2,5-difluoro-Ni-phenylpyrimidine-4,6-diamine 300 with 
Oxygen Nucleophiles 
Reaction of compound 300 with sodium phenoxide resulted in replacement of the fluorine 
atom at the 2-position but no replacement of the either the aniline or ethylamine groups 
reflecting the less labile nature of the ethylamine to that of the phenoxy group. 
1HF,rrw 
300 329, 59°/o 
Scheme 3.25 
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3.9 Conclusion 
The reaction of tetrafluoropyrimidine, 113 with mono nucleophiles demonstrates that 
nitrogen nucleophiles are ideal for the synthesis of mono substituted derivatives over that of 
reaction with oxygen or sulfur nucleophiles. The latter led to disubstituted compounds 
preferentially (see Figure 3.9 for the compounds that were synthesised). 
After reaction with: 
Primary Nitrogen nuc/eophiles 
NEt2 (0) FX:N N 
F I N~F FX:N 
F I N~F 294 
Secondary nitrogen nucleophiles 
295 
OPh SEt FX:N FX:N 
PhO I N~F EtS I N~F Oxygen and Sulfur nuc/eophiles 
296 297 
Figure 3.9. Monofunctionalised pyrimidines synthesised from tetrafluoropyrimidine, 113. 
However, this methodology does have several limitations in that during the second step 
reaction with secondary arnines and ethoxide ions gives regioisomers by competing 
replacement of the fluorine atom at both the 6- and 2-position. This is not too problematic 
because isolation of the desired 6-substuted isomers is readily achieved. 
Similarly, the third step has limitations in that reaction with nucleophiles can lead to 
replacement of a good leaving group such as the phenoxide group at the 6-position if 
forcing conditions or reactive nucleophiles are used. If a less labile group such as 
ethylamine is used this issue can be overcome and a number of compounds synthesised. 
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317 NHB J:318 NHB ~N F. "N sdl~CB I ~CB 
Figure 3.10. Difunctionalised and trifunctionalised pyrimidines synthesised from 
tetrafluoropyrimidine, 113. 
Overall this study has shown that it is possible to form a selection of highly functionalised 
pyrimidine scaffolds by a series of high-yielding nucleophilic aromatic substitution 
processes. The methodology has shown that mono-, di- and trisubstituted pyrimidines can 
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be synthesised with the orientation of nucleophilic attack shown to occur in the general 
order of 4- > 6- > 2- which is consistent with a previous study involving substitution using 
an excess of sodium methoxide (see Figure 3.10 for an outline of the scaffolds synthesised). 
This research has demonstrated that a rapid and easily controlled methodology for the 
synthesis of mono-, di- and tri- substituted pyrimidines is readily achievable and that such a 
scheme may have applicability for designing libraries of compounds amenable for 
biological testing and thus drug discovery. 
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Chapter 4 
Attempted [5,6] Pyrimidine Ring-Fused Heterocycle Syntheses from 
Tetrafluoropyrimidine 
4 Introduction 
As demonstrated in Chapter 1, annulation processes to form pyrimidine ring-fused systems 
are important within the life-science industries which is demonstrated by the wide range of 
drug compounds that contain these systems. However, methodologies to achieve their 
syntheses can be difficult in practice. In Chapter 2 it was outlined how reaction of 5-
chlorotrifluoropyrimidine with a selection of dinucleophiles resulted in no annulation 
products and was thought to be the result of the chlorine at the 5-position being unreactive 
to nucleophilic aromatic substitution processes and cross-coupling methodologies. 
Therefore, our next approach was to replace the chlorine with a fluorine to try to improve 
the reactivity of the system and thus develop a new methodology for the synthesis of a 
range of [6,6] and [5,6] ring-fused based pyrimidine heterocycles from 
tetrafluoropyrimidine. 
4.1 Aims and Approach 
Our approach was to react tetrafluoropyrimidine 113 with a selection of dinucleophiles with 
the aim of synthesising a selection of diverse heteroaromatic compounds through 
nucleophilic aromatic substitution annulation processes in a short and efficient manner. In 
turn the remaining fluorine atoms that are left on the pyrimidine ring have the potential for 
further reaction with other selections of nucleophiles to give novel classes of compounds as 
outlined in the general scheme below. 
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F ~ F~N ~~N ~~F . ~~F 
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113 
1\ 
MeHN NHMe 
N..Jca, N.Jc4 = N, 0 and S centred nucleophiles 
Scheme 4.1 
0·0 
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Precedent for this methodology has been extensively demonstrated using 
pentafluoropyridine in the Durham group (see Chapter 2). 
4.2 Tetrafluoropyrimidine as a Scaffold 
Within the literature there are no examples of the reaction of tetrafluoropyrimidine with 
dinucleophiles. Reactions of tetrafluoropyrimidine and dinucleophiles were performed in 
basic conditions to neutralise any acidic by-products and using a large volume of polar 
solvent to promote the intramolecular cyclisation rather than intermolecular reaction. All 
the reactions were monitored using 19F NMR as a probe to follow the progress of the 
reactions. 
4.2.1 Reaction of Tetrafluoropyrimidine with Difunctional Amine Nucleophiles 
Benzamidine was reacted with compound 113 in an attempt to synthesise a purine analogue 
via a ring-fusion process which as discussed in Chapter 1, is a highly desirable target. 
Reaction at room temperature in the presence of sodium bicarbonate over 65 hours gave 
substitution at the activated 4-position shown in 19F NMR by way of three peaks 
corresponding to compound 330 (-48.6, -84.6 and, -166.7 ppm). There was no evidence for 
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the cyclised compounds either through NMR or mass spectrometry analysis. Compound 
330 was isolated by recrystallisation from ethyl acetate and was fully characterised. 
F FX: Ph I ~ N + A MeCN, 4 eq. NaHC03 
F NAF HN NH2 rt, 65 h 
113 330,50% 
Scheme 4.2 
Single crystal x-ray analysis confirmed the structure of compound 330 with partial co-
crystallistion observed with water when the sample was recrystallised from ethyl acetate. 
F21 
Figure 4.1 The x-ray crystallography structure of compound 330 
Numerous attempts to induce annulation failed even when using a selection of strong bases, 
including n-BuLi and LDA and starting material was recovered in all cases. 
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330 291 
Scheme 4.3 
The next dinucleophile to be screened was N,N'-dimethyl-ethylene-1,2-diamine with the 
aim to create a [6,6] fused-ring system. The reaction was performed at room temperature in 
the presence of sodium bicarbonate but the product that was formed was compound 331, 
which was purified by recrystallisation from ethyl acetate. The reaction was monitored 
using 19F NMR with three new resonances appearing at -48.80, -87.72 and -174.15 ppm 
and with a molecular ion observed at mlz 268. 
113 
1\ 
-NH HN- 4x~ 
l\leO\I 
Scheme 4.4 
F. F (}-I 'N-{~ NM_ N\.._/ kN 
F F F F 
331,45% 
Subsequently a single crystal amenable for x-ray analysis was grown from MeOH which 
was used to confirm the structure of the dipyrimidine compound. 
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Figure 4.2 The x-ray crystallography structure of compound 331 
This result shows that even when high dilution is employed to minimise the intermolecular 
reaction the compound prefers to react at the activated 4-position rather then at the 
considerably less activated 5-position to give the annulated product. At no stage was any 
ring-fused product detected in either the reaction mixture or the isolated crude product. 
The next stage involved screening 2-iminopiperidine hydrochloride and 2-amino-3-picoline 
with the aim to synthesise the associated annulated systems 332 and 333, however in both 
cases a mixture of oligomers was formed under all reaction conditions such as varying the 
solvent, and concentrations of reactants. No products could be isolated from any of the 
reactions attempted. 
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Scheme 4.5 
Reaction of compound 113 with amine dinucleophiles results only in nucleophilic aromatic 
substitution at the activated 4-position and indicates the intermolecular reaction is very 
strongly favoured over the desired intramolecular reaction. 
4.3 Conclusion 
The reactions outlined in this Chapter have shown that compound 113, is a poor candidate 
for the construction of ring-fused systems by reaction with dinucleophiles. This probably 
arises owing to the 5-position being very unreactive towards nucleophilic aromatic 
substitution. This result is similar to that observed for the 5-chlorotrifluoropyrimidine 
system (Chapter 2) and demonstrates that both fluorine and chlorine and the 5-position are 
unlikely to undergo any nucleophilic aromatic substitution processes and that it is not 
possible to form annulated products from these precursors. 
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Chapter 5 
Pyrazine Ring-Fused Heterocycle Synthesis from 
Tetrafluoropyrazine 
5.1 Introduction 
In Chapter 1 it was outlined how ring-fused heterocyclic systems are important within the 
life-science industries but that applications to syntheses of libraries of compounds that are 
amenable for biological testing can be difficult. Methodologies that can overcome such 
problems are of great interest to drug discovery and there is a drive towards the 
development of novel methods for the construction of multifunctional ring-fused 
compounds. 
In Chapter 1 it was demonstrated that heterocycles containing the pyrazine motif are 
important, however there is still a large requirement to create unique pyrazine derived ring-
fused entities and the following study aims to approach this need through the utilisation of 
tetrafluoropyrazine as the starting material and achieve functionalisation by reaction with a 
selection of dinucleophiles and nucleophiles. 
5.1.1 Aims and Approach 
In Chapters 2 and 4 it was envisioned that purine analogues could be synthesised from 
perfluorinated pyrimidine precursors by reaction with suitable dinucleophiles. However, in 
practice, the chlorine and fluorine present in compounds 112 and 113 proved inert to 
nucleophilic aromatic substitution (as well as cross coupling methodologies for compound 
112). It was, therefore, decided to investigate the reactivity of compound 116 with 
dinucleophiles in an attempt to synthesise a set of novel ring-fused pyrazine compounds. In 
tetrafluoropyrazine, all the fluorine atoms are located ortho to ring nitrogens and therefore, 
should be susceptible towards nucleophilic attack. 
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As discussed in Chapter 3 the reactions were performed utilising basic conditions to 
neutralise any acidic by-products and using a large volume of polar solvent to stabilise the 
charged transition state and to promote the intramolecular cyclisation rather than 
intermolecular reaction. 
It was previously noted (Chapter 1, section 1.3.7) that tetrafluoropyrazine has no activating 
nitrogen para to a fluorine atom which can be seen clearly when its reactivity is compared 
to that of reactivity of tetrafluoropyrimidine and suggests longer reaction times are likely. 
Correspondingly, the resulting annulated products would have the possibility for further 
derivatisation through reaction with nucleophiles due to the remaining fluorine atoms and 
thus open up the possibility for libraries of novel pyrazines that have potential for further 
development amenable to screening purposes. 
5.1.2 Background 
As noted in Chapter 1, the development of functionalised pyrazines is important, but few 
methodologies for their syntheses exist within the literature. Some of these methodologies 
have been shown utilise either chloropyrazines or diamino precursors that are 
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functionalised through reaction with electrophiles (see Chapter 1, section 1.1.13). 
The synthesis of [5,6]-ring fused pyrazines is poorly represented within the literature with 
only a few methods, some of which are outlined below. In the following example a range of 
tricyclic pyrazines were synthesised from compound 334 upon reaction with a selection of 
substituted 2-amino pyridines which led to a set of unique fused-pyrazine compounds. 1 
dioxane 15-91% 
R = H, 3-, 4-, 5-, 6-l've, 4,6-~, 3-CEz, 5-0, 5-Br 
Scheme 5.2 
A selection of compounds have been synthesised from compound 334 and this again 
demonstrates the high reactivity of the electron deficient heterocycle with various 
nucleophiles. 
R 
:X»~ 
334 0\1 
70-96% 
Scheme 5.3 
The Durham group has studied the reactivity of compound 116 with a short series of 
dinucleophiles in order to synthesise novel [5,6] and [6,6] fused-ring compounds as shown 
in Chapter 1, section 1.3.8. Here we expand this work to other [5,6] fused-ring systems 
using N,N dinucleophiles. 
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5.2 Reaction of Tetrafluoropyrazine with 2-Amino Pyridine Nucleophiles 
Reaction of pentafluoropyridine with substituted 2-aminopyridines has been demonstrated 
by the Durham group to give a series of novel tricyclic dipyridoimidazoles 335, 336, and 
337 (see Scheme 5.4). 
:o-H 7 ~ Me 
·!:( I ..-:: 
F N F 
10%,335 
srUMe 
I ..-:: F 
N NH2 
·n· I ..-:: 
3 eq NEt3, THF/DMSO, F N F 
mw, 150, °C, 2 h 107 
4 eq NaHC03, 
MeCN 
reflux, 96 h 
Q 
·fi 
F N F 
25%,337 
Scheme 5.4 
MeD Q-Me 
2.2 1 ..-:: '\ 
H2N N FtiN I ..-:: 
MeCN, 4 eq NaHC03, F N F 
Reflux, 70 h 82%,336 
By a similar procedure, tetrafluoropyrazine, 116 was reacted with 2-aminopicoline resulting 
in the formation of compound, 338. The progress of this reaction was followed with 19F 
NMR and showed the formation of two new peaks at -89.52 and -98.62 ppm with 83% 
conversion after 5 days at reflux. Purification was achieved by successive recrystallisations 
from ethyl acetate to remove excess dinucleophile which contributed to the low isolated 
yield that was observed. 
)c:X: + ~)C) ;:, 
116 3()0/o, 338 
Scheme 5.5 
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Confirmation of the structure was shown through x-ray crystallography studies by growing 
a single crystal from MeOH. 
Figure 5.1 The x-ray crystallography structure of compound 338 
Repeating the reaction under microwave conditions for 15 minutes in MeCN at 150 °C gave 
an improved conversion of 87% and also led to a higher isolated yield when recrystallised 
from ethyl acetate. 
F-;x;cNF +)? I ..-:: I ..-:: 
F H.2 
116 
MN, 150°C, 15nin 
WeCN,2NB3 
Scheme 5.6 
SSO/o, 338 
It was decided to react compound 116 with a range of aromatic dinucleophiles to assess the 
scope of this methodology. 
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The screening of potential dinucleophiles (Figure 5.2) under microwave conditions was 
useful to give an indication as to whether they are useful in synthesising unique scaffolds 
and allows for a significant saving of time compared conventional heating methods (see 
Chapter 3, Section 3.6.1). 
Each reaction was performed under the same conditions by heating tetrafluoropyrazine with 
a dinucleophile in the microwave at 150 °C for 5 minutes in acetonitrile and monitored 
using 19F NMR. In all cases no reaction was observed except for the case of 2-amino 
pyridine which gave conversion to the tricyclic product with two peaks in the 19F NMR 
appearing at -89.5, and -99.2 ppm. 
CCN }--Nii! N 
H 
Figure 5.2. 
Repeating the reaction on a larger scale and for a longer reactions time of 1.5 h resulted in 
nearly 100% conversion to product which was readily isolated through recrystallisation 
from ethyl acetate. 
MW, 150 °C, 90 rrin 
THFIDMSO ,2 NB3 
Scheme 5.7 
5.3 Reaction of Compound 116 with Amidine Nucleophiles 
Pentafluoropyridine is reacted to give purine type analogues.2 
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Scheme 5.8 
With this in mind compound 116 was allowed to react with 2-iminopiperidine 
hydrochloride at reflux for 105 h. A 19F NMR spectrum of the reaction mixture showed two 
peaks at -98.41 and -100.38 ppm that correspond to the annulated product. Purification was 
achieved through recrystallisation from DCM to give the product in good yield. 
::x:x: + C).N-1 MeCN. reflux H Nat-0:>a 
116 79D/o, 341 
Scheme 5.9 
Following on from this reaction, compound 116 was reacted with benzamidine at reflux 
which showed nucleophilic substitution of one fluorine atom by 19F NMR spectrum had the 
presence of three distinct peaks at -87.29, -97.78, and -105.02 ppm. No cyclised product 
was observed by 19F NMR and mass spectrometry studies. 
:::(x>~~~= 
116 
Scheme 5.10 
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This compound was then subjected to the same reaction conditions as for 
pentafluoropyridine:2 where LDA was used to induce the cyclisation process . However, all 
attempts to induce cyclisation of compound 342 did not succeed as observed by LCMS or 
19F NMR analysis. 
We observed a similar result when the same reaction was undertaken with the 
tetrachloropyrazine derivative in that initial reaction with benzamidine led to the mono 
substituted product but when cyclisation was attempted with a selection of strong bases 
there was no resulting annulated product. 
A1 
a:n:::c 
A1i(NJ-b LDAorBuU ~N A1 lHF ~N + JNI-b a):}N ;:<:; • ~ ~~a a a lHF 
115 .HCI a a a 
?'E)O/~ 344 345 
Scheme 5.11 
5.4 Reaction of Compound 116 with an N,N-Dinucleophile. 
We decided to take compound 116 and allow it to react with N1 ,N2-dimethylethane-1,2-
diamine to synthesise a seven-membered ring to form a novel [6,7] ring-fused pyrazine. 
Reaction with the diamine performed under microwave conditions led to high conversions 
with 19F NMR showing the presence of a single fluorine peak at -115.73 ppm (C-2). 
Subsequently the compound was purified by passing the mixture through silica gel which 
yielded the compound as a low melting orange solid. 
H H 
/N~N, WMI, 150 OC, 5 nin 
~.2NB3 
Scheme 5.13 
))) 
I 
€)70/o, 346 
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Thus, from the analytical data it has been shown that reaction of compound 112 with N,N-
dinucleophiles allows the synthesis of [6,7]-fused ring systems. 
5.5 Reaction of Tetrafluoropyrazine with C,O Dinucleophiles 
Previously the Durham group has also investigated the reaction of compound 112 with the 
ethylacetoacetate which resulted in the formation of two products with the uncyclised 
product being the major product.3 
F'lfNYF 0 0 THF )l ~ + ~OEt--~~--~ 
F N F NaH 
Fl['N~O,Et Fl['N~ ':t_Q 
F)lNJ-.;- + F)lNXF 'tt 
116 1 2 
23% 273 274 
Scheme 5.14 
Repeating the reaction with a longer reaction time gave only compound 273 which was 
easily purified by column chromatography to provide the cyclised product in moderate 
yield. 
116 
2 0 0 
+ )l_jlCB 11-IF, 23 h, reflux 2NaH 
Scheme 5.15 
sac'/o, 273 
A single crystal of the compound was grown from MeOH and subjected to x-ray analysis to 
confirm the structure. 
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Figure 5.3 The x-ray crystallography structure of compound 273 
Subsequently, a 1,3-dicarbonyl derivative bearing an amide group was reacted with 
compound 116 and led to the formation of a single compound by 19F NMR with a single 
peak appearing at -91.90 ppm. Purification was achieved by column chromatography to 
give the product in moderate yield. 
0 0 2A)( 
NB2 
Scheme 5.16 
A single crystal was also grown from MeOH and subjected to x-ray analysis which 
confirmed the structure. 
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Figure 5.4 The x-ray crystallography structure of compound 347 
5.6 Further Functionalisation of Heterocyclic Cores 
Further functionalisation of the imidazo[4,5-b]pyrazine is a desirable aim as it will help to 
determine fundamental chemical principles pertaining to the selectivity of nucleophilic 
attack on the system. 
5.6.1 Reactions of lmidazo[ 4,5-b ]pyrazines with Nitrogen Mono Nucleophiles 
Thus, compound 341 was reacted with diethylamine which led to the selective substitution 
of the fluorine atom para to the N=C in high yield and 100% conversion with a single peak 
in the 19F NMR at -84.4 ppm. 
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6 HNB:2 _refl_l'vleCN_7:_3_h_ 
ux, 
Scheme 5.19 
Confirmation of this structure was determined by x-ray crystallography by growing a single 
crystal from MeOH. 
Figure S.S The x-ray crystallography structure of compound 348 
Compound 341 was reacted with sodium phenoxide and this also resulted in the 
nucleophilic substitution of the fluorine atom that was para to that of the N=C bond. 
Confirmation of this structure can be seen from the 19F NMR studies which showed a single 
peak at -93.08 ppm. 
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Na<Fh 
reflux, 73 h 
341 54o/q349 
Scheme 5.20 
Mechanistically the reason for the orientation of nucleophilic substitution in both of the 
above examples can be attributed to the Meisenheimer model of the transition state which 
shows delocalisation of the intermediate negative charge around the [5,6] ring-fused system 
is more stabilising than if the incoming nucleophile is meta to the N=C bond. 
Figure 5.6 
Nucleophilic attack meta to the N=C bond does not allow for delocalisation of the 
intermediate charge around the full ring system making attack unfavourable. 
Figure 5.7 
In order to demonstrate the utility of compound 338 as a scaffold it was reacted with 
diethylamine which resulted in a mixture of isomers of compound 350 and 351 in a 1:1 
ratio. Both isomers could be clearly differentiated by the 19F NMR spectrum which 
contained two individual peaks at -75.20 ppm for compound 350 and -84.35 ppm for 
compound 351. Each compound also gave individual peaks in mass spectrometry with a 
mass at rn/z = 273. 
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Separation of the isomers through chromatographic and recrystallisation methods proved to 
be unsuccessful. Final separation of the isomers was achieved through the use of mass 
directed automated purification which utilises reverse phase chromatography and a mass 
ion detector to collect the desired isomers. Crystallisation from MeOH provided a crystal 
that was subjected to x-ray analysis to confirm compound 350. 
B,)):~q 45%,350 
)):~q l\leO\I + 2HNB2 reflux, 73 h + 
338 )):~q VOla, 351 
B2 N 
Scheme 5.22 
Figure 5.8 The x-ray crystallography structure of compound 350 
Similarly reaction of compound 339 with diethylamine also resulted in the formation of two 
isomers in a 1:1 ratio. Both isomers could be clearly differentiated by the 19F NMR 
spectrum which contained two individual peaks at -75.20 ppm for compound 352 and -
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84.35 ppm for compound 353. The mass spectrum of the crude reaction mixture showed 
two separate compounds with the same mass of 273 which also confirmed the presence of 
two distinct isomers. Separation of the isomers was achieved through the use of mass 
directed automated purification. Again a single crystal grown from MeOH was subjected to 
x-ray analysis to give further proof compound 352. 
B,):XP 3f30/o, 352 
::r:xP f\feCN + 21-1NB2 reflux, 73h + 
339 )c):~O 3E)O/o, 353 
B2 N 
Scheme 5.24 
N2 N3 
Figure 5.9 The x-ray crystallography structure of compound 352 
It was previously postulated that if the incoming nucleophile approaches para to the C=N 
bond delocalisation of the intermediate negative charge around the [5,6] ring-fused system 
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is more stabilising and thus approach to the meta position is disfavoured. These results have 
shown that this is not always true and could be due to each position being equivalent in 
compounds 338 and 339. 
Reaction of compound 338 with sodium ethoxide gave substitution of one fluorine atom as 
the only product. This may also indicate that the position attacked in such systems also 
depends upon the hard or soft nature of the incoming nucleophile. 
):):Q 
F N N 
338 
+ NaOEt THF, 3 DIPEA 
rt, 19 h 
Scheme 5.23 
EtO:JCxQ 
F N N 
354,58% 
5.6.2 Reaction of Furo[2,3-b]pyrazines with Nitrogen and Oxygen Mono Nucleophiles 
Compound 273 was reacted with a selection of mono nucleophiles. Reaction of compound 
273 gave products where substitution of the fluorine that was para to the C=C bond. This 
result can be rationalised using the same model as previously cited for compound 338 (see 
section 5.6.1) 
000/o, 355 
l\lk:lQ\la, f\lleCN, 
reflux, 16 h 
273 
Scheme 5.25 
Reaction of compound 347 with diethylamine gave the same selectivity of substitution 
which is para to the C=C bond. 
112 
~N_ '1---:_, _..:...:..::rvleCN:..::::.:....:. ~;er reflux, 21 h 
347 95%,351 
Scheme 5.26 
5. 7 Conclusion 
This chapter has demonstrated the utility of tetrafluoropyrazine for the synthesis of novel 
[5,6] and [6, 7] ring-fused pyrazine systems, demonstrated in Figure 5.10 below, when 
reacted with N,N and C,O dinucleophiles. 
(N,N Systems) 
F~(:c;J F~tx~O \ F)(X~~ F)(:() 
F N N F N N F N N F N N I 
338 339 341 346 
(c,o Systems) 
rl:EI rl:EI' F N F N )[: )[: 
F N 0 F N 0 
273 347 
Figure 5.10 A summary of the reaction of tetrafluoropyrazine, 116, with N,N and C,O 
dinucleophiles 
Moreover, the resulting annulated products have been shown to react with nucleophiles to 
furnish polyfunctional nitrogen, and oxygen-substituted heterocycles due to the remaining 
fluorine atoms that readily undergo nucleophilic aromatic substitution. 
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(N,N Systems) 
Et,N::I(xN;J 
F N N 
348 
Et,N:ICx~o 
F N N 
352 
(c,o Systems) 
F N:J:O Et 
'1~ 
MeO)lN...-:: 0 
355 
PhO::(xN;J 
F N N 
349 
Et,N)(X~;:z 
F N N 
350 
Figure 5.11 The reaction of Imidazo[4,5-b] and Furo[2,3-b]pyrazines with mono 
nucleophiles 
Thus, it has been demonstrated that starting from tetrafluoropyrazine, 116 and reacting with 
nucleophiles, can in a few short and high yielding steps, lead to a series of novel pyrazines. 
Such a methodology has the applicability to be used to synthesise libraries of molecules 
that have potential for further development and could have uses as therapeutic agents. 
114 
5.8 References 
2 
3 
T. Suzuki, Y. Nagae, and K. Mitsuhashi, J. Heterocycl. Chem., 1986, 23, 1419-
1421. 
M. Cartwright, 'Highly Functionalised Fused Heterocycle Synthesis from 
Fluoropyridines', Durham University, 2006. 
R. Slater, 'Polyfunctional Ring Fused Heterocyclic Compounds', Durham 
University, 2005. 
115 
Chapter 6 
Experimental for Chapter 2 
Technical Detail 
Ratios of products were calculated from 19F NMR spectra of reaction mixture unless 
otherwise stated. All starting materials were obtained commercially (Aldrich, Lancaster or 
Fluorochem) or from GlaxoSmithKline's chemical stores, Stevenage. DIPEA bound resins 
were obtained from Biotage. Microwave reactions were performed in a Biotage Initiator 60 
EXP with a power range of 0-400 W at 2.45 GHz. All solvents were dried using either 
literature procedures or via an Innovative Technology solvent purification system. Mass 
Directed Automated Preparative HPLC was carried out using Supleco LCABZ++ column 
and MicroMass MassLynx v4.0 software. Column chromatography was carried out on 
silica gel (Merck no. 109385, particle size 0.040-0.063 mm) or using a Biotage Horizon 
flash chromatography system and TLC analysis was performed on silica gel or aluminium 
oxide TLC plates. NMR spectra were recorded in deuteriocholoroform, unless otherwise 
stated on a Varian VXR 500S NMR spectrometer operating at 500 MHz eH NMR), 376 
MHz e9F NMR) and 125 MHz (13C NMR) with trichlorofluoromethane as an internal 
standard e9F NMR). Mass spectra were recorded on a Thermo Finnigan TRACE GCMS 
system and a Waters Micromass LCT spectrometer. Accurate mass measurements were 
determined on a Micromass Autospec Mass Spectrometer at the national spectrometry 
centre, Swansea. Elemental analyses were obtained on an Exeter Analytical CE-440 
elemental analyser. Melting points and boiling points were recorded at atmospheric 
pressure unless stated and are uncorrected. The progress of each reaction was monitored by 
either 19F NMR spectroscopy or LCMS analysis. All crystallographic data were collected at 
T = 120 K on a Broker SMART-CCD 6000 diffractometer (A.MoKa, ro-scan, 0.3 °/frame). 
The structures were solved by direct methods and refined by full-matrix least squares 
minimisation on F2 for all data using SHELXTL software. All non-hydrogen atoms were 
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refined with anisotropic displacement parameters, H-atoms were located on the difference 
map and refined isotropically. 
5-Chloro-2,6-difluoropyrimidin-4-amine, 121 
112 
l\lleCN, 0 <>c 
4h 
a:t~ 51 "N3 + 
e ~F 
1 
121 122 
A solution of 5-chloro-trifluoropyrimidine 112 (0.50 g, 6.1 mmol) and ammonia (0.5 M in 
dioxan, 1.49 cm3) in acetonitrile (50 cm3) was stirred at 0 °C for 4 h after which time 19F 
NMR spectroscopy indicated complete consumption of the starting material to 5-chloro-
2,6-difluoropyrimidin-4-amine 121 (-48.18 and -69.47 ppm) and 5-chloro-4,6-
difluoropyrimidin-2-amine 122 ( -65.44 ppm) in a 9:1 ratio by 19F NMR. The reaction 
solvent was evaporated in vacuo and the sample dissolved into water (40 cm3). The mixture 
was extracted with DCM (3 x 40 cm\ the organic extracts were combined, dried (MgS04) 
and evaporated in vacuo to give a crude product containing 5-chloro-2,6-difluoropyrimidin-
4-amine 121 and 5-chloro-4,6-difluoropyrimidin-2-amine 122 as a white solid (0.68 g). 
Recrystallisation from ethyl acetate yielded 5-chloro-2,6-difluoropyrimidin-4-amine 121 
(0.56 g, 57%) as white solid; mp 161-162 °C; Oc (d3-acetonitrile) 92.7 (dd, 2JcF 39, 4JcF 8, 
C-5), 159.4 (dd, 1JcF 235, 4JCF 23, C-2), 166.1 (dd, 1Jcp 260, 3Jcp 20, C-6), 165.2 (m, C-4); 
Op -46.72 (lF, s, C-6), -65.63 (lF, s, C-2); mlz (Ef) 165 ([Mt, 52%), 124(4), (ES+) 
(Found: [M+ Ht 165.9978 C4H2ClFzN3requires: [M+ Ht 165.9978) 
(5-Chloro-2,6-difluoro-pyrimidin-4-yl)-ethylamine, 276 
O+r + EIN-\, MaCN, O"C ~l'f F 2h 
112 
A solution of 5-chloro-trifluoropyrimidine 112 (0.50 g, 6.4 mmol), 2.0 M ethylamine in 
THF (2.99 cm3) in acetonitrile (50 cm3) was stirred at stirred at 0 °C for 2 h after which 
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time 19F NMR spectroscopy indicated complete consumption of the starting material to 5-
chloro-N-ethyl-2,6-difluoropyrimidin-4-amine 276 (-47.48 and -70.83 ppm) and 5-chloro-
N-ethyl-4,6-difluoropyrimidin-2-amine 277 ( -63.59 ppm) in an 8:1 ratio by 19F NMR. The 
reaction solvent was evaporated in vacuo and the sample dissolved into water (40 cm\ The 
mixture was extracted with DCM (3 x 40 cm\ the organic extracts were combined, dried 
(MgS04) and evaporated in vacuo to give a crude product containing 5-chloro-N-ethyl-2,6-
difluoropyrimidin-4-amine 276 and 5-chloro-N-ethyl-4,6-difluoropyrimidin-2-amine 277 as 
a yellow oil (0.54 g). Column chromatography (silica, DCM: n-hexane, 1:1) gave 5-chloro-
N-ethyl-2,6-difluoropyrimidin-4-amine 276 (0.36 g, 57%) as a white solid; mp 37-38 °C; 
(Found: C, 37.5; H, 3.2; N, 21.6 C6H6CIF2N3 requires: C, 37.2; H, 3.1; N, 21.7%); 8H 1.22 
(3H, t, 3JHH 7.2, CH3), 3.51 (2H, q, 3JHH 7.2, CH2); 8c 14.8 (s, CH3), 37.3 (s, CH2), 113.45 
(dd, 2JcF 38, 4JcF 8, C-5), 158.9 (dd, 1JcF 216, 3JcF 22, C-2), 162.7 (dd, 3JcF 24, 5JcF 6, C-4), 
165.0 (dd, 1JcF 263, 3JcF 24, C-6); 8F -46.14 (1F, s, C-6), -68.59 (lF, s, C-2); mlz (El+) 193 
([Mt, 44%), 178(62). 
5-Chloro-N,N -diethyl-2,6-dipyrimidin-4-amine, 278 
112 
~.ooc 
DIPEA, 2h 
A solution of 5-chloro-trifluoropyrimidine 112 (1.01 g, 6.0 mmol) and diethylamine (0.43 
g, 6.0 mmol), DIPEA (2.31 g, 8.9 mmol) in acetonitrile (100 cm3) was stirred at 0 °C for 2 
h after which time 19F NMR spectroscopy indicated complete consumption of the starting 
material to 5-chloro-N,N-diethyl-2,4-dipyrimidin-6-amine 278 (-47.81 and -64.26 ppm) and 
5-chloro-N,N-diethyl-2,4-dipyrimidin-6-amine 279 (-65.35 ppm) in a 5:1 ratio by 19FNMR. 
The reaction solvent was evaporated in vacuo and the sample dissolved into water (40 cm\ 
The mixture was extracted with DCM (3 x 40 cm3), the organic extracts were combined, 
dried (MgS04) and evaporated in vacuo to give a crude product containing 5-chloro-N,N-
diethyl-2,4-dipyrimidin-6-amine 278 and 5-chloro-N,N-diethyl-2,6-dipyrimidin-4-amine 
279 as a yellow oil (0.71 g). Column chromatography (silica, DCM: n-hexane, 1:2) gave 5-
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chloro-N,N-diethyl-2,6-dipyrimidin-4-amine 278 (0.63 g, 47%) as a colourless oil; 8H 1.25 
(6H, t, 3JHH 7.2, CH3), 3.68 (4H, q, 3JHH 7.2, CHz); 8c 13.9 (s, CH3), 45.2 (s, CHz), 92.5 (dd, 
2Jcp 22, 4Jcp 9, C-5), 158.5 (dd, 1JcF 190, 3Jcp 24, C-2), 161. 5 (dd, 3Jcp 13, 5JcF 5, C-4), 
168.0 (dd, 1JcF 233, 3Jcp 19, C-6); Op -47.81 (1F, s, C-6), -64.26 (1F, s, C-2); m/z (El+) 
221.0 ([Mt, 80%), 206(86), 192(88), 178(98), (ES+) (Found: [M+ Ht 222.0605 
CsHwClF2N3 requires: [M+ Ht 222.0604) 
N-Benzyl-5-chloro-2,6-difluoropyrimidin-4-amine, 260 
9 F F a;eN a;C;_F + v~ fv1eCN, ooc I~NH + l:lPEA XN3 \) 
6 ~F 112 1 
260 261 
A solution of 5-chloro-trifluoropyrimidine 112 (0.50 g, 3.0 mmol), benzylamine (0.32 g, 
3.0 mmol) and DIPEA (1.15 g, 8.9 mmol) in acetonitrile (50 cm3) was stirred at 0 °C for 2 h 
after which time 19F NMR spectroscopy indicated complete consumption of the starting 
material to N-benzyl-5-chloro-2,6-difluoropyrimidin-4-amine 260 (-45.80 and -67.84 ppm) 
and N-benzyl-5-chloro-2,4-difluoropyrimidin-6-amine 261 ( -48.09 ppm) in a 5:1 ratio by 
19F NMR. The reaction solvent was evaporated in vacuo and the sample dissolved into 
water (40 cm\ The mixture was extracted with DCM (3 x 40 cm\ the organic extracts 
were combined, dried (MgS04) and evaporated in vacuo to give a crude product containing 
N-benzyl-5-chloro-2,6-difluoropyrimidin-4-amine 260 and N-benzyl-5-chloro-2,4-
difluoropyrimidin-6-amine 261 as a yellow solid (0.54 g). Recrystallisation from n-hexane 
yielded N-benzyl-5-chloro-2,6-difluoropyrimidin-4-amine 260 (0.31 g, 41%) as a white 
solid; mp 57-59 °C; IR (neat, V cm-1): 3408, 3281, 2364, 2169, 1739, 1612, 1528, 1447, 
1349, 1129, 695; (Found: C, 51.7; H, 3.1; N, 16.6 C11H8ClF2N3 requires: C, 51.7; H, 3.15; 
N, 16.4%); 8H 4.74 (2H, d, 2JHH 5.8, CH2), 7.39 (5H, m, Ar-H); 8c 46.2 (s, CHz), 93.1 (dd, 
2Jcp 21.4, 4Jcp 8.0, C-5), 128.1 (s, Ar-CH), 128.4 (s, Ar-CH), 129.2 (s, Ar-CH), 136.9 (s, 
Ar-CH), 159.3 (dd, 1JcF 222, 3Jcp 22.1 C-2), 162.6 (dd, 3Jcp 13, 5Jcp 5.4, C-4), 164.5 (dd, 
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1JcF 236.2, 3JcF 18.7, C-6); ()F -45.8 (1F, s, C-6), -67.9 (1F, s, C-2); m/z (El+) 255 ([Mt, 
40%), 218(10), 178(12). 
5-Chloro-2,4-difluoro-6-(piperidin-1-yl)pyrimidine, 284 
0 F F 
:eN a~N Q M3CN,OOC a~N3+ F I ~F+ ~ DIPEA, 1 h 1~0 
a ~F 
112 1 
284 285 
A solution of 5-chloro-trifluoropyrimidine 112 (0.50 g, 6.6 mmol), piperidine (0.25 g, 6.3 
mmol) and DIPEA (1.15 g, 8.9 mmol) in acetonitrile (50 cm3) was stirred at 0 °C for 1 h 
after which time 19F NMR spectroscopy indicated complete consumption of the starting 
material to 5-chloro-2,4-difluoro-6-(piperidin-1-yl)pyrimidine 284 (-48.49 and -65.88 ppm) 
and 5-chloro-4,6-difluoro-2-(piperidin-1-yl)pyrimidine 285 (-63.38 ppm) in a 3:1 ratio by 
19F NMR. The reaction solvent was evaporated in vacuo and the sample dissolved into 
water (40 cm3). The mixture was extracted with DCM (3 x 40 cm\ the organic extracts 
were combined, dried (MgS04) and evaporated in vacuo to give a crude product containing 
5-chloro-2,4-difluoro-6-(piperidin-1-yl)pyrimidine 284 and 5-chloro-4,6-difluoro-2-
(piperidin-1-yl)pyrimidine 285 as a yellow oil (0.61 g). Column chromatography (silica, 
DCM: n-hexane, 10:1) gave 5-chloro-2,4-difluoro-6-(piperidin-1-yl)pyrimidine 284 (0.34 
g, 49%) as an colourless oil; (Found: C, 46.4; H, 4.4; N, 17.9 C9H10ClF2N3 requires: C, 
46.3; H, 4.3; N, 18.0%); oH 1.64 (6H, m, CH2), 3.73 (4H, m, CH2); Oc 24.5 (s, CH2), 26.2 (s, 
CH2), 49.2 (s, CH2), 94.7 (dd, 2JcF 21, 4JcF 9, C-5), 158.3 (dd, 1JcF 222, 3JcF 22, C-2), 162.6 
(dd, 3JcF 13, 5JcF 5, C-4), 164.5 (dd, 1JcF 236, 3JcF 19, C-6); Op -47.63 (lF, s, C-6), -64.17 
(1F, s, C-2); m/z (El+) 233 ([Mt, 70%), 204(100). 
N -tert-Butyl-5-chloro-2,6-difluoropyrimidin-4-amine, 282 
120 
112 
M3CN, ooc 
DIPEA, 2h 
283 
A solution of 5-chloro-trifluoropyrimidine 112 (0.50 g, 6.6 mmol), tert-butylamine (0.23 g, 
6.3 mmol) and DIPEA (1.15 g, 8.9 mmol) in acetonitrile (50 cm3) was stirred at 0 °C for 2 h 
after which time 19F NMR spectroscopy indicated complete consumption of the starting 
material to N-tert-butyl-5-chloro-2,6-difluoropyrimidin-4-amine 282 ( -47.07 and -69.75 
ppm) and N-tert-butyl-5-chloro-4,6-difluoropyrimidin-2-amine 283 (-63.47 ppm) in a 3:1 
ratio by 19F NMR. The reaction solvent was evaporated in vacuo and the sample dissolved 
into water (40 cm\ The mixture was extracted with DCM (3 x 40 cm\ the organic 
extracts were combined, dried (MgS04) and evaporated in vacuo to give a crude product 
containing N-tert-butyl-5-chloro-2,6-difluoropyrimidin-4-amine 282 and N-tert-butyl-5-
chloro-4,6-difluoropyrimidin-2-amine 283 as a colourless solid (0.59 g). Recrystallisation 
from n-hexane yielded, N-tert-butyl-5-chloro-2,6-difluoropyrimidin-4-amine 282 (0.32 g, 
49%) as an colourless solid; mp 52-54 °C; (Found: C, 43.4; H, 4.6; N, 19.1 C8H10ClF2N3 
requires: C, 43.4; H, 4.6; N, 19.0%); ()H 1.12 (m, CH3); <>c 28.9 (s, CH3), 54.0 (s, CCH3), 
93.0 (dd, 2JcF 21, 4JcF 8, C-5), 159.8 (dd, 1JcF 193, 3JcF 23, C-2), 162.1 (dd, 3JcF 20, 5JcF 5, 
C-4), 164.3 (dd, 1Jcp 263, 3JcF 19, C-6); bp -47.02 (lF, s, C-6), -69.70 (lF, s, C-2); m/z (El+) 
221 ([Mt, 38%), 206(100). 
N-(5-Chloro-2,6-difluoropyrimidine-4-yl)benzamidine, 286 
112 
X~ 
_l\.leQ\J __ ._rt_ a:tl4-..;::: N 3 + 
24h .... 1 
6 ~2'F 
1 
286 
121 
A solution of 5-chloro-trifluoropyrimidine 112 (1.10 g, 6.6 mmol), benzamidine 
hydrochloride (0.95 g, 6.3 mmol) and sodium carbonate (2.99 g, 3.6 mmol) in acetonitrile 
(300 cm3) was stirred at room temperature for 24 h after which time 19F NMR spectroscopy 
indicated complete consumption of the starting material to N-(5-chloro-2,6-
difluoropyrimidine-4-yl)benzamidine 286 (-47.75 and -62.91 ppm) and N-(5-chloro-4,6-
difluoropyrimidine-2-yl)benzarnidine 287 ( -111.93 ppm) in a 40:1 ratio by 19F NMR. The 
reaction solvent was evaporated in vacuo and the sample dissolved into water (40 cm3) and 
HCI (5 cm3). The mixture was extracted with DCM (3 x 40 cm3), the organic extracts were 
combined, dried (MgS04) and evaporated in vacuo to give a crude product containing N-(5-
chloro-2,6-difluoropyrimidine-4-yl)benzamidine 286 and N-(5-chloro-4,6-
difluoropyrimidine-2-yl)benzamidine 287 as a yellow solid (1.34 g). Recrystallisation from 
acetonitrile yielded N-(5-chloro-2,6-difluoropyrimidine-4-yl)benzarnidine 286 (1.21 g, 
69%) as an off white solid; mp 164-165 °C; (Found: C, 48.9; H, 2.6; N, 20.7 CIIH7CIF2N4 
requires: C, 49.2; H, 2.6; N, 20.9%); 8H (d6-DMSO) 7.50 (2H, m, CH), 7.59 (lH, m, Ar-H), 
7.61 (2H, m, Ar-H); De (d6-DMSO) 103.8 (dd, 2JcF 14, 4JcF 10, C-5), 129.4 (s, Ar-C), 129.9 
(s, Ar-C) 133.5 (s, Ar-C), 135.2 (s, Ar-C), 158.2 (dd, 1JcF 193, 3JcF 23, C-6), 162.7 (s, 
C=N), 169.0 (dd, 1JcF 225, 3JcF 19, C-2), 170.3 (m, C-4); Op(d6-DMSO) -47.49 (lF, s, C-6), 
-66.06 (lF, s, C-2); m/z (El+) 268 ([Mt, 12%), 233(36). Crystals suitable for x-ray analysis 
were grown from acetonitrile. 
N'-(5-Chloro-2,6-difluoropyrimidin-4-yl)benzamidine, 286 and N'N'-Bis-(5-chloro-
2,6-difluoro-pyrimidin-4-yl)-benzamidine, 288 
X~ 
MeCN, 70 oc a::c 
-...:N + 
96h I ~F 
X F 
a • ~ l~N3 a F 
~~F 
112 286 
1 
288 
A solution of 5-chloro-trifluoropyrimidine 112 (1.07 g, 6.4 mmol), benzamidine 
hydrochloride (0.94 g, 6.0 mmol) and sodium carbonate (2.97 g, 3.6 mmol) in acetonitrile 
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(300 cm3) was stirred at reflux for 96 h after which time 19F NMR spectroscopy indicated 
complete consumption of the starting material to N' -(5-chloro-2,6-difluoropyrimidin-4-
yl)benzamidine 286 and N'N' -Bis-(5-chloro-2,6-difluoro-pyrimidin-4-yl)-benzamidine 288 
. in a 2:1 ratio by 19F NMR. The reaction solvent was evaporated in vacuo and the sample 
dissolved into water (40 cm3) and HCl (5cm\ The mixture was extracted with DCM (3 x 
40 cm3), the organic extracts were combined, dried (MgS04) and evaporated in vacuo to 
give a crude product containing N' -(5-chloro-2,6-difluoropyrimidin-4-yl)benzamidine 286 
and N'N' -Bis-(5-chloro-2,6-difluoro-pyrimidin-4-yl)-benzamidine 288 (0.65 g). Column 
chromatography was performed (silica, n-hexane: DCM, 1: 10) to yield; 
(i) N' -(5-chloro-2,6-difluoropyrimidin-4-yl)benzamidine 286 (0.40 g, 23%). Analysis as 
was found previously. 
(ii) N'N'-Bis-(5-chloro-2,6-difluoro-pyrimidin-4-yl)-benzamidine 288 (0.24 g, 8%) as a 
yellow solid; mp 111-113 °C; (Found: C, 43.1; H, 1.4; N, 20.2 C1sH6ChF4N6 requires C, 
43.2; H, 1.5; N, 20.2%); &H (d6-acetone) 7.47 (4H, m, CH), 7.60 (2H, m, CH), 7.71 (4H, m, 
CH); &c (d6-acetone) 128.92 (s, Ar-C) 129.8 (s, Ar-C), 133.1 (s, Ar-C), 133.9 (s, Ar-C), 
156.8 (s, C=N), 159.2 (dd, 1JcF 158, 3JcF 17, C-6), 168.1 (dd, 1JcF 183, 3JcF 14, C-2), 205.5 
(s, C-4); &F (d6-acetone) -48.00 (2F, s, C-6), -64.40 (2F, s, C-2); mlz (El+) 416 ([Mt. 2%), 
381(4), 339(2), 252(54). 
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Chapter 7 
Experimental to Chapter 3 
2,4,5,6-Tetrafluoropyrimidine, 113 
F O::c KF, autoclave 
'-':N 
I ~F 48JOC 
112 
F F0N 
~~F 
113 
A stainless steel, oven dried 0.5 dm3 autoclave was charged with flame-dried potassium 
fluoride (125 g, 4 mol) and 5-chloro-2,4,6-trifluoropyrimidine, 112 (50 g, 0.6 mol). The 
autoclave was sealed and heated to 480 °C for 19 h after which time the reaction mixture 
was allowed to cool to 200 °C. The gaseous fluorinated products were removed under 
reduced pressure and condensed in a Young's tap-equipped vessel. Distillation of this crude 
material yielded 2,4,5,6-tetrafluoropyrimidine 113 (30 g, 67% ), as a colourless oil; bp 80 
°C; (Found: C, 31.3; N, 18.5 C4N2F4 requires: C, 31.6; N, 18.4%); <>c 132.5 (dtd, 1JcF 249, 
2JcF24, 4JcF 10, C-5), 154.1 (dtd, 1JcF 222, 3JcF21, 4JcF 5, C-2), 162.3 (dm, 1JcF 256, C-4); 
8F -47.15 (1F, m, C-2), -73.49, (2F, m, C-4), -171.44 (lF, m, C-5); m/z (El+) 152 ([Mt, 
100%), 133(30) 
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N-Ethyl-2,5,6-trifluoropyrimidin-4-amine, 292 
lHF, OOC 
DIPEA(3eq) 
292 
A solution of 2,4,5,6-tetrafluoropyrimidine, 113 (2.02 g, 13.3 mmol), ethylamine 2 M in 
THF (6.65 cm3, 13.3 mmol) and DIPEA (5.16 g, 39 mmol) in THF (200 cm3) was stirred at 
0 °C for 2 h after which time 19F NMR indicated 100% conversion of the start material. The 
reaction solvent was evaporated in vacuo and the sample dissolved into water (40 cm\ The 
mixture was extracted with DCM (3 x 40 cm\ the organic extracts were combined, dried 
(MgS04) and evaporated in vacuo to give a crude yellow solid (2.28 g). Column 
chromatography (silica, ethyl acetate: n-hexane, 1:4) yielded N-ethyl-2,5,6-
tri.fluoropyrimidin-4-amine, 292 (1.76 g, 75%) as a yellow solid; mp 57-58 °C; IR (neat, V 
cm-1): 3313, 3001, 1644, 1596, 1448, 1389, 1276, 1136, 1039, 788, 760; (Found: C, 40.7; 
H, 3.4; N, 23.7 C6H6F3N3 requires: C, 40.7; H, 3.4; N, 23.7%); DH 1.29 (3H, t, 3JHH 6.8, 
CH3), 3.56 (2H, q, 3JHH 6.8, CH2); De 14.2 (s, CH3), 36.2 (s, CH2), 127.4 (ddd, 1JcF 250, 2JcF 
23, 4Jcp9, C-5), 154.7 (ddd, 1JcF 217, 3Jcp2l, 4Jcp3, C-2), 155.4 (ddd, 1JcF 247, 2JcF 19, 3!cF 
13, C-6), 156.1 (ddd, 2JCF 18, 3JcF 11, 3JcF 6, C-4); Dp -48.80 (IF, d, 4JFF 25, C-2), -87.72 
(IF, d, 3JFF 16, C-6), -174.15 (lF, s, C-5); m/z (ES+) 176 ([M+ Ht, 85%) 
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N ,N-Diethyl-2,5,6-trifluoropyrimidin-4-amine, 294 
THF, OOC NE~ 
DIPEA A F 
113 294 
A solution of 2,4,5,6-tetrafluoropyrimidine, 113 (1.02 g, 6.7 mmol), diethylamine (0.49 g, 
6.7 mmol) and DIPEA (2.71 g, 20.1 mmol) in THF (50 cm3) was stirred at 0 °C for 1 h after 
which time 19F NMR indicated 100% conversion of the start material. The reaction solvent 
was evaporated in vacuo, DCM (40 cm3) and brine (40 cm3) was added and passed through 
a hydrophobic frit to collect the DCM layer. The DCM was evaporated in vacuo to give a 
crude yellow solid (0.98 g). Recrystallisation from DCM yielded N,N-diethyl-2,5,6-
trifluoropyrimidin-4-amine, 294 (0.34 g, 26%) as a colourless solid; mp 45-49 °C; (Found: 
C, 46.6; H, 4.9; N, 20.4 CsHwF3N3requires: C, 46.8; H, 4.9; N, 20.5%); OH 1.26 (3H, t, 3JHH 
8, CH3), 3.60 (2H, q, 3JHH 8, CHz); Oc 13.6 (s, CH3), 44.7 (d, 6.5, 2 CHz), 128.5 (ddd, 1JcF 
250, 2JcF26, 3JcF9, C-5), 154.1 (dt, 2JcF 19, 3JcF5, C-4), 154.3 (dd, 1JcF 212, 4JcF23, C-2), 
159.0 (ddd, 1JcF 245, 2JcF 19, 3JcF 16, C-6); oF -47.61 (lF, d, 4hF 15, C-2), -86.76 (1F, s, C-
6), -177.38 (1F, d, 3JFF 26, C-5); m/z (ES+) 206 ([M+ Ht, 100 %) 
126 
N-Benzyl-2,5,6-trifluoropyrimidin-4-amine, 293 
113 
~ 6 ll-IF,OOC DIPEA ,& 
293 
A solution of 2,4,5,6-tetrafluoropyrimidine, 113 (1.16 g, 7.7 mmol), benzylamine (0.82 g, 
7.7 mmol) and DIPEA (1.678 g, 22.9 mmol) in THF (50 cm3) was stirred at 0 °C for 1 h, 
after which time 19F NMR indicated 100% conversion of the start material. The reaction 
solvent was evaporated in vacuo, DCM (40 cm3) and brine (40 cm3) was added and passed 
through a hydrophobic frit to collect the DCM layer. The DCM was evaporated in vacuo to 
give a crude yellow oil (1.62 g). Column chromatography (silica, ethyl acetate:n-hexane, 
1:3) yielded N-benzyl-2,5,6-trijluoropyrimidin-4-amine, 293 (1.09 g, 59%) as a yellow 
solid; mp 69-70 °C; (Found: C, 54.9; H, 3.3; N, 17.3 CuH8F3N3 requires: C, 55.2; H, 3.4; 
N, 17.6%); OH 4.71 (2H, d, 3JHH 4, CH2), 7.38 (5H, m, Ar-H); Oc 45.5 (s, CH2), 127.9 (ddd, 
1JcF 251, 2JcF23, 3Jcp9, C-5), 127.9 (s, Ar-CH), 128.2 (s, Ar-CH), 128.9 (s, Ar-CH), 136.7 
(s, Ar-CH), 155.0 (ddd, 1JcF 218, 3Jcp21, 4Jcp4, C-2), 156.1 (ddd, 1JcF 247, 2JcF 19, 3JcF 12, 
C-6), 156.3 (ddd, 2JcF 19, 3JcF 11, 3JcF6, C-4); Op -47.21 (1F, d, 4JFF 25, C-2), -86.61 (lF, d, 
3JFF 16, C-6), -180.69 (lF, s, C-5); m/z (ES+) 239 ([M+ Ht, 100%) 
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2,5,6-Trifluoro-N-phenylpyrimidin-4-amine, 139 
F~N 
~~F+ 
113 
THF,OOC 
DIPEA 
139 
A solution of 2,4,5,6-tetrafluoropyrimidine, 113 (1.01 g, 6.6 mmol), aniline (0.6 g, 6.6 
mmol) and resin bound DIPEA (3 g (4 mmol per g), 12 mmol) in THF (150 cm3) was 
stirred at 0 °C for 2 h after which time 19F NMR indicated 100% conversion of the start 
material. The solution was filtered to remove the resin and the reaction solvent was 
evaporated in vacuo, DCM ( 40 cm3) and brine ( 40 cm3) was added and passed through a 
hydrophobic frit to collect the DCM layer. The DCM was evaporated in vacuo to give a 
crude cream solid (1.36 g). Recrystallisation from n-hexane yielded 2,5,6-trifluoro-N-
phenylpyrimidin-4-amine, 139 (0.64 g, 43%) as a cream solid; mp 91-93 °C; IR (neat, v cm-
1): 3413, 2364, 1628, 1583, 1536, 1478, 1446, 1390, 1290, 1228, 751; (Found: C, 53.0; H, 
2.7; N, 18.4 C10H6F3N3 requires: C; 53.3; H; 2.7; N; 18.7%); c)H 7.26 (1H, m, Ar-H), 7.42 
(1H, m, Ar-H), 7.58 (1H, m, Ar-H); cSc 121.4 (s, Ar-CH), 125_7 (s, Ar-CH), 127.3 (ddd, 1JcF 
278, 2JcF 32, 4JcF 9, C-5), 129.7 (s, Ar-CH), 154.1 (m, C-4), 154.2 (ddd, 1JcF 218, 3JcF 21, 
4JcF 3, C-2), 155.5 (ddd, 1JcF 283, 2JcF 32, 3JcF9, C-6) ; c)F -46.1 (lF, d, 4hF 27, C-2), -84.1 
(1F, d, 3hF 18, C-6), -177.8 (lF, m, C-5); mlz (El+) 224 ([~]. 100%), 205(10), 186(6) 
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2,4,5-Trifluoro-6-morpholinopyrimidine, 295 
DIPEA C) lHF,OOC 
H 
113 
C) 
~;_F 
296 
A solution of 2,4,5,6-tetrafluoropyrimidine, 113 (1.01 g, 6.6 mmol), morpholine (0.6 g, 6.6 
mmol) and resin bound DIPEA (2 g (4 mmol per g), 8 mmol) in THF (150 cm3) was stirred 
at 0 °C for 2 h after which time 19F NMR indicated 100% conversion of the start material. 
The solution was filtered to remove the resin and the reaction solvent was evaporated in 
vacuo, DCM (40 cm3) and brine (40 cm3) was added and passed through a hydrophobic frit 
to collect the DCM layer. The DCM was evaporated in vacuo to give a crude cream solid 
(1.76 g). Recrystallisation from n-hexane yielded 2,4,5-trifluoro-6-morpholinopyrimidine, 
295 (1.22 g, 84%) as a white solid; mp 65-66 °C; (Found: C, 43.7; H, 3.7; N, 19.2 
CsHsF3N30 requires: C, 43.8; H, 3.7; N, 19.2%); 8u 3.79 (4H, m, CH2), 3.85 (4H, m, CH); 
De 46.9 (d, 4Jcp 9, CH2), 66.8 (s, CH2), 129.5 (ddd, 1Jcp 251, 2Jcp 25, 4Jcp 9, C-5), 154.4 
(ddd, 1Jcp 217, 3Jcp23, 4Jcp4, C-2), 154.5 (dt, 2Jcp 16, 3Jcp6, C-4), 159.7 (ddd, 1Jcp 281, 
2Jcp 35, 3Jcp 16, C-6); 8p -47.90 (lF, d, 4Jpp 26, C-2), -84.66 (IF, d, 3Jpp 17, C-6), -172.39 
(1F, m, C-5); mlz (El+) 219 ([M+], 32%), 176(60), 134(100) 
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4,6-Bis( ethylthio )-2,5-difluoropyrimidine, 297 
F 
F~ ~;F+B~ 
113 
lHF, ooc- rt 
SEt 
F~N 
B~~F 
2!¥7 
A solution of 2,4,5,6-tetrafluoropyrimidine, 113 (3.03 g, 19 mmol), and sodium 
ethanethiolate (1.67 g, 19 mmol) in THF (250 cm3) was stirred at 0 °C for 1 hand then for 
19 hat room temperature, after which time 19F NMR indicated 100% conversion of the start 
material. The reaction solvent was evaporated in vacuo and the sample dissolved into water 
(40 cm3). The mixture was extracted with DCM (3 x 40 cm\ the organic extracts were 
combined, dried (MgS04) and evaporated in vacuo to give a crude containing 4,6-
bis( ethylthio )-2,5-difluoropyrimidine, 297 (2.56 g, 54%) as a yellow solid; mp 48-50 °C; 
(Found: C, 40.4; H, 4.3; N, 11.9 C8H10F2N2S2 requires: C, 40.7; H, 4.3; N, 11.9%); 8H 1.34 
(3H, t, 3JHH 8, CH3), 3.13 (2H, q, 3JHH 8, CHz); De 14.7 (s, CH3), 24.1 (s, CH3), 150.7 (dd, 
1Jcp 249, 4JcF 7, C-5), 157.3 (dd, 1JcF 214, 4Jcp9, C-2), 158.0 (dd, 2JcF 33.9, 3JcF 16, C-4); Dp 
-50.25 (1F, d, 5JFF 30, C-2), -139.16 (1F, m, C-5); m/z (Er) 236 ([M+], 100%), 203(81), 
175(63) 
2,5-Difluoro-4,6-bis(phenyloxy )pyrimidine, 296 
THF, OOC- rt20h 
DIPEA 
113 296 
A solution of 2,4,5,6-tetrafluoropyrimidine, 113 (1.05 g, 6.9 mmol), and sodium phenoxide 
(0.80 g, 6.9 mmol) in THF (150 cm3) was stirred at 0 °C for 2 h and then for 20 h at room 
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temperature after which time 19F NMR indicated 100% conversion of the start material. The 
reaction solvent was evaporated in vacuo and the sample dissolved into water (40 cm3). The 
mixture was extracted with ethyl acetate (3 x 40 cm3), the organic extracts were combined, 
dried (MgS04) and evaporated in vacuo to give a crude white solid (0.96 g). 
Recrystallisation from n-hexane yielded 2,5-difluoro-4,6-bis(phenyloxy )pyrimidine, 296 
(0.89 g, 43%) as a white solid; mp 67-68 °C; (Found: C, 63.8; H, 3.3; N, 9.2 C16H10F2N202 
requires: C, 64.0; H, 3.4; N, 9.3%); OH 7.26 (2H, m, Ar-H), 7.37 (2H, m, Ar-H), 7.50 (2H, 
m, Ar-H); Oc 121.7 (s, Ar-CH), 126.7 (s, Ar-CH), 130.2 (s, Ar-CH), 130.4 (dd, 1JcF 258, 
4JcF 10, C-5), 152.2 (s, COC), 152.94 (dd, 1JcF 221, 4JcF 5, C-2); Op -45.9 (IF, s, C-2), -
174.2 (IF, s, C-5); m/z (ES+) 301 ([M+ Ht, 100%) 
N-Benzyl-N'-ethyl-2,5-difluoropyrimidine-4,6-diamine, 298 
298 
+ § -:-PEA_F_, rt_ + 
292 
A solution of N-ethyl-2,5,6-trifluoropyrimidin-4-amine, 292 (1.03 g, 5.8 mmol), 4-
methoxybenzylamine (0.8 g, 5.8 mmol) and DIPEA (3.04 cm3, 17 mmol) in THF (100 cm3) 
was stirred at room temperature for 12 h after which time 19F NMR indicated 100% 
conversion of the start material. The reaction solvent was evaporated in vacuo, DCM (40 
cm3) and brine ( 40 cm3) was added and passed through a hydrophobic frit to collect the 
DCM layer. The DCM was evaporated in vacuo to give a crude yellow solid containing N-
benzyl-N -ethyl-2,5-difluoropyrimidine-4,6-diamine and N-benzyl-N -ethyl-6,5-
difluoropyrimidine-2,4-diamine (1.21 g) in a 19:1 ratio. Recrystallisation from n-hexane 
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yielded N-benzyl-N'-ethyl-2,5-difluoropyrimidine-4,6-diamine, 298 (1.09 g, 61 %) as a 
white solid; mp 77-79 °C; (Found: C, 57.2; H, 5.5; N, 18.8 C1.JI16F2N40requires: C, 57.1; 
H, 5.5; N, 19.0%); BH 1.25 (3H, t, 3JHH 7.6, CH3), 3.48 (2H, m, CH2), 3.82 (3H, s, OCH3), 
2 4.56 (2H, d, JHH 5.6, CH2), 4.66 (lH, s, NH), 4.87 (lH, s, NH), 6.89 (2H, m, Ar-H), 7.28 
(2H, m, Ar-H); Be 14.8 (s, CH3), 35.4 (s, CHz), 43.9 (s, CHz), 54.8 (s, OCH2), 113.6 (s, Ar-
CH), 128.4 (dd, 1JcF 232, 4JcF 7, C-5), 128.7 (s, Ar-CH), 130.1 (s, Ar-CH), 150.7 (dd, 2JcF 
11, 3JcF 10, C-6), 151.3 (dd, 2JcF 11, 3JcF 10, C-4), 156.3 (dd, 1JcF 206, 4JcF 2, C-2), 158.7 
(s, OCH3); BF -49.58 (lF, s, C-2), -186.07 (1F, s, C-5); m/z (ES+) 295 ([M+ Ht, 100%) 
6-Ethoxy-N -ethyl-2,5-difluoropyrimidin-4-amine, 307 
EtO-i, rt 
292 
A solution of N-ethyl-2,5,6-trifluoropyrimidin-4-amine, 292 (1.00 g, 5.71 mmol), and 
sodium ethoxide (0.66 g, 5.71 mmol) in ethanol (150 cm3) was stirred at room temperature 
for 17 h after which time 19F NMR indicated 100% conversion with the formation of 6-
ethoxy·N-ethyl-2,5-difluoropyrimidin-4-amine and 2-ethoxy-N-ethyl-4,5-
difluoropyrimidin-4-amine in a 6:1 ratio. The reaction solvent was evaporated in vacuo, 
DCM (40 cm3) and brine (40 cm3) was added and passed through a hydrophobic frit to 
collect the DCM layer. The DCM was evaporated in vacuo to give a crude containing 6-
ethoxy-N-ethyl-2,5-difluoropyrimidin-4-amine and 2-ethoxy-N-ethyl-4,5-
difluoropyrimidin-4-amine (1.34 g). Recrystallisation from n-hexane yielded 6-ethoxy-N-
ethyl-2,5-difluoropyrimidin-4-amine, 307 (0.88 g, 77%) as a white solid; mp 81-83 °C; 
(Found: C, 47.3; H, 5.5; N, 20.7 C8H11F2N30 requires: C, 47.3; H, 5.5; N, 20.7%); BH 1.24 
(3H, t, 3JHH 7, CH3), 1.41 (3H, t, 3JHH 7, CH3), 3.49 (2H, q, 3JHH 6, NCHz), 4.41 (2H, q, 3JHH 
6, OCHz), 4.87 (lH, s, NH); Be 14.8 (s, CH3), 15.3 (s, CH3), 36.3 (s, CHz), 63.8 (s, CHz), 
130.5 (dd, 1JcF 231, 4JcF 9, C-5), 154.5 (dd, 2JcF 30, 3JcF 11, C-4), 154.8 (dd, 1JcF 214, 4JcF 
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4, C-2), 156.3 (dd, 2JcF 27, 3JcF 10, C-6); 8F -49.33 (IF, d, 5JFF 27, C-2), -I86.07 (IF, d, 5JFF 
27, C-5); mlz (Ef") 203 ([Mt, 32%), I88(40) 
N-Ethyl-2,5-difluoro-6-(phenyloxy )-4-pyrimidinamine, 304 
11-IF, rt ~F 
292 304 
A solution of N-ethyl-2,5,6-trifluoropyrimidin-4-amine, 292 (l.OI g, 5.7 mmol), and 
sodium phenoxide (0.66 g, 5.7 mmol) in THF (50 cm3) was stirred at room temperature for 
17 h after which time 19F NMR indicated 100% conversion of the start material. The 
reaction solvent was evaporated in vacuo and the sample dissolved into water (40 cm3). The 
mixture was extracted with ethyl acetate (3 x 40 cm3), the organic extracts were combined, 
dried (MgS04) and evaporated in vacuo to give a crude yellow solid (1.56 g). 
Recrystallisation from n-hexane yielded N-ethyl-2,5-difluoro-6-(phenyloxy )-4-
pyrimidinamine, 304 (0.9I g, 63%) as a white solid; mp 97-99 °C; (Found: C, 57.3; H, 4.3; 
N, 16.6 C12H11F2N30 requires: C, 57.4; H, 4.4; N, 16.7%); ()H 1.32 (3H, t, 3JHH 7.2, CH3), 
3.58 (2H, m, CHz), 7.20 (2H, m, Ar-H), 7.29 (IH, m, Ar-H), 7.43 (2H, m, Ar-H); <ic I4.3 (s, 
CH3), 35.7 (s, CH2), 120.4 (s, Ar-CH), 124.9 (s, Ar-CH), 128.0 (dd, 1JcF, 4JcF, C-5), 129.0 
(s, Ar-CH), 151.8 (s, COC), 152.7 (m, C-6), 153.8 (dd, 1JcF. 4JcF. C-2), 157.8 (m, C-4); ()F-
47.8 (IF, s, C-2), -180.2 (IF, s, C-5); mlz (ES+) 252 ([M+ Ht, IOO%) 
133 
N-Ethyl-6-( ethylthio )-2,5-difluoropyrimidin-4-amine, 310 
NHEt 
ll-IF, rt F0N 
~~F 
292 310 
A solution of N-ethyl-2,5,6-trifluoropyrimidin-4-amine, 292 (1.50 g, 8.5 mmol), and 
sodium ethanethiolate (0.71 g, 8.5 mmol) in THF (50 cm3) was stirred at room temperature 
for 17 h after which time 19F NMR indicated 100% conversion of the start material. The 
reaction solvent was evaporated in vacuo, DCM (40 cm3) and brine (40 cm3) was added and 
passed through a hydrophobic frit to collect the DCM layer. The DCM was evaporated in 
vacuo to give a crude yellow solid (1.56 g). Recrystallisation from n-hexane yielded N-
ethyl-6-(ethylthio)-2,5-di.fluoropyrimidin-4-amine, 310 (0.95 g, 51%) as a yellow solid; mp 
54-55 °C; (Found: C, 43.6; H, 5.0; N, 18.9 C12HuF2N30 requires: C, 43.8; H, 5.1; N, 
3 3 . 3 19.2%); 8H 1.25 (3H, t, JHH 7.2, CH3), 1.35 (3H, t, JHH 7.2, CH)), 3.15 (2H, q, JHH 7.2, 
CH2), 3.49 (2H, m, CH2); Be 14.3 (s, CH3), 14.4 (s, CH3), 24.0 (s, CH2), 36.2 (s, CH2), 
138.7 (dd, 1JcF 230, 4JcF 8, C-5), 152.1 (m, C-4), 153.4 (m, C-6), 153.8 (dd, 1JcF 210, 4JcF 5, 
C-2); Op -56.67 (lF, s, C-2), -167.93 (lF, s, C-5); mlz (El+) 219 ([~], 90%), 186(100), 
176(75) 
N-Ethyl-2,5-difluoro-6-(phenylthio )pyrimidin-4-amine, 311 
F~t 
~~F+ A1SNa 
THF, rt 
292 
A solution of N-ethyl-2,5,6-trifluoropyrimidin-4-amine, 292 (1.52 g, 8.5 mmol), and 
' . . 
sodium be~zenethiol (0.71 g, 8.5 mmol) in THF (50 cm3) was stirred at room temperature 
134 
for 17 h after which time 19F NMR indicated 100% conversion with the formation of N-
ethyl-2,5-difluoro-6-(phenylthio)pyrimidin-4-amine. The reaction solvent was evaporated 
in vacuo, DCM (40 cm3) and brine (40 cm3) was added and passed through a hydrophobic 
frit to collect the DCM layer. The DCM was evaporated in vacuo to give a crude yellow 
solid ( 1.56 g). Recrystallisation from n-hexane yielded N-ethyl-2,5-difluoro-6-
(phenylthio)pyrimidin-4-amine, 311 (1.35 g, 60%) as a yellow solid; mp 99-100 °C; 
(Found: C, 53.9; H, 4.1; N, 15.7 Ct2H11F2N3S requires: C, 53.9; H, 4.2; N, 15.7%); 8H 1.30 
(3H, t, 3JHH 7.2, CH3), 3.54 (2H, m, CH2), 5.16 (1H, s, NH), 7.40 (2H, m, Ar-H), 7.55 (lH, 
m, Ar-H); De 14.9 (s, CH3), 36.3 (s, CH2), 127.3 (s, CSC), 129.4 (s, Ar-CH), 129.7 (s, Ar-
. CH), 135.4 (s, Ar-CH), 140.9 (dd, 1Jcp 239, 4JcF 7, C-5); 8p -48.55 (1F, d, 5Jpp 27, C-2), -
159.3 (IF, d, 5Jpp 25, C-5); m/z (ES+) 268 ([M+ Ht, 85%) 
N-( 4-Methoxybenzyl)-2,5-difluoro-6-morpholinopyrimidin-4-amine, 299 
DIPEA, lHF 
rt, 12 h 
A solution of 2,4,5-trifluoro-6-morpholinopyrimidine, 295 (1.03 g, 4.7 mmol), 4-
methoxybenzylamine (0.64 g, 4.7 mmol) and DIPEA (3.04 cm3, 17 mmol) in THF (100 
cm3) was stirred at room temperature for 12 h after which time 19F NMR indicated 100% 
conversion of the start material with the formation of N-benzyl-N -ethyl-2,5-
difluoropyrimidine-4,6-diamine and N-benzyl-N-ethyl-6,5-difluoropyrimidine-2,4-diamine 
135 
in a 16:1 ratio. The reaction solvent was evaporated in vacuo, DCM (40 cm3) and brine (40 
cm3) was added and passed through a hydrophobic frit to collect the DCM layer. The DCM 
was evaporated in vacuo to give a crude yellow solid containing N-benzyl-N'-ethyl-2,5-
difluoropyrimidine-4,6-diamine and N-benzyl-N'-ethyl-6,5-difluoropyrimidine-2,4-diamine 
( 1.21 g). Recrystallisation from n-hexane yielded N-benzyl-N'-ethyl-2,5-di.fluoropyrimidine-
4,6-diamine 299 (1.04 g, 66%) as a white solid; mp 85-87 °C; (Found: C, 57.0; H, 5.4; N, 
16.6 C16H1sFzN402 requires: C, 57.1; H, 5.4; N, 16.7%); oH 3.65 (4H, m, CHz), 3.74 (4H, 
m, CH2), 3.65 (3H, s, CH3), 4.56 (2H, d, 3JHH 5.6, CH2), 6.87 (2H, m, Ar-H), 7.24 (2H, m, 
Ar-H); Oc 44.8 (s, CHz), 46.7 (d, 4JcF 7, CHz), 55.6 (s, CH3), 67.0 (s, CHz), 114.4 (s, Ar-
CH), 128.7 (dd, 1JcF 240, 4JcF 8, 5-CF), 130.5 (s, CCN), 150.4 (dd, 2JcF 18, 4JcF 4, C-4), 
154.8 (dd, m, C-6), 155.4 (dd, 1JCF 209, 4JcF 4, 2-CF), (ddd, 2JcF 18, 3JcF 11, 3JcF6, 4-CN); 
OF -49.99 (1F, d, 5hF28, C-2), -175.45 (1F, d, 5JFF25, C-5); mlz (ES+) 337 ([M+ Ht, 100%) 
N-Ethyl-2,5-difluoro-6-morpholin-4-ylpyrimidin-4-amine, 301 
C) 
DIPEA, THF F0 
rt,121 ~J_F 
295 301 
A solution of 2,4,5-trifluoro-6-morpholinopyrimidine, 295 (1.03 g, 4.7 mmol), ethylamine 
(0.21 g, 4.7 mmol) and DIPEA (3.04 cm3, 17 mmol) in THF (100 cm3) was stirred at room 
temperature for 12 h after which time 19F NMR indicated 100% conversion of the start 
material. The reaction solvent was evaporated in vacuo, DCM (40 cm3) and brine (40 cm3) 
was added and passed through a hydrophobic frit to collect the DCM layer. The DCM was 
evaporated in vacuo to give a crude yellow solid (1.33 g). Recrystallisation from n-hexane 
yielded N-ethyl-2,5-di.fluoro-6-morpholin-4-ylpyrimidin-4-amine, 301 (0.68 g, 61 %) as a 
white solid; mp 61-62 °C; (Found: C, 49.2; H, 5.8; N, 22.8 CwH14F2N40 requires: C, 49.2; 
H, 5.8; N, 22.9%); OH 1.23 (3H, t, 3JHH 7.2, CH3), 3.47 (2H, m, CHz), 3.67 (4H, m, CHz), 
136 
3.75 (4H, m, CHz), 4.81 (lH, NH); be 15.3 (s, CH3), 36.2 (s, CH3), 46.7 (d, 4JcF 7, CHz), 
67.0 (s, CH), 128.0 (dd, 1JcF228, 4JcF7, C-5), 150.1 (dd, 2JcF 14, 4JcF4, C-4), 154.9 (m, C-
6), 157.1 (dd, 1JcF206, 4JcF3, C-2); bF-50.11 (lF, d, 5hF28,C-2), -175.77 (lF, d, 5JFF26, 
C-5); m/z (ES+) 245 ([M+ Ht, 100%) 
2,5-Difluoro-N -phenyl-6-(piperidin-1-yl)pyrimidin-4-amine, 302 
C) 
)r;_F + 
295 
0 
H 
ll-IF, rt 
DIPEA 
C) 
::eN 1~0 
A solution of 2,4,5-trifluoro-6-morpholinopyrimidine, 295 (1.01 g, 4.7 mmol), piperidine 
(0.39 g, 4.7 mmol) and DIPEA (3.04 cm3, 17mmol) in THF (100 cm3) was stirred at room 
temperature for 14 h after which time 19F NMR indicated 100% conversion with the 
formation of two products including 2,5-difluoro-4-morpholino-6-(piperidin-1-
yl)pyrimidine and 4,5-difluoro-4-morpholino-2-(piperidin-1-yl)pyrimidine in a 1:1 ratio. 
The reaction solvent was evaporated in vacuo, DCM (40 cm3) and brine (40 cm3) was 
added and passed through a hydrophobic frit to collect the DCM layer. The DCM was 
evaporated in vacuo to give a crude yellow solid containing 2,5-difluoro-N-phenyl-6-
(piperidin-1-yl)pyrimidin-4-amine and 2,5-difluoro-N-phenyl-6-(piperidin-1-yl)pyrimidin-
4-amine in a 3: 1 ratio. Column chromatography (silica, ethyl acetate:n-hexane, 1 :3) yielded 
2,5-difluoro-N-phenyl-6-(piperidin-1-yl)pyrimidin-4-amine, 302 (0.68 g, 51%) as white 
solid; mp 59-60 °C; (Found: C, 54.7; H, 6.4; N, 19.5 C13H1sFzN40 requires: C, 54.9; H, 6.4; 
N, 19.7%); bH 1.61 (6H, m, CH2), 3.63 (8H, m, CH2), 7.78 (4H, m, CH2), 7.43 (2H, m, 
CHz); be 24.9 (s, CHz), 26.3 (s, CHz), 47.5 (d, 4JcF 7, CHz), 48.3 (d, 4JcF 7, CHz), 67.1 (s, 
CH2), 128.0 (dd, 1JcF 240, 4JcF 8, C-5), 154.1 (m, C-4), 154.2 (m, C-6), 153.8 (dd, 1JcF 203, 
4JcF 2, C-2); bF -50.66 (lF, d, 5JFF 27, C-2), -163.61 (lF, d, 5JFF 27, C-5); m/z (ES+) 285 
([M+ Ht, 100%) 
137 
4-(6-Ethoxy-2,5-difluoropyrimidin-4-yl)morpholine, 309 
C) 
F~N ~~F+ EtO\a 
295 
EtO-I, rt 
309 
A solution of 2,4,5-trifluoro-6-morpholinopyrimidine, 295 (1.00 g, 5.7 mmol), and sodium 
ethoxide (0.31 g, 5.7 mmol) in ethanol (150 cm3) was stirred at room temperature for 18 h 
after which time 19F NMR indicated 100% conversion with the formation of 4-(6-ethoxy-
2,5-difluoropyrimidin-4-yl)morpholine and 4-(2-ethoxy-4,5-difluoropyrimidin-4-
yl)morpholine in a 6:1 ratio. The reaction solvent was evaporated in vacuo, DCM (40 cm3) 
and brine (40 cm3) was added and passed through a hydrophobic frit to collect the DCM 
layer. The DCM was evaporated in vacuo to give a crude containing 4-(6-ethoxy-2,5-
difluoropyrimidin-4-yl)morpholine and 4-(2-ethoxy-4,5-difluoropyrimidin-4-yl)morpholine 
(1.48 g). Recrystallisation from n-hexane yielded 4-(6-ethoxy-2,5-difluoropyrimidin-4-
yl)morpholine, 309 (0.79 g, 71 %) as a white solid; mp 97-98 °C; (Found: C, 48.8; H, 5.3; 
N, 17.1 C10H13F2N302requires: C, 49.0; H, 5.3; N, 17.1%); 8H 1.42 (3H, t, 3JHH 7.2, CH3), 
3.76 (8H, m, CH2), 4.43 (2H, q, 3JHH 7.2, CH2); 8c 14.7 (s, CH3), 47.0 (d, 4Jcp 7, NCH2), 
64.2 (s, CH2), 66.9 (s, OCH2), 128.4 (dd, 1JcF 244, 4Jcp 9, C-5), 152.6 (dd, 2JcF 22, 3Jcp 4, 
C-4), 154.0 (dd, 1Jcp 210, 4JcF 3, C-2), 160.7 (m, C-6); 8p -49.59 (lF, d, 5Jpp 27, C-2), -
172.81 (1F, m, C-5); m/z (ES+) 246 (~ + H+, 100%) 
138 
2,5-Difluoro-4-morpholino-6-phenoxypyrimidine, 306 
C) 
F0N ~~F+ PtO\la 
295 
TI-IF, rt 
DIPEA 
C) 
F0N 
~~F 
306 
A solution of 2,4,5-trifluoro-6-morpholinopyrimidine, 295 (1.00 g, 0.49 mmol), and sodium 
phenoxide (0.53 g, 0.49 mmol) in THF (100 cm3) was stirred at room temperature for 19.5 
h after which time 19F NMR indicated 100% conversion of the start material. The reaction 
solvent was evaporated in vacuo and the sample dissolved into water (40 cm\ The mixture 
was extracted with ethyl acetate (3 x 40 cm\ the organic extracts were combined, dried 
(MgS04) and evaporated in vacuo to give a crude containing yellow solid (1.05 g). 
Recrystallisation from n-hexane yielded 2,5-di.fluoro-4-morpholino-6-pheno.xypyrimidine, 
306 (1.05 g, 78%) as a white solid; mp 128-130 °C; (Found: C, 57.3; H, 4.5; N, 14.3 
C14H13F2N302 requires: C, 57.3; H, 4.5; N, 14.3%); oH 3.79 (8H, m, CH2), 7.16 (2H, m, 
CH), 7.25 (1H, m, CH), 7.40 (2H, m, CH); Oc 46.8 (d, 4JcF 7, NCH2), 66.9 (s, OCH2), 121.4 
(s, Ar-CH), 126.0 (s, Ar-CH), 129.9 (Ar-CH), 132.0 (dd, 1JcF 244, 4JcF 9, C-5), 152.5(s, 
COC), 153.6 (m, C-4), 154.0 (dd, 1JcF 213, 4Jcp3, C-2), 159.9 (m, C-6); Op -48.3 (lF, d, 5JFF 
28, C-2), -170.7 (IF, d, 5Jpp28, C-5); mlz (ES+) 294 ([M+ H]\ 100%) 
139 
2,5-Difluoro-4-morpholino-6-(phenylthio )pyrimidine, 314 
C) 
F0N ~~F+ AlSNa 
295 
THF, rt 
DIPEA 
C) 
F0N 
Al~~F 
314 
A solution of 2,4,5-trifluoro-6-morpholinopyrimidine, 295 (1.00 g, 4.6 mmol), and sodium 
thiophenolate (0.66 g, 5.0 mmol) in THF (100 cm3) was stirred at room temperature for 19 
h after which time 19F NMR indicated 100% conversion of the start material. The reaction 
solvent was evaporated in vacuo, DCM (40 cm3) and brine (40 cm3) was added and passed 
through a hydrophobic frit to collect the DCM layer. The DCM was evaporated in vacuo to 
give a crude containing yellow solid (1.23 g). Recrystallisation from n-hexane yielded 2,5-
difluoro-4-morpholino-6-(phenylthio)pyrimidine, 314 (0.76 g, 54%) as a yellow solid; mp 
120-122 °C; (Found: C, 54.5; H, 4.2; N, 13.4 C14H13F2N30Srequires: C, 54.4; H, 4.2; N, 
13.6%); oH 3.7 (8H, m, CH2), 7.4 (3H, m, CH2), 7.6 (2H, m, CH); Oc 46.8 (d, 4JcF 8, CH2), 
66.9 (s, CH2), 47.5 (d, 4JcF 7, CH2), 48.3 (d, 4JcF 7, CH2), 67.1 (s, CH2), 128.0 (dd, 1JcF 240, 
41cF 8, C-5), 154.1 (m, C-4), 154.2 (m, C-6), 153.8 (dd, 1JcF 203, 41cF 2, 2-CF); OF -49.1 
(IF, s, 2-CF), -149.2 (lF, s, 5-CF); m/z (ES+) 310 ([M+ Ht, 100%) 
140 
lt-Ethyl-2,5-difluoro-N' -phenylpyrimidine-4,6-diamine, 300 
~ 
F0N + Et~ 
~~F 
139 
lHF,rt 
DIPEA 
~ F0N 
sJ~F 
300 
A solution of 2,4,5-trifluoro-6-morpholinopyrimidine, 139 (1.01 g, 4.4 mmol), ethylamine 
(0.20 g, 4.4 mmol) and DIPEA (3.04 cm3, 17 mmol) in THF (100 cm3) was stirred at 40 °C 
for 12 h after which time 19F NMR indicated 100% conversion with the formation of It-
ethyl-2,5-difluoro-Ni -phenylpyrimidine-4,6-diamine. The reaction solvent was evaporated 
in vacuo, DCM (40 cm3) and brine (40 cm3) was added and passed through a hydrophobic 
frit to collect the DCM layer. The DCM was evaporated in vacuo to give a crude yellow 
' 
solid (1.09 g). Recrystallisation from n-hexane yielded ~-ethyl-2,5-difluoro-ff-
phenylpyrimidine-4,6-diamine, 300 (0.99 g, 88%) as a orange solid; mp 131-132 °C; 
(Found: C, 57.3; H, 4.8; N, 22.2 C1zH12FzN4 requires: C, 57.6; H, 4.8; N, 22.4%); 8H 1.28 
(3H, t, 3JHH 7, CH3), 3.51 (2H, q, 3JHH 6, CH2), 4.81 (lH, s, NH), 6.58 (lH, s, NH), 7.16 
(lH, s, Ar-H), 7.34 (2H, m, Ar-H), 7.52 (2H, m, Ar-H); 8c 15.4 (s, CH3), 36.2 (s, CHz), 
120.5 (s, Ar-CH), 123.8 (s, Ar-CH), 128.2 (dd, 1JcF 234, 4JcF 7 5-CF), 129.5 (s, Ar-CH), 
138.4 (s, CNC), 148.6 (dd, 2JcF 29, 3JcF 9, 4-CN), 152.6 (dd, 2JcF 31, 3JcF 11, 6-CN), 157.4 
(dd, 1JcF 207, 4JcF 3, 2-CF); 8p -49.1 (IF, s, 2-CF), -149.2 (IF, s, 5-CF); mlz (ES+) 251 
([M+ Ht, 100%) 
141 
6-Etboxy-2,5-difluoro-N-pbenylpyrimidin-4-amine, 308 
~~ ~~ ~~ 
~J-/ 80\Ja Tl-IF, rt )CN + )t;_F ~ B F 
195 1 5 
308 
A solution of 2,4,5-trifluoro-6-morpholinopyrimidine, 195 (1.00 g, 4.4 mmol), and sodium 
ethoxide (0.31 g, 4.4 mmol) in ethanol (150 cm3) was stirred at room temperature for 18 h 
after which time 19F NMR indicated 100% conversion with the formation of 6-ethoxy-2,5-
difluoro-N-phenylpyrimidin-4-amine and 2-ethoxy-5,6-difluoro-N-phenylpyrimidin-4-
amine in a 5:1 ratio. The reaction solvent was evaporated in vacuo, DCM (40 cm3) and 
brine (40 cm3) was added and passed through a hydrophobic frit to collect the DCM layer. 
The DCM was evaporated in vacuo to give a crude containing 6-ethoxy-2,5-difluoro-N-
phenylpyrimidin-4-amine and 2-ethoxy-5,6-difluoro-N-phenylpyrimidin-4-amine (1.48 g). 
Recrystallisation from n-hexane yielded 6-ethoxy-2,5-di.fluoro-N-phenylpyrimidin-4-amine, 
308 (0.56 g, 50%) as a pink solid; mp 105-106 °C; (Found: C, 57.2; H, 4.4; N, 16.9 
C12H11 F2N30 requires: C, 57.4; H, 4.4; N, 16.7%); ()H 1.47 (3H, t, 3JHH 7, CH3), 4.49 (3H, t, 
3JHH 7, CH2), 7.16 (1H, m, Ar-H), 7.53 (2H, m, Ar-H), 7.57 (2H, m, Ar-H); <>c 14.7 (s, 
CH3), 64.3 (s, CH2), 120.8 (s, Ar-CH), 124.5 (s, Ar-CH), 128.9 (dd, 1JcF 253, 4JcF 9, C-5), 
129.4 (s, Ar-CH), 137.8 (s, OCH2), 151.5 (dd, 2JcF 29, 3JcF 9, C-4), 154.4 (dd, 1JcF 216, 4JcF 
4, C-2), 158.0 (dd, 2JcF 27, 3JcF 10, C-4); ()F -49.97 (IF, d, 5JFF28, C-2), -179.31 (IF, m, 5-
CF); m/z (ES+) 252 ([M+ Ht, 100%) 
142 
2,5-Difluoro-6-phenoxy-N-phenylpyrimidin-4-amine, 305 
H,A) 
~N A'1Cl\a THF, rt 
~~F+ 
196 305 
A solution of 2,5,6-trifluoro-N-phenylpyrimidin-4-arnine, 195 (1.02 g, 4.4 mmol), and 
sodium phenoxide 0.57 g, 4.4 mmol) in THF (100 cm3) was stirred at room temperature for 
19 h after which time 19F NMR indicated 100% conversion of the start material. The 
reaction solvent was evaporated in vacuo and the sample dissolved into water (40 cm\ The 
mixture was extracted with ethyl acetate (3 x 40 cm3), the organic extracts were combined, 
dried (MgS04) and evaporated in vacuo to give a crude product as a yellow solid. (1.32 g). 
Recrystallisation from n-hexane yielded 2,5-difluoro-6-phenoxy-N-phenylpyrimidin-4-
amine, 305 (0.98 g, 70%) as a white solid; mp 128-130 °C; (Found: C, 64.1; H, 3.7; N, 14.0 
C16H11F2N30 requires: C, 64.2; H, 3.7; N, 14.0%); oH 6.9 (lH, NH), 7.2 (3H, m, Ar-CH), 
7.3 (lH, m, Ar-CH), 7.4 (4H, m, Ar-CH), 7.5 (2H, m, Ar-CH); oc 121.0 (s, Ar-CH), 121.4 
(s, Ar-CH), 124.9 (s, Ar-CH), 126.1 (s, Ar-CH), 129.1 (dd, 1JcF 248, 4Jcf9, C-5), 129.2 (s, 
Ar-CH), 129.9 (s, Ar-CH), 137.4 (s, CNC), 152.4 (s, 4-CN), 152.5 (dd, 2JcF 10, 3JcF 9, 6-
CO), 154.3 (dd, 1JcF 217, 4JcF4, 2-CF), 156.6 (dd, 2JcF 10, 3JcF 7, 6-CO); OF -46.5 (IF, s, C-
2), -176.9 (lF, s, C-5); m/z (El+) 299 ([M+], 17%), 259(5) 
143 
6-(Ethylthio )-2,5-difluoro-N -phenylpyrimidin-4-amine, 312 
~~ 
F~N ~~F+ BSN:i 
195 
THF, rt 
H,~ 
F~N 
B~~F 
312 
A solution of 2,5,6-trifluoro-N-phenylpyrimidin-4-amine, 195 (1.03 g, 4.4 mmol), and 
sodium ethanethiolate 0.37 g, 4.4 mmol) in THF (100 cm3) was stirred at room temperature 
for 19 hrs after which time 19F NMR indicated 100% conversion of the start material. The 
reaction solvent was evaporated in vacuo, DCM (40 cm3) and brine (40 cm3) was added and 
passed through a hydrophobic frit to collect the DCM layer. The DCM was evaporated in 
vacuo to give a crude product as a yellow solid. (1.39 g) Recrystallisation from n-hexane 
yielded 6-( ethylthio )-2,5-difluoro-N-phenylpyrimidin-4-amine, 312 (0.83 g, 69%) as a 
yellow solid; mp 101-102 °C; (Found: C, 53.8; H, 4.1; N, 15.8 C12HnF2N3S requires: C, 
53.9; H, 4.2; N, 15.7%); OH 1.44 (3H, t, 3JHH 7.4, CH3), 3.23 (3H, q, 3JHH 7.4, CH2), 6.82 
.(lH, NH), 7.20 (lH, m, Ar-H), 7.39 (2H, m, Ar-H), 7.61 (2H, m, Ar-H); oc 15.1 (s, CH3), 
24.0 (s, CH3), 121.0 (s, Ar-CH), 124.8 (s, Ar-CH), 129.4 (s, Ar-CH), 137.4 (s, CNC), 139.1 
(dd, 1Jcp252, 4Jcp7, C-5), 150.2 (dd, 2Jcp40, 3JcF 11, 4-CN), 155.2 (t, 3JcF 17, 6-CS), 
155.6 (dd, 1JcF 246, 4Jcp3, 2-CF); op -48.5 (IF, d, 5JFF 29, C-2), -158.5 (IF, d, 5JFF 29, C-5); 
m/z (El+) 267 ([M+], 100%), 234(74) 
144 
2,5-Difluoro-N-phenyl-6-(phenylthio)pyrimidin-4-amine, 313 
~~ 
F0N ~~F+ PhSr'a 
195 
TI-IF, rt 
A solution of 2,5,6-trifluoro-N-phenylpyrimidin-4-amine, 195 (1.02 g, 4.4 mmol), and 
sodium thiophenolate (0.61 g, 9.8 mmol) in THF (100 cm3) was stirred at room temperature 
for 19 h after which time 19F NMR indicated 100% conversion of the start material. The 
reaction solvent was evaporated in vacuo, DCM (40 cm3) and brine (40 cm3) was added and 
passed through a hydrophobic frit to collect the DCM layer. The DCM was evaporated in 
vacuo to give a crude yellow solid. (1.32 g) Recrystallisation from n-hexane yielded 2,5-
di.fluoro-N-phenyl-6-(phenylthio)pyrimidin-4-amine, 313 (0.46 g, 32%) as a yellow solid; 
mp 143-144 °C; (Found: C, 61.0; H, 3.5; N, 13.4 C16HllF2N3S requires: C, 60.9; H, 3.5; N, 
13.3%); ()H 6.92 (lH, NH), 7.35 (lH, m, Ar-H), 7.45 (5H, m, Ar-H), 7.62 (4H, m, Ar-H); De 
121.0 (s, Ar-CH), 125.0 (s, Ar-CH), 126.6 (s, CSC), 129.5 (s, Ar-CH), 129.6 (s, Ar-CH), 
130.0 (s, Ar-CH), 135.7 (s, Ar-CH), 137.2 (s, CNC), 138.5 (dd, 1JcF 248, 4JcF9, C-5), 150.8 
(dd, 2JcF 20, 3JcF 11, C-6), 154.2 (m, 6-CNH), 155.4 (dd, 1JcF 210, 4JcF 8, C-2); ()F -47.3 
(IF, d, 5hF29, C-2), -157.1 (lF, d, 5hF26, C-5); m/z (ES+) 316 ([M+ Ht, 100%) 
145 
5:·--::_· 
2,5-Difluoro-N -(phenylmethyl)-6-(1-piperidinyl)-4-pyrimidinamine, 303 
J 
F~N + 
~~F 
293 
Q 
H 
THF,rt 
DIPEA 
A solution of N,N-diethyl-2,5,6-trifluoropyrimidin-4-amine, 293 (100 mg, 0.49 mmol), 
piperidine (36 mg, 0.42 mmol) and DIPEA (0.333 ml, 1.47 mmol) in THF (10 cm3) was 
stirred at room temperature for 19 h after which time 19F NMR indicated 100% conversion 
of the start material. The reaction solvent was evaporated in vacuo, DCM (40 cm3) and 
brine (40 cm3) was added and passed through a hydrophobic frit to collect the DCM layer. 
The DCM was evaporated in vacuo to give a crude containing 2,5-difluoro-N-
(phenylmethyl)-6-( 1-piperidinyl)-4-pyrimidinamine and 5,6-difluoro-N-(phenylmethyl)-2-
(1-piperidinyl)-2-pyrimidinamine in a 1:1 ratio (65 mg). Mass-directed auto-preparation 
HPLC purification gave 5,6-di.fluoro-N-(phenylmethyl)-2-( 1-piperidinyl)-4-pyrimidinamine, 
303 (46 mg, 36%) as a red solid; mp 133-135 °C; ()H 1.56 (6H, m, CH2), 3.64 (4H, m, CH), 
4.66 (2H, d, 3JHH 6, CH2), 5.08 (1H, m, NH), 7.34 (5H, m, Ar-H); De 24.7 (s, CH2), 28.3 (s, 
CH2), 47.3 (d, 4JcF 7, CH2), 47.6 (d, 4JcF 7, CH2), 128.3 (dd, 1JcF 240, 4JcF 8, C-5), 126.8 (s, 
Ar-CH), 127.4 (s, Ar-CH), 129.3 (s, Ar-CH), 140.1 (s, NNC), 143.1 (m, C-4), 144.2 (m, C-
2), 153.8 (dd, 1JcF 203, 4JcF 2, C-6); <iF -50.1 (1F, s, C-2), -194.3 (lF, s, C-5); m/z (ES+) 305 
([M+ Ht, 100%). Crystals suitable for x-ray analysis were grown from MeOH. 
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2,6-Jl)iethoxy-N-ethyl-5-fluoropyrimidin-4-amine, 317 and 2-etboxy-N-ethyl-5-fluoro-
6-phenoxypyrimidin-4-amine, 318 
NHB 
ll-IF, rrw 140 0C F0N + 
15rrin J~CB 
1.5 
304 317 
1 
318 
A solution of N-ethyl-2,5-difluoro-6-(phenyloxy)-4-pyrimidinamine, 304 (1.01 g, 4.1 
mmol), and sodium ethoxide (0.59 g, 8.7 mmol) in THF (50 cm3) was stirred in a 
microwave at 140 °C for 15 min after which time 19F NMR indicated 100% conversion of 
the start material. The reaction solvent was evaporated in vacuo, DCM (40 cm3) and brine 
(40 cm3) was added and passed through a hydrophobic frit to collect the DCM layer. The 
DCM was evaporated in vacuo to give a crude yellow solid (1.56 g) and this was passed 
through a silica plug to yield a crude white solid containing 2,6-diethoxy-N-ethyl-5-
fluoropyrimidin-4-amine and 2-ethoxy-N-ethyl-5-fluoro-6-phenoxypyrimidin-4-amine in a 
1.5:1 ratio. Chromatography was performed using a reverse phase column with a gradient 
running from 5%:95% MeCN:H20 (0.1% formic acid in both) to 85%:15% to yield; 
(i) 2,6-diethoxy-N-ethyl-5-.fluoropyrimidin-4-amine, 317 (0.15 g, 16%) as a white solid; mp 
58-60 °C; (Found: C, 52.3; H, 7.0; N, 18.3 C12HI6FN302 requires: C, 52.4; H, 7.0; N, 
18.3%); &n 1.27 (3H, t, 3Jnn 7.2, CH3), 1.38 (6H, t, 3Jnn 7.2, CH3), 3.49 (2H, q, 3Jnn 6, 
CHz), 3.49 (4H, m, CHz); De 14.8 (s, CH3), 14.9 (s, CH3), 15.5 (s, CH3), 36.1 (s, CHz), 62.8 
(s, CHz), 63.4 (s, CHz), 127.3 (d, 1JcF237, C-5), 153.7 (d, 2JcF 10, C-4), 156.2 (d, 2JcF 9, C-
6), 158.6 (d, 4JcF 4, C-2); DF -191.2 (lF, s, C-5); m/z (El+) 229 ([W], 40%), 214(44), 
201(42). Crystals suitable for x-ray analysis were grown from MeOH. 
(ii) 2-ethoxy-N-ethyl-5-.fluoro-6-phenoxypyrimidin-4-amine, 318 (0.14 g, 13%) as a white 
solid; mp 109-110 °C; (Found: C, 60.39; H, 5.80; N, 15.15 CI4HI6FN302 requires: C, 60.64; 
H, 5.82; N, 15.15%); &n 1.25 (3H, m, CH3), 1.29 (6H, m CH3), 3.55 (2H, q, 3Jnn 6, CHz), 
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4.13 (4H, m, CHz), 7.32 (5H, m, Ar-CH); be 14.6 (s, CH3), 15.3 (s, CH3), 36.2 (s, CH2), 
63.6 (s, CH2), 121.2 (s, CH), 125.0 (s, CH), 127.7 (d, 1JcF 241, C-5), 129.5 (s, CH), 153.20 
(s, CO), 154.7 (d, 2JcF 9, C-4), 154.8 (d, 2JcF 10, C-6), 158.7 (d, 4JcF 4, C-2); bp -185.2 (1F, 
s, C-5); mlz (El+) 277 ([~], 20%), 262(8), 234(10). Crystals suitable for x-ray analysis 
were grown from MeOH. 
N2 -Butyl-~ -ethyl-5-fluoro-6-phenoxypyrimidine-2,4-diamine, 316 
304 
NHEt 
lHF, rrw 140 <>c F0N 
1h ~~NHEt 
316 
A solution of N-ethyl-2,5-difluoro-6-(phenyloxy)-4-pyrimidinamine, 304 (1.02 g, 4.1 
mmol), and ethylamine (0.34 g, 8.2 mmol) in THF (50 cm3) was stirred in a microwave at 
140 °C for 1 h after which time 19F NMR indicated 100% conversion with the formation of. 
The reaction solvent was evaporated in vacuo, DCM (40 cm3) and brine (40 cm3) was 
added and passed through a hydrophobic frit to collect the DCM layer. The DCM was 
evaporated in vacuo to give a crude brown solid (1.12 g). Recrystallisation from n-hexane 
yielded N2,~-diethyl-5-jluoro-6-phenoxypyrimidine-2,4-diamine, 316 (0.91 g, 63%) as a 
light brown solid; mp 88-89 °C; (Found: C, 60.7; H, 6.2; N, 20.3 C1~17FN40 requires: C, 
60.9; H, 6.2; N, 20.3%); bH 1.30 (3H, t, 3JHH 7.2, CH3), 3.38 (2H, m, CHz), 3.44 (2H, m, 
CH), 4.56 (lH, s, NH), 7.07 (3H, m, CH), 7.26 (2H, m, CH); be 15.2 (s, CH3), 15.4 (s, 
CH3), 36.0 (s, CH2), 36.8 (s, CH2), 121.0 (s, CH), 124.6 (s, CH), 125.4 (d, 1JcF 237, C-5), 
129.3 (s, CH), 153.8 (s, COC), 154.2 (d, 2JcF 10, C-4), 154.5 (d, 2JcF 8, C-6), 156.8 (d, 4JcF 
6, C-2); bp -189.8 (lF, s, C-5); m/z (El+) 276 ([M]+, 100%), 234(70). Crystals suitable for x-
ray analysis were grown from MeOH. 
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N -lEthyl-5-fluoro-6-phenoxy-2-(piperidin-1-yl)pyrimidin-4-amine, 315 
6 1 
304 315 
A solution of N-ethyl-2,5-difluoro-6-(phenyloxy)-4-pyrimidinamine, 304 (1.01 g, 4.1 
mmol), and piperidine (1.37 g, 16.0 mmol) in THF (50 cm3) was stirred in a microwave at 
140 °C for 15 min after which time 19F NMR indicated 100% conversion with the 
formation of N-ethyl-5-fluoro-6-phenoxy-2-(piperidin-1-yl)pyrimidin-4-amine and N-ethyl-
5-fluoro-2,6-di(piperidin-1-yl)pyrimidin-4-amine in a 6:1 ratio by 19F NMR. The reaction 
solvent was evaporated in vacuo, DCM (40 cm3) and brine (40 cm3) was added and passed 
through a hydrophobic frit to collect the DCM layer. The DCM was evaporated in vacuo to 
give a crude yellow solid (1.56 g). Column chromatography (silica, ethyl acetate:n-hexane, 
1: 15) yielded N-ethyl-5-.fluoro-6-phenoxy-2-(piperidin-1-yl)pyrimidin-4-amine, 315 (0.92 g, 
73%) as a yellow solid; mp 78-80 °C; (Found: C, 64.5; H, 6.6; N, 17.4 C17H21 FN40 
requires: C, 64.5; H, 6.7; N, 17.7%); bH 1.30 (3H, t, 3JHH 7.2, CH3), 3.38 (2H, m, CH2), 3.44 
(2H, m, CH), 4.56 (lH, s, NH), 7.07 (3H, m, Ar-H), 7.26 (2H, m, Ar-H); be 15.4 (s, CH3), 
25.0 (s, CH2), 25.8 (s, CH2), 36.0 (s, CH2), 45.3 (s, CH2), 120.9 (s, Ar-CH), 124.3 (s, Ar-
CH), 125.4 (d, 1Jcp 238, C-5), 129.2 (s, Ar-CH), 153.9 (s, COC), 153.9 (d, 2Jcp 10, C-4), 
154.1 (d, 2Jcp 8, C-6), 156.1 (d, 4JcF 4, C-2); bp -190.7 (lF, s, C-5); mlz (ES+) 317 ([M+ 
Ht, 100%) 
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4-(5-Fiuoro-6-phenoxy-2-(piperidin-1-yl)pyrimidin-4-yl)morpholine, 320 
C) 
Y~: 
306 
0 
H 
C) 
lHF, nw 100 <>c __ F~ N 
1h ~~ 0 
320 
A solution of 2,5-difluoro-4-morpholino-6-phenoxypyrimidine, 306 (1.00 g, 3.4 mmol), 
and piperidine (0.29 g, 3.4 mmol) in THF (15 cm3) was stirred in a microwave at 100 °C for 
1 h after· which time 19F NMR indicated 100% conversion. The reaction solvent was 
evaporated in vacuo and the sample dissolved into water (40 cm\ The mixture was 
extracted with ethyl acetate (3 x 40 cm3), the organic extracts were combined, dried 
(MgS04) and evaporated in vacuo to give a crude yellow solid (1.45 g). Recrystallisation 
from n-hexane yielded 4-( 5 -.fluoro-6-phenoxy-2-(piperidin-1-yl )pyrimidin-4-yl )morpholine, 
320 (1.10 g, 90%) as a white solid; mp 128-130 °C; (Found: C, 64.0; H, 6.6; N, 15.4 
C19H23FN402 requires: C, 63.7; H, 6.5; N, 15.6%); oH 1.49 (6H, m, CH2), 3.44 (4H, m, 
CH2), 3.70 (4H, m, CH), 3.79 (4H, m, CH), 7.16 (3H, m, CH), 7.23 (2H, m, CH); Oc 24.4 (s, 
CH2), 24.8 (s, CH2), 44.3 (s, CH2), 46.5 (s, CH2), 66.5 (s, CH2), 120.4 (s, Ar-CH), 124.0 (s, 
Ar-CH), 126.5 (d, 1Jcp243, C-5), 129.8 (s, Ar-CH), 153.2 (s, 4-CN), 153.6 (s, COC), 156.0 
(m, 2-CN), 158.1 (m, 6-CO); Op -180.0 (1F, s, C-5); m/z (ES+) 359 ([M+ Ht, 100%). 
Crystals suitable for x-ray analysis were grown from MeOH. 
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N-Butyl-5-fluoro-4-morpholino-6-phenoxypyrimidin-2-amine, 319 
C) 
Y;_; 
306 
. THF, rrw 140 0C 
DIPEA, ro mn 
319 
A solution of 2,5-difluoro-4-morpholino-6-phenoxypyrimidine, 306 (1.00 g, 3.4 mmol), 
and butylamine (0.99 g, 13.6 mmol) in THF (15 cm3) was stirred in a microwave at 140 °C 
for 30 min after which time 19F NMR indicated 100% conversion. The reaction solvent was 
evaporated in vacuo and the sample dissolved into water (40 cm\ The mixture was 
extracted with DCM (3 x 40 cm\ the organic extracts were combined, dried (MgS04) and 
evaporated in vacuo to give a crude white solid (1.46 g). Recrystallisation from n-hexane 
yielded N-butyl-5-jluoro-4-morpholino-6-phenoxypyrimidin-2-amine, 319 (0.59 g, 50%) as 
a white solid; mp 126-127 °C; (Found: C, 62.4; H, 6.7; N, 16.1 C 18H23FN40 2 requires: C, 
62.4; H, 6.7; N, 16.2%); oH 0.89 (3H, t, 3JHH 7.6, CH3), 1.28 (2H, m, CH2), 1.44 (2H, m, 
CH2), 3.16 (2H, m, CH2), 3.71 (4H, m, CH2), 3.79 (4H, m, CH2), 4.76 (lH, NH), 7.13 (3H, 
m, CH2), 7.35 (2H, m, CH2); Oc 14.1 (s, CH3), 20.3 (s, CH2), 32.0 (s, CH2), 41.7 (s, CH2), 
46.9 (d, 4JcF 7.3, CH2), 67.1 (s, CH2), 121.4 (s, Ar-CH), 124.8 (s, Ar-CH), 127.5 (d, 1JcF 
240, C-5), 129.4 (s, Ar-CH), 152.8 (s, 4-CN), 153.3 (s, COC), 154.2 (m, 2-CN), 158.4 (m, 
6-CO); OF -179.4 (1F, s, C-5); m/z (ES+) 347.2 ([M+ Ht, 100%). Crystals suitable for X-
ray analysis were grown from MeOH. 
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4-(2-Ethoxy-5-fluoro-6-phenoxypyrimidin-4-yl)morpholine, 321 
C) C) C) 
Y;_: 1.5 NaOEt TI-F, 1 h, 00 "C ~ "N + ~> l~ce -A_ CEt 
7 1 
306 
321 322 
A solution of 2,5-difluoro-4-morpholino-6-phenoxypyrimidine, 306 (0.50 g, 1.7 mmol), 
and sodium ethoxide (0.17 g, 2.55 mmol) in THF (50 cm3) was stirred in a microwave at 90 
°C for 1 h after which time 19F NMR indicated 67% conversion with the formation of 4-(2-
ethoxy-5-.fluoro-6-phenoxypyrimidin-4-yl)morpholine and 4 -( 2, 6-diethoxy-5-
.fluoropyrimidin-4-yl)morpholine in a 7:1 ratio. The reaction solvent was evaporated in 
vacuo and the sample dissolved into water (40 cm\ The mixture was extracted with ethyl 
acetate (3 x 40 cm\ the organic extracts were combined, dried (MgS04) and evaporated in 
vacuo to give a crude cream solid (0.68g). Column chromatography (silica, n-hexane: Ethyl 
acetate, 12: 1) of the solid was performed and the solid recrystallised from n-hexane yielded 
4-(2-ethoxy-5-.fluoro-6-phenoxypyrimidin-4-yl)morpholine, 321 (0.14 g, 26%) as a white 
solid; mp 87-88 °C; (Found: C, 59.96; H, 5.73; N, 13.36 C 16H1sFN30 3 requires: C, 60.18; 
H, 5.68; F, 5.95; N, 13.16; 0, 15.03%); &H 1.23 (3H, t, 3JHH 7.2, CH3), 3.79 (8H, m, CH2), 
4.15 (2H, q, 3JHH 7.2, CH2), 7.18 (2H, m, Ar-H), 7.19 (lH, m, Ar-H), 7.39 (2H, m, Ar-H); 
&c 14.1 (s, CH3), 46.6 (s, CH2), 63.4 (s, CH2), 66.7 (s, CH2), 120.4 (s, Ar-CH), 125.8 (s, Ar-
CH), 129.5 (d, 1Jcp244, C-5), 129.8 (s, Ar-CH), 153.1 (s, 4-CN), 153.5 (s, COC), 157.8 (m, 
2-CN), 158.2 (m, 6-CO); Op -175.0 (1F, s, C-5); mlz (Et) 319 ([Mt, 90%), 234(100) 
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N-Ethyl-5-fluoro-N'-phenyl-2-piperidin-1-ylpyrimidine-4,6-diamine 
~ ~ 
4 0 lHF, rrw Y~o XN + ~ DIPEA H B F 
300 328 
A solution of ~-ethyl-2,5-difluoro-_Ni-phenylpyrimidine-4,6-diamine, 300 (1.03 g, 4.0 
mmol), piperidine (1.40 g, 16.1 mmol) and DIPEA resin (3.0 g (4 mmol per g), 12 mmol) 
in THF (15 cm3) was stirred in a microwave at 140 °C for 15 min after which time 19F 
NMR indicated 90% conversion. The solution was filtered to remove the resin and the 
reaction solvent was evaporated in vacuo and the sample dissolved into water (40 cm\ The 
mixture was extracted with DCM (3 x 40 cm3), the organic extracts were combined, dried 
(MgS04) and evaporated in vacuo to give a crude orange solid (1.59 g). Recrystallisation 
from n-hexane:DCM yielded N-ethyl-5-fluoro-N'-phenyl-2-piperidin-1-ylpyrimidine-4,6-
diamine, 328 (1.86 g, 56%) as a peach solid; mp 131-132 °C; (Found: C, 64.6; H, 7.0; N, 
22.1 C17H22FNs requires: C, 64.7; H, 7.0; N, 22.2%); ()H 1.25 (3H, t, 3JHH 7.6, CH3), 1.60 
(6H, m, CHz), 3.47 (2H, m, CHz), 3.68 (4H, m, CHz), 4.23 (1H, s, NH), 6.16 (lH, s, NH), 
6.96 (lH, m, Ar-H), 7.29 (1H, m, Ar-H); <>c 15.7 (s, CH3), 25.2 (s, CHz), 26.0 (s, CHz), 35.8 
(s, CH2), 45.3 (s, CH2), 45.7 (s, CH2), 119.4 (s, Ar-CH), 122.0 (s, Ar-CH), 127.5 (d, 1JcF 
223, C-5), 129.0 (s, Ar-CH), 140.2 (s, 4-CNC), 147.0 (d, 2Jcp 7, C-4), 151.1 (d, 2Jcp 8, C-6), 
156.8 (d, 4JcF 4, C-2); <ip -191.96 (lF, s, C-5); m/z (ES+) 316 ([M+ Ht, 100%) 
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N -Ethyl-5-fluoro-2-phenoxy-N'-phenylpyrimidine-4,6-diamine, 329 
300 
11-IF, rrw 
15nin 
329 
A solution of ~-ethyl-2,5-difluoro-Afi-phenylpyrimidine-4,6-diamine, 300 (1.01 g, 4.0 
mmol), and sodium phenoxide (0.46 g, 4.1 mmol) in THF (15 cm3) was stirred in a 
microwave at 140 °C for 15 min after which time 19F NMR indicated 100% conversion 
with the formation of N-ethyl-5-fluoro-2-phenoxy-N -phenylpyrimidine-4,6-diamine. The 
reaction solvent was evaporated in vacuo, DCM (40 cm3) and brine (40 cm3) was added and 
passed through a hydrophobic frit to collect the DCM layer. The DCM was evaporated in 
vacuo to give a crude containing N-ethyl-5-.fluoro-2-phenoxy-N'-phenylpyrimidine-4,6-
diamine as a white solid (1.59 g). Recrystallisation from n-hexane:DCM yielded N-ethyl-5-
.fluoro-2-phenoxy-N'-phenylpyrimidine-4,6-diamine, 329 (1.06 g, 79%) as a white solid; mp 
124-112 °C; (Found: C, 66.7; H, 5.3; N, 17.4 C1sHnFN40 requires: C, 66.7; H, 5.3; N, 
17.3%); 8H 1.22 (3H, t, 3JHH 7.2, CH3), 3.58 (2H, m, CH2), 4.76 (lH, NH), 6.42 (IH, NH), 
6.98 (2H, m, CH), 7.19 (2H, m, CH), 7.23 (4H, m, CH), 4.41 (2H, m, CH); 8c 15.5 (s, CH3), 
36.1 (s, CH2), 119.2 (s, CH), 122.6 (s, CH), 122.7 (s, CH), 125.0 (s, CH), 127.4 (d, 1JcF 
235, C-5), 129.4 (s, CH), 139.2 (s, 4-CNC), 147.3 (d, 2JcF 8, C-4), 152.3 (d, 2JcF 10, C-6), 
153.9 (s, 2-COC), 156.8 (d, 4JcF 4, C-2); 8F -186.3 (IF, s, C-5); m/z (ES+) 325 ([M+ Ht, 
100%) 
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Chapter 8 
Experimental to Chapter 4 
N-(2,4,6-Trifluoropyrimidine-4-yl)benzamidine, 330 
M:CN,~ 
rt, 65 h 
330 
A solution of tetrafluoropyrimidine, 113 (0.50 g, 3.3 mmol), benzamidine hydrochloride 
(0.52 g, 3.3 mmol) and sodium bicarbonate (1.10 g, 13.2 mmol) in acetonitrile (200 cm3) 
was stirred at room temperature for 65 h after which time 19F NMR indicated 100% 
conversion. The reaction solvent was evaporated in vacuo and the sample dissolved into 
water (40 cm\ The mixture was extracted with DCM (3 x 40 cm3), the organic extracts 
were combined, dried (MgS04) and evaporated in vacuo to give a crude white solid (0.46 
g). Recrystallisation from acetonitrile yielded N-(2,4,6-trifluoropyrimidine-4-
yl)benzamidine, 330 (0.41 g, 50%) as a colourless solid; mp 151-153 °C; (Found: C, 52.3; 
H, 2.8; N, 22.2 C11H7F3N4 requires: C, 52.4; H, 2.8; N, 22.2%); bH 7.54 (2H, m, Ar-CH), 
7.60 (lH, m, Ar-CH), 8.03 (2H, m, Ar-CH); be 128.6 (s, Ar-C), 129.2 (s, Ar-C), 132.7 (s, 
Ar-C), 134.5 (s, Ar-C), 135.3 (dd, 2JcF 9.6, 3JcF 10.6, C-5), 148.3 (ddd, 1JcF 188, 2JcF 17.2, 
3Jcp4.5, C-6), 159.5 (ddd, 1JcF 211.2, 3JcF 14.5, 4Jcp4.9, C-2), 162.3 (m, C-4), 162.2 (s, Ar-
C); bp -48.6 (IF, s, C-6), -84.6 (IF, s, C-5), -166.7 (IF, m, C-2); m/z (El+) 268 ([Mt, 
I2%), 233 (36). 
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N ,N' -dimethyl-N ,N' -bis(2,5,6-trifluoropyrimidin-4-yl)ethane-1,2-diamine, 331 
113 
1\ 
-NH HN-
A solution of tetrafluoropyrimidine, 113 (2.05 g, 13 mmol), N,N'-dimethyl-ethylene-1,2-
diamine (1.16 g, 13 mmol) and sodium hydrogen carbonate (4.40 g, 52 mmol) in 
acetonitrile (300 cm3) was stirred at reflux for 127 h after which time 19F NMR indicated 
100% conversion. The reaction solvent was evaporated in vacuo and the sample dissolved 
into water ( 40 cm\ The mixture was extracted with DCM (3 x 40 cm\ the organic 
extracts were combined, dried (MgS04) and evaporated in vacuo to give a crude colourless 
solid (3.29 g). Recrystallisation from ethyl acetate gave N,N'-dimethyl-N,N'-bis(2,5,6-
trifluoropyrimidin-4-yl)ethane-1,2-diamine, 331 (2.16 g, 45%) as a colourless solid; mp 
100-102 °C; (Found: C, 40.7; H, 2.8; N, 23.7 C12H10F6N6 requires: C, 40.9; H, 2.9; N, 
23.9%); 8H 3.24 (3H, s, CH3), 3.87 (2H, s, CH2); 8c 38.6 (s, CH3), 49.7 (s, CH2), 130.7 
(ddd, 1JcF 234, 2JcF 15, 4JcF 9, C-5), 154.7 (ddd, 1JcF 187, 2JcF 21, 3JcF 3, C-2), 155.6 (dt, 
2JcF 19, 3JcF 5, C-4), 160.1 (ddd, 1JcF 241, 2JcF 21, 3JcF 9, C-6); 8F -48.8 (lF, d, 4JFF 25, C-
3 + . + 2), -87.7 (1F, d, JFF 16, C-6), -174.2 (1F, s, C-5); m/z (ES) 353 ([M+ H] , 100%) 
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Chapter 9 
Experimental to Chapter 5 
N-(3,5,6-Trichloro-pyrazin-2-yl)-benzamidine, 344 
a:(:Ja + 
a ~a 
115 
Ph lHF 
~~ 
.HCI 
4 
344 
A solution of tetrachloropyrazine, 115 (1.06 g, 4.5 mmol), benzamidine hydrochloride 
(0.72 g, 4.5 mmol) and sodium carbonate (1.54 g, 18 mmol) in acetonitrile (300 cm3) was 
stirred at reflux for 99 h after which time TLC indicated 100% conversion form the start 
material. The reaction solvent was evaporated in vacuo and the sample dissolved into water 
(40 cm\ The mixture was extracted with ethyl acetate (3 x 40 cm\ the organic extracts 
were combined, dried (MgS04) and evaporated in vacuo to give a crude product containing 
N-(3,5,6-Trichloro-pyrazin-2-yl)-benzamidine as a yellow solid. Recrystallisation from 
acetonitrile yielded N-(3,5,6-Trichloro-pyrazin-2-yl)-benzamidine, 344 (1.12 g, 76%) as a 
yellow solid; mp 199-201 °C; (Found: C, 43.8; H, 2.3; N, 18.4, C11 H7Cl3N4 requires: C, 
43.8; H, 2.3; N, 18.6%); DH 7.57 (4H, m, Ar-H), 8.07 (lH, m, Ar-H); De 128.4 (s, Ar-CH), 
129.1 (s, Ar-CH), 132.4 (s, Ar-CH), 133.69 (s, CCN), 135.04 (s, C-3), 140.31 (s, C-5), 
141.47 (s, C-6), 154.27 (s, CN), 160.26 (C-2) mlz (ES+) 301 ([M+ Ht, 100%) 
2,3,5,6-Tetrafluoropyrazine, 116 
a:(:Ja 
a ~a 
115 
KF 
autoclave, 31 CPC 
1 
).F-;GN 2 F 6 I "' ~ 3 
s F 
4 1'16. 
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A stainless steel, oven dried 0.5 dm3 autoclave was charged with flame-dried potassium 
fluoride (125 g, 4 mol) and tetrachloropyrazine, 115 (50 g, 0.6 mol). The autoclave was 
sealed and heated to 310 °C for 19 h after which time the reaction mixture was allowed to 
cool to 200 °C. The gaseous tetrafluoropyrazine, 116 was removed under reduced pressure 
and condensed in a Young's tap-equipped vessel. Analysis as outlined by Chambers et al. 1 
N-(3,5,6-Trifluoro-pyrazin;.2-yl)-benzamidine, 342 
116 
A1 
HN~~ 
.HO 
11-iF 
A1~~ 
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A solution of tetrafluoropyrazine, 116 (1.00 g, 6.6 mmol), benzarnidine hydrochloride (1.24 
g, 6.6 mmol) and sodium hydrogen carbonate (2.21 g, 26 mmol) in acetonitrile (300 cm3) 
was stirred at reflux for 101 h after which time 19F NMR indicated 82% conversion of the 
start material. The reaction solvent was evaporated in vacuo and the sample dissolved into 
water (40 cm3) and HCI (5 cm\ The mixture was extracted with DCM (3 x 40 cm\ the 
organic extracts were combined, dried (MgS04) and evaporated in vacuo to give a crude 
product containing N-(3,5,6-trifluoro-pyrazin-2-yl)-benzamidine (1.87 g) as an yellow 
solid. Recrystallisation from ethyl acetate yielded N-( 3,5,6-tri.fluoro-pyrazin-2-yl)-
benzamidine, 342 (1.09 g, 67%) as an yellow solid; mp 121-123 °C; (Found: [M+ Ht 
253.0698 C 11H7F3N4 requires: [M+ Ht 253.0696); ()H 7.45 (3H, m, Ar-H), 7.91 (2H, m, 
Ar-H); <>c 128.3 (s, Ar-CH), 129.1 (s, Ar-CH), 132.2 (s, Ar-CH), 135.3 (s, Ar-CH), 136.6 
(dm, 1JcF 191, C-6), 140.4 (dm, 1Jcp 175, C-5), 142.3 (m, C-3), 147.1 (dm, 1JcF 205, C-2), 
160.4 (s, C=N); bp -87.29 (1F, dd, 1Jpp 54, 3Jpp 17, C-2), -97.78 (lF, dd, 1JFF 39, 3JFF 31, C-
3), -105.02 (lF, dd, 1Jpp 18, 3Jpp 13, C-5); m/z (El+) 252 ([Mt, 12%), 233(16), 216(2), 
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2,3-Difluoro-6,7 ,8,9-tetrahydropyrido[1 ',2': 1,2]imidazo[ 4,5-b ]pyrazine, 341 
116 
(l MeCN, reflux 
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H 
.I-CI 
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A solution of tetrafluoropyrazine, 116 (1.02 g, 6.7 mmol), 2-iminopiperidine hydrochloride 
(1.33 g, 9.9 mmol) and sodium hydrogen carbonate (3.31 g, 40 mmol) in acetonitrile (300 
cm3) was stirred at reflux for 105 h after which time 19F NMR indicated 100% conversion 
of the start material. The reaction solvent was evaporated in vacuo and the sample 
dissolved into water ( 40 cm\ The mixture was extracted with DCM (3 x 40 cm\ the 
organic extracts were combined, dried (MgS04) and evaporated in vacuo to give a crude 
product containing 2,3-difluoro-6, 7 ,8,9-tetrahydropyrido[l ',2': 1 ,2]imidazo[4,5-b ]pyrazine 
(1.82 g) as an yellow solid. Recrystallisation from DCM gave 2,3-difluoro-6,7,8,9-
tetrahydropyrido[l',2':1,2]imidazo[4,5-b]pyrazine, 341 (1.12 g, 79%) as an yellow solid; 
mp 144-146 °C; (Found: [M+ Ht 211.0792 C9HsF2N4 requires: [M+ Ht 211.0790); 8H 
1.97 (2H, m, CH2), 2.05 (2H, s, CH2), 3.06 (2H , t, 3JHH 6.4, CH2), 4.13 (2H , t, 3JHH 6, 
CH2); 8c 19.9 (s, CH2), 21.9 (s, CH2), 26.1 (s, CH2), 42.5 (s, CH2), 134.2 (d, 3Jcp 10, C-9a), 
140.3 (dd, 1Jcp 210, 2Jcp 33.1, C-2), 141.9 (dd, 1Jcp 210, 2JcF 33.1, C-3), 142.1 (dd, 3Jcp 12, 
4Jcp 4, C-4a), 154.7 (dd, 1Jcp 207, 2Jcp 31, C-8a); Op -98.41 (IF, dd, 3Jpp 25, C-2), -100.38 
(IF, dd, 3Jpp27, C-3); mlz (El+) 210 ([Mt, 100%), 182(68), 155(30) 
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2,3-Difluoro-6-methylpyrido[l' ,2': 1,2]imidazo[ 4,5-b ]pyrazine, 338 
5 6 
n;F F-),:~;t4a ~F): I ~ i(a;!\ 
2 9a N 1 
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A solution of tetrafluoropyrazine, 116 (1.50 g, 10 mmol), 2-amino-3-picoline (1.57 g, 15 
mmol) and sodium carbonate (3.32 g, 39 mmol) in THF (300 cm3) was stirred at room 
temperature for 19 h after which time 19F NMR indicated 100% conversion. The reaction 
solvent was evaporated in vacuo and the sample dissolved into water (40 cm\ The mixture 
was extracted with ethyl acetate (3 x 40 cm\ the organic extracts were combined, dried 
(MgS04) and evaporated in vacuo to give a crude product containing 2,3-difluoro-6-
methylpyrido[l',2': 1,2]imidazo[4,5-b]pyrazine (3.21 g). Recrystallisation from ethylacetate 
yielded 2,3-difluoro-6-methylpyrido[ 1 ',2':1,2]imidazo[4,5-b]pyrazine, 338 (1.04 g, 30%) as 
brown solid; mp 213-215 °C; (Found: C, 54.4, H, 2.7, N, 25.5 C10H6F2N4 requires: C, 54.6, 
H, 2.8, N, 25.5%); &H (d6-DMSO) 2.57 (3H, s, CH3), 7.15 (lH, m, Ar-H), 7.61 (lH, m, Ar-
H), 8.74 (lH, m, Ar-H); 8c (d6-DMSO) 18.5 (s, CH3), 117.9 (s, C-8), 122.0 (s, Ar-CH), 
129.0 (s, Ar-CH), 129.1 (m, C-4a), 132.1 (s, Ar-CH), 140.2 (dd, 1JcF 377, 2JcF 35, C-3), 
I 2 · 6 143.9 (m, C-9a), 144.1 (dd, Jcp 374, Jcp3l, C-2), 151.3 (s, C-8a); 8p (d -DMSO) -89.52 
(IF, d, 3JFF 27, C-2), -98.62 (IF, d, 3JFF 27, C-3); m/z (El+) 220 ([M]+, 100%), 192(6), 
167(2) 
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2,3-Difluoro-6-methylpyrido[l' ,2' :1,2]imidazo[ 4,5-b]pyrazine, 338 
)(x: + ~)0 :;,~"'" 
116 
A solution of tetrafluoropyrazine, 116 (100 mg, 0.66 mmol), 2-amino-3-picoline (70 mg, 
0.66 mmol) and diethylamine (180 mg, 1.38 mmol) in acetonitrile (1 cm3) was stirred in a 
microwave for 5 min at 150 °C after which time 19F NMR indicated 87% conversion. The 
reaction solvent was evaporated in vacuo and the sample dissolved into water (40 cm\ The 
mixture was extracted with ethyl acetate (3 x 40 cm\ the organic extracts were combined, 
dried (MgS04) and evaporated in vacuo to give a crude product containing 2,3-difluoro-6-
methylpyrido[1 ',2': 1,2]imidazo[4,5-b]pyrazine (130 mg). Recrystallisation from ethyl 
acetate yielded 2,3-difluoro-6-methylpyrido[ 1 ',2':1,2]imidazo[4,5-b]pyrazine as brown 
solid (90 mg, 56%). Analysis data is as found previously. 
2,3-Difluoro-6-methylpyrido[l' ,2': 1,2]imidazo[ 4,5-b ]pyrazine, 339 
n-F 
116 
A solution of tetrafluoropyrazine, 116 (0.50 g, 3.3 mmol), 2-amino-pyridine (0.93 g, 10 
mmol) and sodium carbonate (3.32 g, 39 mmol) in THF (20 cm3) was stirred was stirred in 
a microwave for 5 min at 150 °C after which time 19F NMR indicated 87% conversion. The 
reaction solvent was evaporated in vacuo and the sample dissolved into water (40 cm\ The 
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mixture was extracted with ethyl acetate (3 x 40 cm\ the organic extracts were combined, 
dried (MgS04) and evaporated in vacuo to give a crude product containing 2,3-
difluoropyrido[l',2': 1,2]imidazo[4,5-b]pyrazine (1.21 g). Recrystallisation from methanol 
yielded 2,3-difluoropyrido[l',2':1,2]imidazo[4,5-b]pyrazine, 339 (0.22 g, 32%) as brown 
solid; mp 217-219 °C; ([M+ Ht 214.1022 C9H~2N4requires; [M+ Ht2I4.1025); ()H 6.93 
(lH, m, Ar-H), 7.11 (IH, m, Ar-H), 7.53 (lH, m, Ar-H), 8.31 (IH, m, Ar-H); <>c 111.8 (s, 
Ar-CH), 116.0 (s, Ar-CH), 119.3 (s, Ar-CH), 127.9 (s, Ar-CH), 128.0 (d, 3JcF 9, C-3), 131.5 
(s, CH2), 145.2 (dd, 1JcF 377, 2JcF 35, C-5), 143.9 (dd, 1JcF 374, 2JcF 31, C-6); Op- 89.67 
(IF, d, 3JFF 27, 2-CF), -96.72 (IF, d, 3JFF 27, 3-CF); m/z (El) 207 (~. 100%), 192(6), 
167(2) 
2,3-Difluoro-6, 7 ,8,9-tetrahydro-5,9-dimethyi-5H -pyrazino[2,3-b ][1 ,4]diazepine, 346 
:;t~':7 
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A solution of tetrafluoropyrazine, 116 (1.00 g, 6.6mmol), N1 ,N2 -dimethyl ethane- I ,2-
diamine (0.58 g, 6.6mmol) and diethylamine (1.80 g, 13 mmol) in acetonitrile (10 cm3) was 
stirred in a microwave for 5 min at 150 °C after which time 19F NMR indicated 100% 
conversion. The reaction solvent was evaporated in vacuo and the sample dissolved into 
water (40 cm\ The mixture was extracted with DCM (3 x 40 cm\ the organic extracts 
were combined, dried (MgS04) and evaporated in vacuo to give a crude product containing 
2,3-difluoro-6,7 ,8,9-tetrahydro-5 ,9-dimethyl-5H-pyrazino[2,3-b] [1 ,4]diazepine ( 1.14 g). 
The sample was then dissolved into ethyl acetate and passed through a silica plug to yield 
2,3-di.fluoro-6, 7,8,9-tetrahydro-5,9-dimethyl-5H-pyrazino[2,3-b][ 1,4 ]diazepine, 346 (1.09 
g, 67%) as an brown solid; mp 18-19 °C; (Found: [M+ Ht 214.1022 C9H 12F2N4 requires: 
[M+ Ht 214.1025); DH 1.89 (2H, q, 3JHH 6, CHz), 2.86 (6H, s, CH3), 3.38 (4H, t, 3JHH 6.2, 
CHi); <>c 25.8 (s, CHz), 40.2 (s, CH2), 51.4 (s, CHz), 138.6 (dd, 1JcF 202, 2Jcp34, C-2 and C-
162 
3), 143.1 (m, C-4a and C-9a); 8F -115.73 (2F, s, C-2); m/z (El+) 213.9 ([M]\ 82%), 
185(100), 171(26) 
N,N-Diethyl-2,3-difluoro-7-methylfuro[2,3-b ]pyrazine-6-carboxamide, 347 
116 
ll-IF 
l\laH 
N,N'-diethylacetoacetamide (4.40 g, 30 mmol) and sodium hydride (60% in mineral oil, 
1.31 g, 30 mmol) was added to tetrahydrofuran (400 cm3) and stirred at room temperature 
for 2 h before the addition of 2,3,5,6-tetrafluoropyrazine, 116 (2.07 g, 14 mmol). The 
reaction mixture was then stirred at reflux for 23 h after which time 19F NMR indicated 
100% conversion of the start material. The reaction solvent was evaporated in vacuo and 
the sample dissolved into water (40 cm3). The mixture was extracted with ethyl acetate (3 x 
40 cm\ the organic extracts were combined, dried (MgS04) and evaporated in vacuo to 
give a crude product containing N,N-diethyl-2,3-difluoro-7 -methylfuro[2,3-b ]pyrazine-6-
carboxamide (5.43 g). Column chromatography (silica, ethylacetate:n-hexane, 1:4) gave 
N,N-diethyl-2,3-difluoro-7-methylfuro[2,3-b]pyrazine-6-carboxamide, 347 (2.04 g, 60%) as 
yellow crystals; mp 73-75 °C; (Found: C, 53.7; H, 4.9; N, 15.4 C12H13F2N30 2 requires: C, 
53.5; H, 4.9; N, 15.6%); 8H 1.04 (3H, t, 3JHH 6.8, CH3), 1.17 (3H, t, 3JHH 6.8, CH3), 2.56 
(1H, s, CH3), 3.30 (2H, q, 3JHH 7.2, CH2), 3.50 (2H, q, 3JHH 7.2, CH2); 8c 13.6 (s, CH3), 14.3 
(s, CH3), 15.1 (s, CH3), 39.6 (s, CH2), 43.3 (s, CH2), 114.2 (s, C-7), 131.9 (dd, 4JcF 7, 5JcF5, 
C-7a), 144.5 (dd, 1JcF 215, 2JcF34, C-2) 147.2 (dd, 1JcF 133, 2JCF22, C-3), 147.4 (s, C-4a), 
147.5 (s, C=O), 161.4 (s, 6-C); 8F -95.80 (lF, d, 3JFF 23, C-2), -97.37 (1F, d, 3JFF 25, C-3); 
m/z (El+) 269 ([Mt, 48%), 196(100), 141(18) 
163 
Ethyl 2,3-difluoro-6-methylfuro[2,3-b ]pyrazine-7 -carboxylate, 273 
116 
Ethylacetoacetate (2.56 g, 13 mmol) and sodium hydride (60% in mineral oil, 0.75 g, 19 
mmol) was added to tetrahydrofuran 250 cm3 and stirred at room temperature for 2 h before 
the addition of 2,3,5,6-tetrafluoropyrazine, 116 (1..5 g, 10 mmol). The reaction mixture was 
then stirred at reflux for 26 h after which time 19F NMR indicated 100% conversion of the 
start material. The reaction solvent was evaporated in vacuo and the sample dissolved into 
water (40 cm\ The mixture was extracted with ethyl acetate (3 x 40 cm\ the organic 
extracts were combined, dried (MgS04) and evaporated in vacuo to give a crude product 
containing ethyl 2,3-difluoro-6-methylfuro[2,3-b ]pyrazine-7 -carboxylate (2.52 g). Column 
chromatography (silica, ethylacetate:n-hexane, 1:4) gave ethyl 2,3-difluoro-6-
methylfuro[2,3 -b ]pyrazine-7-carboxylate, 273 (1.70 g, 71% ). Analysis as outlined in 
Rachel Slater thesis.2 Crystals suitable for x-ray analysis were grown from MeOH. 
2-(Diethylamino )-N,N -diethyl-3-fluoro-6-methylfuro[2,3-b ]pyrazine-7 -carboxamide, 
357 
347 
t-INEt2, l\lleCN, 
reflux, 21 h 
N,N-diethyl-2,3-difluoro-7 -methylfuro[2,3-b ]pyrazine-6-carboxamide, 347 (0.50 g, 1.9 
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mmol) and diethylamine (0.28 g, 3.8 mmol) in acetonitrile (40 cm3) was stirred at reflux for 
21 h after which time 19F NMR indicated 100% conversion of the start material. The 
reaction solvent was evaporated in vacuo and the sample dissolved into water (40 cm\ The 
mixture was extracted with ethyl acetate (3 x 40 cm\ the organic extracts were combined, 
dried (MgS04) and evaporated in vacuo to give a crude product containing 2-
( diethylamino )-N,N-diethyl-3 -fluoro-6-methylfuro[2, 3 -b ]pyrazine-7 -carboxamide, 357 
(0.56 g, 95%) as yellow crystals; mp 66-68 °C, IR (neat, v cm-1): 2973, 2361, 1702, 1590, 
1510, 1453, 1431, 1400, 1265, 1028, 993; (Found: C, 59.4; H, 7.2; N, 17.2 C16H23FN40 2 
requires: C, 59.6; H, 7.2; N, 17.4%); OH 1.03 (3H, t, 3JHH 7.2, CH3), 1.17 (3H, m, CH3), 2.41 
(3H, s, CH3), 2.28 (IH, q, 3JHH 7.2, CH3), 3.48 (2H, m, 7.2, CH2); Oc 13.7 (s, CH3), 13.8 (s, 
. 4 CH3), 14.0 (s, CH3), 15.1 (s, CH3), 39.6 (s, CH2), 43.2 (s, CH2), 44.8 (d, JcF 5.7, CH2), 
113.7 (s, C-7), 120.8 (d, 3JcF 13.4, C-7a), 140.7 (d, 2JcF25.9, 3-CN), 148.1 (d, 1JcF244, C-
2), 151.1 (s, C-4a), 154.1 (s, C-6), 162.5 (s, C=O); oF -83.54 (IF, s, C-2); mlz (El+) 322 
([Mt, 96%), 249(100), 221(94) 
2-(Diethylamino )-3-fluoro-6-methylfuro[2,3-b ]pyrazine-7 -carboxylate, 356 
273 356 
Ethyl 2,3-difluoro-6-methylfuro[2,3-b ]pyrazine-7 -carboxylate, 273 (0.42 g, 1. 7 mmol) and 
diethylamine (0.25 g, 3.4 mmol) in acetonitrile (50 cm3) was stirred at reflux for 18 h after 
which time 19F NMR indicated 100% conversion of the start material. The reaction solvent 
was evaporated in vacuo and the sample dissolved into water (40 cm3). The mixture was 
extracted with ethyl acetate (3 x 40 cm\ the organic extracts were combined, dried 
(MgS04) and evaporated in vacuo to give a crude product containing ethyl 2-
(diethylamino)-3-jluoro-6-methylfuro[2,3-b]pyrazine-7-carboxylate, 356 (0.48 g, 95%) as a 
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yellow solid; mp 43-45 °C; (Found: C, 56.7; H, 6.2; N, 14.2 C 14H18FN303 requires: C, 56.9; 
H, 6.1; N, 14.2%); DH 1.19 (3H, t, 3JHH 7, CH3), 1.37 (3H, t, 3JHH 7, CH3), 2.68 (3H, s, CH3), 
3.52 (lH, q, 3JHH 7.5, CH3), 4.37 (lH, q, 3JHH 7.5, CH3); De 13.8 (s, CH3), 14.7 (s, CH3), 15.0 
(s, CH3), 44.9 (d, 4JcF 5.4, CH2), 61.0 (s, CH2), 109.2 (s, C-7), 120.4 (d, 3JcF 11.1, C-7a), 
141.0 (d, 2Jcp2l, 3-CN), 148.3 (s, C-4a), 151.4 (d, 1JcF 196, C-2), 161.8 (s, C-6), 163.2 (s, 
C=O); Dp -82.54 (IF, s, C-2); m/z (El+) 295 ([Mt, 52%), 280(100), 249(62) 
Ethyl 2-fluoro-3-methoxy-6-methylfuro[2,3-b ]pyrazine-7 -carboxylate, 355 
F'(~ }~ M<Nl ~ ~;er refl~Z!lrs 
A solution of Ethyl 2,3-difluoro-6-methylfuro[2,3-b ]pyrazine-7 -carboxylate, 273 (300 mg, 
1.2 mmol), and sodium methoxide (60 mg, 1.2 mmol) in methanol (50 cm3) was stirred at 
room temperature for 16 h after which time 19F NMR indicated 100% conversion. The 
reaction solvent was evaporated in vacuo and the sample dissolved into water (40 cm\ The 
mixture was extracted with ethyl acetate (3 x 40 cm\ the organic extracts were combined, 
dried (MgS04) and evaporated in vacuo to give a crude product containing ethyl 2-fluoro-
3-methoxy-6-methylfuro[2,3-b ]pyrazine-7 -carboxylate. Recrystallisation from ethyl acetate 
yielded ethyl2-fluoro-3-methoxy-6-methyl.furo[2,3-b]pyrazine-7-carboxylate, 355 (270 mg, 
89%) as white needles; mp 159-160 °C; IR (neat, v cm-1): 1706, 1589, 1503, 1456, 1399, 
1321, 1150, 1031, 800; (Found: C, 51.7; H, 4.3; N, 10.8 C 11H 11FN204requires: C, 52.0; H, 
4.4; N, 11.0% ); DH 1.37 (3H, t, 3JHH 7, CH3), 2.75 (3H, s, CH3), 4.03 (3H, s, OCH3), 4.39 
(2H, q, 3JHH 7, CH3); De 14.63 (s, CH3), 15.14 (s, CH3), 55.18 (s, OCH3), 61.26 (s, CH2), 
109.60 (s, C-7), 125.01 (d, 3JcF 12.4, C-7a), 145.01 (d, 2Jcp30.5, C-3), 147.09 (d, 1JcF 248, 
C-2), 149.11 (s, C-4a), 162.71 (s, C-6), 164.29 (s, C=O); Dp -91.90 (1F, s, C-2); mlz (El+) 
254 ([Mt, 14%), 208(100), 180(82) 
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N ,N-Diethyl-3-fluoro-6,7 ,8,9-tetrahydropyrido[l ',2' :1,2]imidazo[ 4,5-b ]pyrazin-2-
amine, 348 
:t):P+~ reflux, 73h 
341 
348 
A solution of 2,3-difluoro-6, 7 ,8,9-tetrahydropyrido[1',2': 1 ,2]imidazo[4,5-b ]pyrazine, 341 
(0.30 g, 1.4 mmol) and diethylamine (0.63 g, 8.6 mmol) in acetonitrile (50 cm3) was stirred 
at reflux for 73 h after which time 19F NMR indicated 100% conversion of the start 
material. The reaction solvent was evaporated in vacuo and the sample dissolved into water 
(40 cm\ The mixture was extracted with ethyl acetate (3 x 40 cm\ the organic extracts 
were combined, dried (MgS04) and evaporated in vacuo to give a crude product containing 
N,N-diethyl-3-fluoro-6, 7 ,8,9-tetrahydropyrido[ 1',2': 1 ,2]imidazo[ 4,5-b ]pyrazin-2-amine 
(0.28 g). Recrystallisation from DCM gave N,N-diethyl-3-jluoro-6,7,8,9-
tetrahydropyrido[l',2':1,2]imidazo[4,5-b]pyrazin-2-amine, 348 (0.26 g, 69%) as yellow 
solid; mp 89-91 °C; (Found: C, 59.2; H, 6.9; N, 26.5 C13H 18FN5 requires: C, 59.3; H, 6.9; 
N, 26.6%); 8H 1.15 (3H, t, 3JHH 7, CH3), 2.06 (4H, m, CHz), 3.00 (2H, t, 3JHH 6.4, CHz), 
3.48 (4H, q, 3JHH 5.4, CHz) 4.03 (2H ,t, 3JHH 6, CHz); be 13.7 (s, CH3), 20.7 (s, CHz), 22.5 
(s, CHz), 26.0 (s, CHz), 41.7 (s, CHz), 44.8 (d, 4JcF 5.7, CHz), 135.5 (d, 3JcF 13.4, C-9a), 
136.0 (s, C-4a), 140.8 (d, 2JcF 13.4, C-3), 145.79 (d, 1JcF 247, C-2), 151.03 (m, C-8a); 8F-
84.37 (s, C-2); m/z (ES+) 264 ([M+ Ht, 100%), 
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N ,N-Diethyl-3-fluoro-6,7,8,9-tetrahydropyrido[l ',2' :1,2]imidazo[ 4,5-b ]pyrazin-2-
amine,349 
Fl!N Np ~;c~ + 1\Ja.a='h reflux, 73 h 
341 349 
A solution of 2,3-difluoro-6, 7 ,8,9-tetrahydropyrido[1',2': 1 ,2]imidazo[ 4,5-b ]pyrazine, 341 
(0.30 g, 1.4 mmol) and sodium phenoxide (0.63 g, 8.6 mmol) in acetonitrile (50 cm3) was 
stirred at reflux for 73 h after which time 19F NMR indicated 100% conversion of the start 
material. The reaction solvent was evaporated in vacuo and the sample dissolved into water 
(40 cm\ The mixture was extracted with DCM (3 x 40 cm\ the organic extracts were 
combined, dried (MgS04) and evaporated in vacuo to give a crude product containing N,N-
diethyl-3-fluoro-6, 7 ,8,9-tetrahydropyrido[ 1',2': 1 ,2]imidazo[4,5-b ]pyrazin-2-amine (0.28 g). 
Recrystallisation from hexane gave N,N-diethyl-3-fluoro-6,7,8,9-
tetrahydropyrido[ 1',2':1,2]imidazo[4,5-b]pyrazin-2-amine, 349 (0.22 g, 54%) as a white 
solid; mp 108-110 °C; (Found: C, 63.2; H, 4.6; N, 19.6 C15H13FN40 requires: C, 63.4; H, 
4.6; N, 19.7%); &H 2.07 (4H, m, CH2), 3.13 (2H, t, 3JHH 6, CH2), 4.04 (4H, t, 3JHH 5, CH2), 
7.14 (1H, m, Ar-H), 7.25 (lH, m, Ar-H), 7.39 (4H, m, Ar-H); &c 20.8 (s, CH2), 22.6 (s, 
CH2), 26.5 (s, CH2), 42.7 (s, CH2), 120.6 (s, Ar-CH), 125.4 (s, Ar-CH), 130.3 (s, Ar-CH), 
134.9 (d, 4JcF 2, C-9a), 140.9 (d, 3JcF 12, C-4a), 143.5 (d, 2JcF 30, C-3), 149.0 (d, 1JcF 247, 
C-2), 154.9 (s, C-8a), 155.8 (d, 4JcF 2, CO); &F -93.08 (s, C-2); m/z (El+) 284 ([Mt, 90%), 
255(77), 206(33) 
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N ,N-Diethyl-2-fluoro-6-methylpyrido[l 1,21 : 1,2]imidazo[ 4,5-b ]pyrazin-3-amine, 350 
and N,N -Diethyl-3-fluoro-6-methylpyrido[1 1,21 : 1,2]imidazo[ 4,5-b ]pyrazin-2-amine, 
351 
)(X~~ +2~2 
338 
M3CN 
reflux, 73 h + 
A solution of 2,3-difluoropyrido[1',2': 1,2]imidazo[4,5-b]pyrazine, 338 (200 mg, 0.9 mmol), 
diethylamine (140 mg, 1.8 mmol) and DIPEA (376 mg, 2.7 mmol) in THF (50 cm3) was 
stirred at room temperature for 20 h after which time LCMS indicated 100% conversion 
with the formation N,N-diethyl-3-fluoropyrido[1',2':1,2]imidazo[4,5-b]pyrazin-2-amine and 
N,N-diethyl-2-fluoropyrido[1',2': 1,2]imidazo[4,5-b ]pyrazin-3-amine in a 1:1 ratio by 19F 
NMR. The reaction solvent was evaporated in vacuo, DCM (40 cm3) and brine (40 cm3) 
was added and passed through a hydrophobic frit to collect the DCM layer. The DCM was 
evaporated in vacuo to give a crude containing N,N-diethyl-2-fluoro-6-
methylpyrido[1',2': 1 ,2]imidazo[4,5-b ]pyrazin-3-amine and N,N-diethyl-3-fl uoro-6-
methylpyrido[ 1' ,2': 1 ,2]imidazo[ 4,5-b ]pyrazin-2-amine ( 149mg). Mass-directed auto-
preparation HPLC purification yielded; 
(i) N,N-diethyl-3-fluoro-6-methylpyrido[ 1 ',2': 1 ,2]imidazo[ 4,5-b ]pyrazin-2-amine, 351 
which was then recrystallised from methanol to give N,N-diethyl-3-fluoro-6-
methylpyrido[1',2':1,2]imidazo[4,5-b]pyrazin-2-amine (34 mg, 27%) as a yellow solid; mp 
159 °C, (Found: C, 61.3; H, 5.9; N, 25.7 C14H16FNs requires: C, 61.5; H, 5.9; N, 25.6%); ()H 
1.30 (3H, t, 3JHH 7, CH3), 2.68 (3H, s, CH3), 3.68 (2H, q, 3JHH 6, CHz), 6.85 (lH, m, Ar-H), 
7.22 (1H, m, Ar-H), 8.33 (1H, m, Ar-H); 8c 13.7 (s, CH3), 17.3 (s, CH3), 45.0 (d, 4JcF 6, 
CH2), 111.6 (s, C-8), 121.7 (s, Ar-CH), 126.9 (s, Ar-CH), 128.3 (s, Ar-CH), 130.3 (s, C-
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9a), 137.3 (d, 3JcF 15, C-4a), 140.6 (d, 2JcF 26, C-2), 147.2 (d, 1JcF 115, C-3), 149.9 (s, C-
8a); oF -84.45 (IF, s, C-3), mlz (ES+) 274 ([M+ Ht, 85%) 
(ii) N,N-diethyl-2-jluoro-6-methylpyrido[J',2':1,2]imidazo[4,5-b]pyrazin-3-amine, 350 
which was then recrystallised from methanol to yield N,N-diethyl-2-fluoro-6-
methylpyrido[l',2':1,2]imidazo[4,5-b]pyrazin-3-amine (56 mg, 45%) as a brown solid; mp 
146-147 °C; (Found: C, 61.5; H, 5.9; N, 25.9 C14H16FN5 requires: C, 61.5; H, 5.9; N, 
25.6%); OH 1.28 (3H, t, 3JHH 7, CH3), 2.67 (3H, s, CH3), 3.64 (2H, q, 3JHH 6, CH2), 6.82 (1H, 
m, Ar-H), 7.18 (1H, m, Ar-H), 8.37 (1H, m, Ar-H); Oc 13.9. (s, CH3), 17.3 (s, CH3), 44.9 (d, 
4JcF 6, CH2), 111.8 (s, C-8), 121.1 (d, 3JcF 11, C-9a), 121.6 (s, Ar-CH), 127.7 (s, Ar-CH), 
127.8 (s, Ar-CH), 143.6 (d, 1JcF 256, C-2), 144.7 (d, 2JcF 28, C-3), 145.9 (s, C-8a), 148.7 (d, 
4JcF6, C-4a); mlz (ES+) 274 ([M+ Ht, 85%) 
2-(Ethyloxy)-3-fluoro-6-methylpyrido[l ',2' :1,2]imidazo[ 4,5-b ]pyrazine, 354 
338 
NaOEt TJ-F, DIPEA 
rt, 19 h 
5 6 
E)~Y'~F): ~~~ 
2N9a.N 
1 9 
354 
A solution of 2,3-difluoro-6-methylpyrido[1',2':1,2]imidazo[4,5-b]pyrazine, 338 (100 mg, 
0.45 mmol), sodium ethoxide (32 mg, 0.45 mmol) and DIPEA (175 mg, 1.36 mmol) in 
THF (1 0 cm3) was stirred at room temperature for 16 h after which time LCMS indicated 
100% conversion with the formation 2-(ethyloxy)-3-fluoro-6-
methylpyrido[1',2': 1 ,2]imidazo[4,5-b ]pyrazine. The reaction solvent was evaporated in 
vacuo, DCM (40 cm3) and brine (40 cm3) was added and passed through a hydrophobic frit 
to collect the DCM layer. The DCM was evaporated in vacuo to give a crude containing 2-
(ethyloxy)-3-fluoro-6-methylpyrido[1',2': 1 ,2]imidazo[4,5-b ]pyrazine (111 mg). 
Recrystallisation from methanol gave 2 ~( ethyloxy )-3 -jluoro~6-
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methylpyrido[ 1',2':1,2]imidazo[4,5-b]pyrazine, 354 (65 mg, 58%) as a orange solid; mp 
125-126 °C; (Found: C, 58.5; H, 4.5; N, 22.6 C12H1IFN40 requires: C, 58.5; H, 4.5; N, 
22.8;%); 8H 1.53 (6H, m, CH3), 2.68 (3H, s, CH3), 4.60 (2H, q, 3JHH 8, CH2), 4.68 (2H, q, 
3 JHH 8, CHz), 6.85 (1H, m, Ar-H), 7.18 (lH, m, Ar-H), 8.38 (1H, m, Ar-H); 8c 13.9 (s, 
CH3), 17.3 (s, CH3), 44.9 (d, 4JcF 6, CHz), 111.8 (s, C-8), 121.1 (d, 3JcF 11, C-4a), 121.6 (s, 
Ar-CH), 127.7 (s, Ar-CH), 127.8 (s, Ar-CH), 143.6 (d, 1JcF 256, C-2), 144.7 (s, C-8a), 
148.0 (d, 2Jcp24, C-3), 148.9 (s, C-9a); m/z (ES+) 247 ([M+ Ht, 100%) 
N ,N-Diethyl-3-fluoropyrido[l 1,2 1 :1,2]imidazo[ 4,5-b ]pyrazin-2-amine, 352 and N ,N-
Diethyl-2-fluoropyrido[l 1,21 : 1,2]imidazo[ 4,5-b ]pyrazin-3-amine, 353 
5 6 
B~).:4l4a ~F): I /. );-;;;! 
2 9aN 
1 9 
352 
339 
THF, DIPEA 
rt, 20 h 
353 
A solution of 2,3-ditluoropyrido[1 ',2': 1,2]imidazo[4,5-b]pyrazine, 339 (200 mg, 0.9 mmol), 
diethylamine (140 mg, 1.8 mmol) and DIPEA (376 mg, 2.7 mmol) in THF (50 cm3) was 
stirred at room temperature for 20 h after which time LCMS indicated 100% conversion 
with the formation N,N-diethyl-3-tluoropyrido[1 ',2': 1,2]imidazo[4,5-b]pyrazin-2-amine and 
N,N-diethyl-2-tluoropyrido[1',2':1,2]imidazo[4,5-b]pyrazin-3-amine in a 1:1 ratio by 19F 
NMR. The reaction solvent was evaporated in vacuo, DCM (40 cm3) and brine (40 cm3) 
was added and passed through a hydrophobic frit to collect the DCM layer. The DCM was 
evaporated in vacuo to give a crude containing N,N-diethyl-3-
fluoropyrido[1 ',2': 1 ,2]imidazo[4,5-b ]pyrazin-2-amine and N,N-diethyl-2-
fluoropyrido[l ',2': 1,2]imidazo[4,5-b ]pyrazin-3-amine (269 mg). Mass-directed auto-
;" 
preparation HPLC purification gave; 
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- (i) N,N-diethyl-3-fluoropyrido[ 1 ',2':1,2}imidazo[4,5-b}pyrazin-2-amine, 352 which was 
then recrystallised from methanol to give N,N-diethyl-3-fluoropyrido[1 ',2': 1,2]imidazo[4,5-
b]pyrazin-2-amine as a brown solid (96 mg, 38%), mp 134-137 °C; (Found: C, 61.5; H, 5.9; 
N, 25.9 C14H16FNs requires: C, 61.5; H, 5.9; N, 25.6%); OH 1.25 (3H, t, 3JHH 7, CH3), 3.65 
(2H, q, 3JHH 6, CH2), 6.95 (IH, m, Ar-H), 7.42 (1H, m, Ar-H), 7.77 (IH, m, Ar-H), 8.23 
(IH, m, Ar-H); <>c 13.7 (s, CH3), 45.0 (d, 4JcF 6, CH2), II1.6 (s, Ar-CH), I21.7 (s, Ar-CH), 
I26.9 (s, Ar-CH), I28.3 (s, Ar-CH), I29.9 (s, C-9a), I37.8 (d, 3JcF I4, C-4a), I41.I (d, 2JcF 
26, C-2), 146.6 (d, 1JcF I63, C-3), I50.0 (s, C-8a); Op -75.2 (IF, s, C-2); m/z (ES+) 274 ([M+ 
Ht, 85%) 
(ii) N,N-diethyl-2-fluoropyrido[ 1 ',2':1,2}imidazo[4,5-b]pyrazin-3-amine, 353 which was 
then recrystallised from methanol to give N,N-diethyl-2-fluoropyrido[I',2':I,2]imidazo[4,5-
b]pyrazin-3-amine as a yellow solid (94 mg, 36%), mp I39-I40 °C, (Found: C, 61.3; H, 
5.9; N, 25.7 C14H16FNs requires: C, 61.5; H, 5.9; N, 25.6%); 8H 1.30 (3H, t, 3JHH 7, CH3), 
2.68 (3H, s, CH3), 3.68 (2H, q, 3JHH 6, CH2), 6.85 (lH, m, Ar-H), 7.22 (IH, m, Ar-H), 8.33 
(IH, m, Ar-H); 8c I2.6 (s, CH3), 43.9 (d, 4JcF 6, CH2), Il0.8 (s, Ar-CH), II6.5 (s, Ar-CH), 
I20.5 (d, 3JcF 5, C-9a), 124.2 (s, Ar-CH), 128.5 (s, Ar-CH), I43.7 (d, 1JcF 257, C-2), I45.I 
(d, 2JcF 22, C-3), I45.7 (s, C-8a), 148.0 (d, 4JcF 4, C-4a); Op -84.45 (IF, s, C-3), mlz (ES+) 
274 ([M+ Ht, 85%) 
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